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ABSTRACT
Polyamines are small organic bases, ubiquitous in all living cells. They are vital for cell growth
and differentiation, having multiple different roles in cell processes. In normal healthy cells, the
intracellular levels of polyamines are strictly regulated, but in several pathological conditions
polyamine homeostasis has been found to be disrupted. The polyamine metabolic pathways
display also important interspecies differences, e.g. totally different molecules and enzymes.
These features provide a potential target for the design of specific drugs for example against
parasitic infections, and some cancers, as well as potential biochemical markers for diagnosis of
diseases and their progression. N-alkylated polyamine analogues can influence several stages of
polyamine metabolism and function, and are potential therapeutic agents for polyamine related
diseases. Unfortunately, most of the clinical trials so far have failed due to apparent toxicity
and/or low efficacy of the investigated compounds. One reason for the low cell response to
polyamine analogues may be the catabolism of the active drug by different oxidases. However,
also their antitumour activity has been shown to be attributable to the active catabolism of the
natural cellular polyamines to cell toxic metabolites. Thus it is necessary to gain better
understanding of the key polyamine catabolising enzymes acetylpolyamine oxidase PAO and
spermine oxidase SMO relative to N-alkylated polyamine stability and their possible function.
This study is the first to reveal that both PAO and SMO are capable of metabolizing several N-
alkylated polyamine derivatives, this being demonstrated with purified enzymes as well as in cell
culture, a factor that can have significant impact on the efficiency of polyamine-based drugs, and
hence for the development of novel N-alkylated polyamine analogues. In addition, also N-
alkylated polyamine analogue catabolism might have an important role in the drug-mediated
cytotoxic response, especially after the natural polyamines have been depleted.
Most of the existing methods for polyamine metabolic studies are based on analysis of different
derivatives using LC and UV detection. However, direct methods, which do not need
derivatization, would be more desirable to avoid drawbacks such as the different reactivities of
the analytes and instability of the derivatization products. In addition, since it may be essential to
measure low concentration of these natural and synthetic polyamines, more selective and
sensitive analytical methods are required. LC-MS/MS is one of the most powerful methods for
metabolite analysis, but surprisingly, it has not yet been utilized widely in polyamine analysis,
especially the use of this technique without derivatization. Thus, in this work, a new quantitative
isotope dilution LC-MS/MS method was developed and validated to analyze polyamines, their
derivatives and metabolites without the need for derivatization. In the study a simple and
straightforward method was also developed to synthesize N-alkylated, deuterium labelled
polyamines suitable for internal standards in quantitative polyamine analysis. In comparison with
conventional methods for polyamine analysis, the developed LC–MS/MS method is easier to use
and is substantially faster since there is minimal sample pre-treatment followed by rapid
chromatographic separation. Moreover, the method allows clear identification of the products by
the highly sensitive MS technique and the possibility to eliminate interfering peaks arising from
the matrix by selective MS/MS. This new method was used in metabolic studies and it might also
help to solve some of the other physiological and pathophysiological functions of polyamines
and their analogues, which still await clarification.
Universal Decimal Classification: 543.51, 543.544.5, 547.415, 577.152.1
National Library of Medicine Classification: QU 61, QU 140
Medical Subject Headings: Polyamines; Oxidoreductases Acting on CH-NH Group Donors; Metabolism; Isotope Labe-
ling; Deuterium; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Chromatography, High Pres-
sure Liquid; Reference Standards
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ABBREVIATIONS
ACN acetonitrile
ADDP 1,1’-(azodicarbonyl)dipiperidine
AdoDATAD S-adenosyl-1,12-diamino-3-thio-9-azadodecane
AdoDATO S-adenosyl-1,8-diamino-3-thiooctane
AdoMet S-adenosylmethionine
AdoMetDC S-adenosylmethionine decarboxylase
AMPA 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid
APCI atmospheric pressure chemical ionisation
ATP adenosine triphosphate
AZ antizyme protein
BA butyric acid
BnDAP N1-benzyl-propane-1,3-diamine
BnDAP-4D N1-benzyl-2,2,3,3-2H4-propane-1,3-diamine
BnEtSPM N-(3-benzylaminopropyl)-N'-(3-ethylaminopropyl)butane-1,4-diamine
BnEtSPM-8D N-(3-benzylamino-1,1,2,2-2H4-propyl)-N'-(3-ethylamino-1,1,2,2-2H4-
propyl)butane-1,4-diamine
BnNH2 benzylamine
BnNH2-2D ???-2H2-benzylamine
BnSPD N1-(3-benzylaminopropyl)butane-1,4-diamine
BnSPD-4D N1-(3-benzylamino-1,1,2,2-2H4-propyl)butane-1,4-diamine
BnSPM N-(3-aminopropyl)-N'-(3-benzylaminopropyl)butane-1,4-diamine
BnSPM-4D N-(3-aminopropyl)-N'-(3-benzylamino-1,1,2,2-2H4-propyl)butane-1,4-
diamine
Boc tert-butyl carbamate
CAD cadaverine, pentane-1,5-diamine
Cbz benzyloxycarbonyl
CE capillary electrophoresis
CHENSPM N1-(cycloheptylmethyl)-N11-ethylnorspermine
CID collision induced dissociation
CNLSD condensation nucleation light scattering
CPENSPM N1-(cyclopropylmethyl)-N11-ethyl-norspermine
CZE capillary zone electrophoresis
DAH heptane-1,7-diamine
Dansyl 5-(dimethylamino)naphthalene-1-sulfonyl
DAO diamine oxidase
DAP propane-1,3-diamine
DAP-2D 1,1-2H2-propane-1,3-diamine
DBSPM N,N´-bis(3-benzylaminopropyl)butane-1,4-diamine
DBSPM-8D N,N´-bis(3-benzylamino-1,1,2,2-2H4-propyl)butane-1,4-diamine
DENSPM diethylnorspermine, N,N'-bis(3-ethylaminopropyl)propane-1,3-diamine
DESPM N,N´-bis(3-ethylaminopropyl)butane-1,4-diamine
DESPM-4D N,N´-bis(3-ethylamino-1,1-2H2-propyl)butane-1,4-diamine
dcAdoMet decarboxylated AdoMet, S-adenosyl-1-amino-3-thiomethyl-propane
DEAD diethylazodicarboxylate
de novo a molecule is synthesized anew from simple molecules
DEHSPM N1,N14-diethylhomospermine
DENSPM N1,N11-diethylnorspermine
DESPM N1,N12-diethylspermine
DFMO 2-(difluoromethyl)ornithine
DIPSPM N1,N12-di-isopropylspermine
ECL electrochemiluminescence
eIF5A eucaryotic translation initiation factor 5A
ELISA enzyme-linked immunosorbent assay
ESI electrospray ionization
EtDAP N1-ethylpropane-1,3-diamine
EtDAP-2D N1-ethyl-3,3-2H2-propane-1,3-diamine
EtSPD N1-(3-ethylaminopropyl)butane-1,4-diamine trihydrochloride
EtSPD-2D N1-(3-ethylamino-1,1-2H2-propyl)butane-1,4-diamine
EtSPM N-(3-aminopropyl)-N'-(3-ethylaminopropyl)butane-1,4-diamine
EtSPM-2D N-(3-aminopropyl)-N'-(3-ethylamino-1,1-2H2-propyl)butane-1,4-diamine
FA formic acid
FAD flavin-adenine dinucleotide
FDA food and drug administration
FIA flow injection analysis
Fmoc 9-fluorenylmethoxycarbonyl
Fms1 yeast spermine oxidase
Fr fragmentor voltage
GC gas chromatography
HFBA heptafluorobutyric acid
hPAO recombinant human polyamine oxidase
HPLC high pressure liquid chromatography
HSPM homospermine, N,N’-bis(4-aminobutyl)butane-1,4-diamine
IC ion-exchange
IC50  inhibitor concentration at which the enzyme reaction velocity is 50% of the
uninhibited reaction
in vitro in glass, referring to a study in the laboratory usually involving isolated
organ, tissue, cell, or biochemical systems
in vivo in the living body, referring to a study performed on a living organism
IPAD integrated pulsed amperometric detection
IPENSPM (S)-N1-(2-methyl-1-butyl)-N11-ethyl-norspermine
IR infrared
IS internal standard
ISWD integrated square wave
IVD integrated voltameter
kcat  the maximum number of enzymatic reactions catalyzed per second per
active center
kcat/Km kinetic parameter used in comparisons of the relative rates of an enzyme
acting on alternative substrates, sometimes termed as catalytic efficiency
Ki  the concentration of inhibitor which is required to decrease the maximal rate
of the reaction to half of the uninhibited value
Kir inward rectifier potassium ion channel
Km initial concentration of the substrate required to reach half of Vmax
LC liquid chromatography
LSD1 lysine-specific demethylase 1
LLOQ lower limit of quantification
LOD limit of detection
MAO monoamine oxidase
MDL72527 N1,N4-bis(2,3-butadienyl)-1,4-butanediamine
MGBG methylglyoxal-bis(guanylhydrazone)
MS mass spectrometry
MS/MS tandem mass spectrometry
MTA 5’-deoxy-5’-S-methylthioadenosine
MtsCl mesitylenesulfonylchloride,  2,4,6-trimethylbenzenesulfonyl chloride
N number of theoretical plates
N1-AcSPD N1-acetylspermidine
N8-AcSPD N8-acetylspermidine
N1-AcSPM N1-acetylspermine
NMDA N-methyl-D-aspartic acid
NMR nuclear magnetic resonance
N1,N12-DiAcSPM N1,N12-diacetylspermine
NsCl nosyl chloride, 2-nitrobenzenesulfonylchloride
NSPM norspermine, N,N’-bis(4-aminopropyl)propane-1,3-diamine
ODC ornithine decarboxylase
OPA o-phthalaldehyde, benzene-1,2-dicarboxaldehyde
PAD pulsed amperometric detection
PAO polyamine oxidase
PFPA pentafluopropropionic acid
Pht phthalyl
pKa acid dissociation constant
PPh3 triphenylphosphine
PrA propionic acid
PUT putrescine, butane-1,4-diamine
PUT-8D 1,1,2,2,3,3,4,4-2H8-butane-1,4-diamine
QC quality control
QL qualifier ion
QQQ triple quadrupole
QT quantifier ion
RIA radioimmunoassay
RP reversed phase
Rt retention time
SAO serum amine oxidase
siRNA silencing RNA
SMO spermine oxidase (PAOh1)
SPD spermidine N1-(3-aminopropyl)butane-1,4-diamine
SPD-2D N1-(3-amino-1,1-2H2-propyl)butane-1,4-diamine
SpdSyn spermidine synthase
SPM spermine, N,N’-bis(4-aminopropyl)butane-1,4-diamine
SPM-4D N-(3-amino-1,1,2,2-2H4-propyl)-N'-(3-aminopropylbutane-1,4-diamine
SpmSyn spermine synthase
SRM selected reaction monitoring
SSAT spermidine/spermine N1-acetyltransferase
TFA trifluoroacetic acid
TsCl toluenesulfonyl chloride, 4-methylbenzene sulfonyl chloride
UV-Vis ultraviolet-visible light
Vmax the maximum velocity or rate at which the enzyme catalyzes the reaction
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1. INTRODUCTION
Cancer is a leading cause of death worldwide and the total number of cases globally is
increasing, stroke is the third most common cause of death and the leading cause of disability
among adults in the Western world, and parasitic diseases like malaria, leishmaniasis and
trypanosomiasis, caused by protozoan parasites, are a worldwide problem having a major impact
on public health in the developing countries. [World Health Organization, http://www.who.int]
Compounds interfering with polyamine metabolism or function are potential therapeutics or
protective agents for all these severe diseases as well as many other symptoms (see chapters 2.1.5
and 2.1.6). Some single polyamine biosynthesis inhibitors have already yielded clinically useful
tools, particularly for the treatment of parasitic diseases. However, because of the complexity of
the polyamine metabolic system, in some cases their therapeutic effects may be blocked due to
simultaneous upregulation of polyamine uptake. In addition, some organisms may not synthesise
their own polyamines and are thus resistant to biosynthesis inhibitors. In contrast, N-alkylated
polyamine analogues are multi-site inhibitors, which can influence several stages of polyamine
metabolism and function, and thus can better overcome any compensatory mechanisms to the
decreased de novo polyamine formation, which has hampered the development of most of the
single enzyme inhibitors examined so far. Unfortunately, most of the clinical trials have still
failed due to apparent toxicity and/or low efficacy of the test compounds. One reason for the low
cell response to polyamine analogues may be the catabolism of the active drug by different
oxidases. [Lawson et. al. 2002] In previous studies it has been shown that acetyl polyamine
oxidase PAO is capable of metabolizing some polyamine analogues. However, at the same time
also the biological activity of these compounds has been shown to originate from the active
catabolism of the natural cellular polyamines to cell toxic hydrogen peroxide, aldehydes and
acrolein. It is also known that relatively modest structural modifications in the polyamine
backbone or incorporation of different terminal N-alkyl substituent(s) may evoke significant
differences in their chemical and biological behaviour. [Casero & Marton 2007, Li et. al. 2007,
Kim et. al. 2009, Müller et. al. 2008, Heby et. al. 2007]
Since the first discovery of spermine from human semen in 1678 by Antonie van Leeuwenhoek,
polyamines have been an active field of research that has been continuously growing. During the
last 10 years more than 2/3 of the published work concerning polyamines has been devoted to
some aspects of metabolism. However, the relative number of papers on polyamine oxidases, one
group of the key enzymes in polyamine catabolism, has remained low. [Montañez et. al. 2007] In
addition, despite the growing interest of utilizing polyamine analogues as multitarget drugs, there
is still very little information available on the real targets and key actions of these compounds.
[Amendola et. al. 2009] Furthermore, although cellular oxidases, such as PAO and also spermine
oxidase SMO, may significantly affect the efficacy of polyamine-based drugs, there have been
very few metabolic studies conducted with purified enzymes and N-alkylated polyamine
analogues, and the metabolism of these compounds in the host has remained incompletely
defined. Knowledge on the precise role of polyamine analogues as well as clarification of the
properties of the enzymes involved in their metabolism would be fundamental in drug
development in order to understand the mechanism of action of these novel drugs, and to avoid
low efficacy due to drug metabolism, or dramatic toxic side effects. Thus, one of the aims of this
work was to gain a better understanding of the two polyamine catabolising enzymes, PAO and
SMO, as related to N-alkylated polyamine stability and their possible function. The substrate
properties of several N-alkylated polyamine analogues were thoroughly investigated with
purified human PAO and SMO. In addition, experiments were performed to evaluate the cellular
accumulation, catabolism, and excretion of the metabolites of N,N’-bis-alkylated spermine
analogues in DU145 prostate cancer cells. The results of this study may explain the low efficacy
of the polyamine-based drugs in some cell lines and the limited clinical activity observed to date.
Most importantly, the results of these studies provide important information of the substrate
properties of these two catabolic enzymes that will be of benefit in future drug design.
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Due to the poorly volatile, non-fluorescent and weakly UV absorbing nature of polyamine
backbone, most of the existing methods to study polyamine metabolism are based on analysis of
different derivatives. [Teti et. al. 2002] However, several drawbacks have been associated with
the derivatization and thus direct methods, which do not need derivatization, would be more
desirable. In addition, traditional polyamine quantification using LC and UV detection of
derivatives suffers from lack of sensitivity and selectivity as the analysis relies on retention time,
peak area and UV spectral characteristics, especially, if interferences from co-eluting or
overlapping peaks are present. Also, with low concentrations, more selective and sensitive
analytical methods are required. Tandem mass spectrometric (MS/MS) detection and
quantification utilizing electrospray ionization, combined to liquid chromatography/mass
spectrometry is one of the most powerful techniques for the analysis of metabolites. [Kostiainen
et. al. 2003] However, due to the polar nature of polyamines, LC-MS/MS has not yet been
utilized widely in polyamine analysis, especially without derivatization. In this work a new
quantitative isotope dilution LC-MS/MS method was developed and validated to analyze
polyamines, their derivatives and metabolites without any derivatization.
If one wishes to achieve acceptable reliability, then internal standards are needed to compensate
for the variability in MS detection. Stable isotope labelled analogues are the most appropriate
standards for this purpose in LC-MS/MS studies, and deuterium labelling offers the most
convenient way to create these analogues. Various protocols have already been developed for
polyamine synthesis and labelling, but there are much fewer strategies to obtain deuterium
labelled polyamines, and there was no general method to prepare N-alkylated polyamine
derivatives with a deuterium label. One of the aims of this study was to develop a simple and
straightforward method to synthesize N-alkylated, deuterium labelled polyamines suitable for
internal standards in quantitative polyamine analysis. These labelled analogues may also serve as
potential biochemical probes in future studies.
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2. REVIEW OF THE LITERATURE
2.1  OVERVIEW OF POLYAMINES
2.1.1  Structure, naming, and chemical properties of polyamines
The structures of the three most common natural polyamines in mammalian cells, asymmetric
triamine spermidine (SDP), symmetric tetramine spermine (SPM) and their diamine precursor
putrescine (PUT), are shown in Fig. 1. In addition, a large number of other linear, some branched
chain and cyclic polyamines and their derivatives, as well as conjugates with carbohydrates,
steroids, and phospholipids, as an example, have been isolated from all kinds of living organisms.
[Cohen 1998, Bienz et. al. 2005]
 Figure 1. Structures, trivial names and common abbreviations of some polyamines and their derivatives
Generally, the term ‘polyamine’ refers a small oligoamine, the molecule which contain three or
more amino groups as one part of various length of the hydrophobic, aliphatic methylene chain.
For the simplicity, although not strictly correctly in the chemical sense, also some diamines are
usually included in the polyamine family due to their role as obligatory precursors, as well as
being degradation and excretion products of the higher polyamines. In the more restricted sense,
the term ‘polyamines’ refers only to SPM, SPD and PUT, and thus other oligoamines and
diamines, such as norspermine (NSPM) and cadaverine (CAD), although occurring naturally, are
not included within the term ‘polyamines’. [Wallace 2003a] However, the term polyamine has
been used in the literature also in a more generic sense to include PUT, SPD, SPM, other amines,
and various derivatives. Moreover, also the terms ‘polyamine analogues’, ‘polyamine
homologues’, ‘polyamine derivatives’, ‘polyamine metabolites’, ‘polyamine conjugates’,
‘polyamine complexes’ etc. have been used, either for natural or for synthetic products.
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As the chemical names of the different polyamine structures can often be quite complicated and
long, trivial names and abbreviations are generally used for the most common backbone
structures (see examples in Fig 1.). In addition to the trivial names, the backbone structure of
polyamines can be abbreviated by simply denoting the number of carbons between each amino
group. Thus PUT becomes ‘4’, spermidine ‘3-4’ and spermine ‘3-4-3’. [Morgan 1998] As an
example of the various existing names for polyamines, the synonyms for SPM are given in Table
1.
 Table 1. Synonyms for spermine
1.* N,N’-Bis(3-aminopropyl)butane-1,4-diamine 9. 1,5,10,14-Tetraazatetradecane
2. N,N’-Bis(3-aminopropyl)-1,4-tetramethylenediamine 10. Gerontine
3. N,N’-Bis(3-aminopropyl)-1,4-butanediamine 11. Musculamine
4. N1,N4-Bis(3-aminopropyl)-1,4-butanediamine 12. Neuridine
5. Diaminopropyltetramethylenediamine 13. Spermine
6. 4,9-Diaza-1,12-dodecanediamine 14. Spermin
7. 4,9-Diazadodecanemethylenediamine 15. SPM
8. 4,9-Diazadodecane-1,12-diamine 16. 3-4-3
* 1. = Chemical IUPAC name
Polyamines are very polar compounds that are susceptiple to oxidation, absorb UV light only
below 200 nM and do not  absorb visible  light.  The chemical  reactivities  of  the polyamines are
distinctively different from those of monoamines. PUT, DAP, and CAD are examples of primary
diamines,  while  SPD  and  SPM  contain  primary  and  secondary  amine  groups.  However,  some
more unusual polyamines may include also tertiary or even quaternary ammonium nitrogen.
Generally, the basicity increases with the number of amino groups, as does the ability to complex
metal ions, and the distinctive fragmentation behavior in MS. [Bienz et. 2005, and Bencini et. al.
1999]
Under normal physiological ionic and pH conditions, all the amino groups in the polyamines are
usually positively charged, although some structures may also contain uncharged amines.
[Bencini et. al.1999] For the sake of simplicity, all the structures in this thesis are presented in
their unprotonated form. Table 2. shows pKa values  for  PUT,  SPD  and  SPM.  [Bencini  et.
al.1999] The charge is distributed along the entire length of the carbon chain, making the
polyamines unique and distinct from the point charges of the cellular bivalent cations, such as
Ca2+ and Mg2+. It is likely that this polycharged nature and the conformational flexibility, as well
as the hydrocarbon chains and their steric effects on the positive charges, are very important in
determining the physiological actions of polyamines.
 Table 2. pKa values of primary and secondary amino groups in polyamines (0.1M, 298K)
pK1 pK2 pK3 pK4
PUT 9.44 10.72 - -
SPD 8.24 9.81 10.89 -
SPM 7.96 8.85 10.02 10.80
2.1.2  Distribution
Polyamines are found in almost all living species, e.g. bacterias and fungi, plants and viruses as
well as in mammalian cells. Only two families of Archaea bacteria have been found which seem
to grow without polyamines. The nature and relative amouts of polyamines differs between
species and in mammalian cells between tissues. Bacteria contain mainly PUT and SPD, while in
mammalian cells SPD and SPM generally predominate, with PUT being found in much lower
amounts. In humans, the highest tissue concentrations of polyamines are found in the prostate
gland, liver and pancreas. Also high amounts are present in semen and in circulating blood,
especially in erythrocytes and leukocytes. Polyamines exist also in the brain, where they have
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been localized in neurons and glial cells. The most important site of cellular storage is the cytosol
and nucleus. Intracellular distribution studies have shown SPD and SPM to be mainly
concentrated in the nucleus. [Tabor & Tabor 1964a, Wallace 1996, Cohen 1998, Gugliucci 2004,
Kusano et. al. 2008, Fiori & Turecki 2008, Shin et. al. 2008]
2.1.3  Concentration
Intracellular polyamine pools are actively regulated according to needs of de novo synthesis,
degradation, as well as for excretion and uptake from extracellular sources. In general, the
concentrations are higher in rapidly proliferating tissues, like embryos and tumours, and their
levels increase rapidly when growth or differentiation is induced within cells. Polyamine
depletion may cause inhibition of cell growth and even cell death. In mammalian cells, the total
intracellular concentration of the polyamines exists in the micromolar to millimolar range, if the
compounds are assumed to be uniformly distributed throughout the cell volume. However, most
of the cellular as well as plasma polyamines are conjugated or bound by strong interactions with
polyanionic macromolecules and to membrane structures. Only around 7 –10% of the total cell
content appears as unbound polyamines, called biogenic amines. The major urinary excretion
form of polyamines are their monoacetyl derivatives, the tissue levels of which are usually very
low, but may be enhanced after intoxication, food deprivation and other pathophysiological
conditions. [Seiler 1986, Cohen 1998, Gugliuggi 2004, Fiori & Turecki 2008]
2.1.4  Polyamine sources
In mammalian cells, polyamines are available from different sources. They can be synthesised de
novo from amino acids like L-ornithine and L-methionine, or preformed extracellular polyamines
can be taken up into the cell (see chapter 2.2.). Possible sources for extracellular polyamines are
those liberated during normal body cell or tumour cell turnover. Polyamines can also be taken up
from the diet. The polyamines are found in fruits and vegetables, some foods of animal origin
(milk, eggs, fish, and meat), and fermented food products like cheese, beer, red wine and
sauerkraut. Also human breast milk contains large amounts of polyamines and this is the main
source of polyamines for newborns. The polyamine content in foods varies from a few
nanomoles as much as micromoles per gram, and also the proportions of the different polyamines
vary with the food type. However, the daily polyamine intake for an adult has been estimated to
be around 350-550 µmol. In addition to dietary intake, intestinal microbes produce their own
polyamines from ornithine and lysine which are available to the host either through active
excretion of the polyamines or as a result of leakage from dead or dying micro-organisms.
[Wallace 1996, Cohen 1998, Kalac & Krausová 2005, Larqué et. al. 2007]
2.1.5  Physiological roles in mammalian cells
Polyamines are known to have multiple different roles in cellular processes, only a small part of
which are presented here. Although all biological effects and definitive mechanisms of the
various known functions of polyamines are still not fully elucidated, they have been undoubtedly
shown to be essential for life. They have specific roles for example in embryonic development,
cell cycle, neurochemistry, pulmonary and immune system function. Depletion of cellular
polyamines blocks cell growth, and both decrease and increase in polyamine levels may induce
apoptosis, a programmed cell death, the failure of which can lead to auto-immune diseases or
cancer. [Cohen 1998, Oredsson 2003, Thomas & Thomas 2001, Wallace 2000, Wallace et. al.
2003b, Li et. al. 2007, Kusano et. al. 2008]
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Due to the multiple positive charges, the polyamines can interact electrostatically with negatively
charged moieties in cells, such as DNA, RNA, chromatin, proteins and phospholipids. These
interactions may include different regions of these anionic compounds, and thus can stabilize or
destabilize their structures, and alter the function of these molecules. Polyamines affect also
DNA, RNA and protein synthesis in various ways. They have ability to induce DNA
conformational transitions, which may be essential for the normal transcriptional activity of
genes. Polyamines are also believed to be involved in RNA translation processes and protein
conformational changes may alter enzyme activity. Additionally, the polyamines are involved in
membrane stabilization and in many signalling pathways through their effects on G proteins,
protein kinases, nucleotide cyclases and receptors. Polyamines may also function as direct
antioxidants and/or interact with DNA backbone phosphate groups, which are thought to protect
DNA from strand breaks and subsequent mutations induced by ionization and reactive oxygen
species. However, in specific instances, polyamines may also serve as the source of damaging
reactive oxygen species. [Rider et. al. 2007] In addition, the ability of polyamines to alter DNA-
protein and protein-protein interactions might be disruptive to cellular functions. [Thomas &
Thomas 2001] Polyamines can also electrostatically interact with cellular phosphate anions and
form aggregates, which are also able to alter the DNA conformation and protect DNA, even more
efficiently than single polyamines. [D’Agostino & Luccia 2002]
In addition to ionic interactions, polyamines may also form covalent linkages. For example, SPD
is needed in the synthesis of the unusual amino acid hypusine, a part of an essential protein for
eucaryotic cell proliferation, named eucaryotic translation initiation factor 5A (eIF5A). [Park
2006] Polyamines may serve as modulating inhibitors of protein cross-linking by acting as
acceptors for the cross-linking forming, transglutaminase enzyme activated glutamyl carboxyls.
Polyamines may also themselves serve to cross-link proteins with transglutaminase. Due to the
role in transglutaminase function, polyamines may be included in blood clotting, wound healing,
tissue development and organization, as well as in cancer and metastasis. Polyamines are also
believed to have a role in protein cross-link formation in normal and the psoriatic epidermal
envelope in the skin. [Cohen 1998, Lentini et. al. 2007]
The polyamines can interact with, or regulate, several ion channels and receptors. Potassium
channels are integral membrane proteins which maintain normal membrane electrical activity,
and inwardly rectifying K+ (Kir) channels are an important class of K+ channels. Inward
rectification refers to the ability of an ion channel to allow greater influx than efflux of ions. In
the  case  of  Kir channels, inward rectification is attributable to cytoplasmic ions such as
polyamines and Mg2+, which plug the conduction pathway on depolarization and thereby impede
the  outward  flow  of  K+, an essential property for normal electrical activity. Intracellular
polyamine depletion prevents inward rectification. [Williams 1997, Wallace 2000, Bichet et. al.
2003] Different types of Kir channels are found in many different cell types, and their roles in
cellular physiology vary across cell types. In neurons, they shape action potentials and set the
resting membrane potential and thus control the neuronal signalling. In cardiac muscle cells, they
regulate heart rate by helping maintain a more prolonged cardiac action potential, and failure of
potassium channels to function properly may cause life-threatening arrhythmias. In pancreatic
cells, they control insulin release and thus malfunction can lead to diabetes. [Bichet et. al. 2003]
Regulation of Kir channels by polyamines have also been connected to the importance of
maintaining proper hearing and balance. [Wang et. al. 2009] Polyamines have also multiple
effects on glutamate receptors (N-methyl-D-aspartic acid (NMDA), 2-amino-3-(5-methyl-3-oxo-
1,2-oxazol-4-yl)propanoic acid (AMPA), and kainate receptors), which mediate the fast synaptic
transmission in the central nervous system. In the NMDA receptors, SPM is known to bind to an
allosteric site on the receptor, distinct from the channel, and to activate the receptor. It has been
also suggested that SPM may bind within the channel at the Mg2+ site. Receptor activity can be
blocked by polyamine analogues. Since the receptor controls the entrance of activating or
potentially toxic cations, polyamines are examined as possible cures for stroke. Polyamines are
also believed to modulate learning and memory by interacting with the polyamine binding site at
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the NMDA receptors. The polyamine system is also potentially involved in the normal process of
brain ageing. [Cohen 1998, Liu et. al. 2008, Williams 1997] Polyamines can also cause
rectification of AMPA and kainate receptors through blocking the pore of the receptor channel
and thus prevent the flux of sodium (and calcium). [Li et. al. 2007] Polyamine based toxins can
selectively block Ca2+ permeable AMPA receptors. [Strømgaard & Mellor 2004]
2.1.6  Polyamines in pathological conditions
Changes in the levels of the individual polyamines, as well as alterations in the expression and
activity of polyamine metabolic enzymes (chapter 2.2), have been observed in multiple
pathological conditions. A variety of tumours and tumour-derived cell lines have been shown to
have dysregulated polyamine metabolism and homeostasis, thus during the last decades,
polyamine metabolism has attracted great interest as a target for antiproliferative therapy.
[Casero & Marton 2007] Alterations in intracellular and extracellular polyamines have also been
found in non-tumoural pathological conditions, such as infections, psoriasis, polycythemia rubra
vera, systemic lupus erythematosus, uremia, chronic nephritis, liver cirrhosis, cystic fibrosis,
insulin-dependent diabetes mellitus, muscular dystrophy, periodontal diseases and Alzheimer’s
disease have been demonstrated [Teti et. al. 2002] Polyamines are also linked to mental
disorders, like schizophrenia, mood disorders, anxiety and suicidal behaviour. [Fiori & Turecki
2008] Increased polyamines have been found in red blood cells of patients with ALS
(Amyotrophic lateral sclerosis) and Parkinson´s disease, [Gomes-Trolin et. al. 2002] and brain
polyamine levels change dramatically following cerebral ischemia, caused by stroke, traumatic
spinal cord and brain injury. [Li et. al. 2007, Kim et. al. 2009] Polyamine system dysfunction
may also contribute to aged-related impairments in hippocampal neurogenesis and deficits in
learning and memory. [Liu et. al. 2008]
Increased polyamine catabolism has been linked to inflammation, acute pancreatitis as well as in
cancer. [Babbar et. al 2007, Alhonen et. al. 2000] In addition, differences between the host and
parasite polyamine metabolism provide a target for the treatment of parasitic diseases such as
African sleeping sickness and malaria [Müller et. al. 2008, Heby et. al. 2007, Bacchi & Yarlett
2002]
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2.2  METABOLISM OF POLYAMINES
2.2.1  Polyamine biosynthesis
In mammalian cells polyamines are synthesised de novo from two amino acids, L-ornithine and
L-methionine. The general pathway for polyamine biosynthesis is shown in Fig 2.
Figure 2. Polyamine biosynthesis, interconversion and some related reactions
In the first step, cytosolic L-ornithine is decarboxylated to PUT in a reaction catalysed by
ornithine decarboxylase (ODC). Ornithine is available from extracellular sources or from
arginine by via the action of arginase. In some microorganisms and in plants, PUT may also be
synthesised within the cell starting from arginine by arginine decarboxylase, however, there is no
evidence for the precence of a mammalian arginine decarboxylase. ODC is very strictly regulated
and has a very short half life, usually from several minutes to  1  hr.  ODC  activity  varies  in
response to many stimuli and its degradation is controlled by the level of antizyme protein (AZ),
which responds to the polyamine concentration. A variety of polyamine analogues have also been
shown to be effective inducers of antizyme. [Pegg 2006, Schipper & Verhofstad 2002] The most
widely used inhibitor of ODC is 2-(difluoromethyl)ornithine (DFMO, Fig. 4 on page 34). This
enzyme-activated irreversible inhibitor causes a decrease in intracellular PUT and SPD levels,
but  not  in  SPM.  [Seiler  2003a]  Although  DFMO  was  ineffective  as  a  single  drug in vivo for
cancer treatment, it has proved to be a promising agent for cancer chemoprevention. For example,
DFMO combined with an anti-inflammatory drug sulindac is in clinical trials as a
chemopreventive strategy for recurrent colon carcinoma and has produced promising results.
[Gerner & Meyskens 2009] DFMO has also shown acceptable safety and effectiveness for the
treatment of African sleeping sickness caused by the protozoan Trypanosoma brucei, [Priotto et.
al. 2008] and it is used for treatment of unwanted facial hair in women. [Hamzavi et. al. 2007,
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Hoffmann 2008] Competitive inhibitors of ODC have proven to be of limited value. [Woster
2006]
In the next step, PUT is converted to SPD via the attachment of an aminopropyl group. The chain
elongation is catalyzed by spermidine synthase (SpdSyn), using decarboxylated S-
adenosylmethionine (dcAdoMet) as a donor of the propylamine residue. SPD is essential for
cells.  It  is  the  growth-promoting  member  of  the  polyamine  family,  since  it  is  a  precursor  of
hypusine, an unusual amino acid acting as the prosthetic group in eIF5A, which is essential for
eukaryotes. [Park 2006] Human SpdSyn is highly specific for PUT as the amine acceptor. [Wu
et. al. 2007a] Both substrate analogues, or transition state analogue inhibitors for SpdSyn have
been described, though the S-adenosyl-1,8-diamino-3-thiooctane (AdoDATO, Fig. 4 on page 34)
is currently the most popular because of its high selectivity and potency. [Seiler 2003a]
DcAdoMet is synthesised from S-adenosylmethionine (AdoMet) in the decarboxylation reaction
catalysed by S-adenosylmethionine decarboxylase (AdoMetDC). AdoMet is in turn derived from
L-methionine using AdoMet synthase. ATP is utilized when methionine is converted into
AdoMet. Methylglyoxal-bis(guanylhydrazone) (MGBG, Fig. 4 on page 34) is one of the potent
competitive inhibitors of AdoMetDC which also blocks diamine oxidase (see chapter 2.2.2.2). A
huge number of other compounds have been identified as inhibitors of AdoMetDC. However,
AdoMet synthase was known to be a poor target for inhibitors, since even a very potent
inhibition of this enzyme, evoked by L-2-amino-4-methoxy-cis-but-3-enoic acid (Fig. 4 on page
34) had little effect on AdoMet pools. [Seiler 2003a]
SPM is synthesised by the transfer of another aminopropyl moiety in the same way as to SPD is
formed by spermine synthase (SpmSyn). SpdSyn can be found in all organisms, but SpmSyn
have been found only from yeast, and higher eukaryotic cells including plants. The rate of the
formation of SPD and SPM depends on the availability of dcAdoMet. [Ikeguchi et. al. 2006]
SPM is clearly required for normal development in mammals. The rare human Snyder-Robinson
syndrome, a mental retardation condition, is caused by mutations in SpmSyn located in the X
chromosome that drastically reduces the amount of SpmSyn. [Cason et. al. 2003] The SpmSyn
deficiency has also been postulated to lead to deafness. [Wang et. al. 2009] The synthesis of SPD
as well as SPM converts dcAdoMet into 5’-methylthioadenosine (MTA), which is salvaged back
to methionine and adenosine via a series of reactions. MTA acts as an inhibitor of SpmSyn,
SpdSyn and ODC, but it has also other biological functions. [Avila et. al. 2004] A transition state
analogue S-adenosyl-1,12-diamino-3-thio-9-azadodecane (AdoDATAD, Fig. 4 on page 34) is a
specific inhibitor of SpmSyn [Woster 2006]
The crystal structures of the four mammalian enzymes in the polyamine biosynthetic pathway
(ODC [Almrud et. al. 2000], AdoMetDC [Tolbert et. al. 2001], SpdSyn [Wu et. al. 2007a], and
SpmSyn [Wu et. al. 2008]) have been solved and have provided much information on their
substrate-binding specificity and mechanisms of catalysis and regulation.
2.2.2  Polyamine catabolism
Polyamines can be catabolised in two ways. They can be converted back into PUT via the so-
called interconversion pathway, where SPM and SPD are catabolized in the carbon atom which is
adjacent to the secondary amine. The other route is the irreversible deamination of primary
amines, called terminal degradation. Terminal degradation together with polyamine excretion are
the two major possibilities for cells to diminish their intracellular polyamine pools. However,
although the oxidation of polyamines is responsible for the formation of metabolites to be
excreted, it also represents the main process by means of which polyamines are irreversibly
converted into molecules having different physiological functions, such as the major inhibitory
neurotransmitter ?-aminobutyric acid. In addition, H2O2 and amino aldehydes, produced during
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the degradation of polyamines, have biological significance as these agents may trigger
apoptosis. [Cohen 1998, Thomas & Thomas 2001, Seiler 2004, Agostinelli et. al. 2004]
2.2.2.1 Polyamine interconversion pathway
In the mammalian polyamine interconversion pathway (Fig. 2), the predominantly cytosolic
spermidine/spermine N1-acetyltranserase (SSAT) adds acetyl groups to the aminopropyl ends of
SPD and SPM using acetyl coenzyme A as a cosubstrate. This leads to the formation of N1-
AcSPD and N1-AcSPM, respectively. These acetylated intermediates are either exported from the
cell, or in the second step, the acetamidopropyl moieties are released after oxidation with
polyamine oxidase (PAO, see chapter 2.3) leading to PUT and SPD, respectively. Stoichiometric
amounts of hydrogen peroxide and 3-acetamidopropanal are formed as a byproduct in these
steps. N1-AcSPM can also be converted into N1,N12-DiAcSPM by SSAT which can be oxidised
to N1-AcSPD by PAO. Acetylation is a rate limiting step in these interconversion steps, as PAO
prefers acetylated polyamines as substrates. [Seiler 2004, Pegg 2008] In addition, mammalian
cells contain also N8-acetylspermidine (N8-AcSPD), and N1,N8-diacetylspermidine which have
been found in urine, but the enzymes involved in their formation have not yet been clarified. A
function of N8-acetylation is suggested to be the removal of SPD from the cell nucleus. [Seiler
2004]
SSAT is very strictly regulated, and under resting conditions, the SSAT activity in the cell is very
low. However SSAT is induced by exogenous polyamines under situations where the total
polyamine pool needs to be rapidly decreased. Certain polyamine analogues can mimic the
induction and increase the stability of SSAT and cause a loss of normal polyamines. This may
have utility in cancer chemotherapy. SSAT activity is also induced via a variety of other stimuli
including toxins, hormones, cytokines, non-steroidal anti-inflammatory agents, natural products
and stress pathways and ischemia-reperfusion injury. [Pegg 2008] Alterations in SSAT have been
linked to a variety of pathological conditions, e.g. death of pancreatic cells, blockade of
regenerative tissue growth, obesity and diabetes, keratosis follicularis spinulosa decalvans,
behavioral changes affecting a tendency to suicide, cell migration, gene regulation and
carcinogenesis. Thus, it has been suggested that SSAT may also be a useful target in diseases
other than cancer. [Pegg 2008] The SSAT has been cloned [Casero et. al.1991] and the crystal
structure of human SSAT has been determined. [Bewley et. al. 2006] A range of polyamines with
the general structure of H2N(CH2)3NHR are excellent substrates for SSAT, but also di- and
polyamines separated with two methylenes can be acetylated. However, a potent, specific and
cell permeable inhibitor of SSAT is not yet available. [Pegg 2008]
In addition to PAO, there is another polyamine catabolising enzyme in the interconversion
pathway, named spermine oxidase (SMO, see chapter 2.3), which is able to convert SPM directly
to SPD without acetylation, and in the absence of SSAT. However, SMO is not able to catabolise
SPD further. Little is known about the importance of the direct oxidation of SPM vs. its
degradation via acetylation. However, although SPM is not absolutely essential for life, its
transformation into SPD is a fundamental reaction, since without catabolism, SPM accumulates
in blood and causes lethal toxic effects. Extracellular SPM is also known to be cytotoxic. [Seiler
2004, Amendola et. al. 2009]
2.2.2.2 Terminal degradation of polyamines
In addition to PAO/SSAT and SMO mediated degradation, also other oxidases, like copper
containing amine oxidases (such as diamine and serum amine oxidases, DAO and SAO) and
other flavin dependent oxidases (like monoamine oxidase MAO), can metabolize polyamines by
selectively removing primary N-terminal amine. This oxidative deamination of primary amino
groups can lead to corresponding aldehydes which can subsequently be converted to carboxylic
acids by aldehyde dehydrogenases. In addition, terminal deamination may also lead to
subsequent spontaneous ?-elimination of acrolein, i.e. is cleavage at the exo side of the secondary
amine. [Lee & Sayre 1998, Seiler 1995 and 2004, Tabor et. al. 1964b] There are several copper
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containing amine oxidases, but DAO is the most important in polyamine metabolism, being able
to use diamines and the natural polyamines, including most acetyl derivatives, as substrates.
However, although SAO activity is normally low in human plasma, the enzyme is expressed at
considerable levels only in pregnancy and during some pathological conditions such as cancer
diseases, [Agostinelli et. al. 2004] SAO is rich in ruminant serum, which is a component of many
tissue culture media, and thus is a possible source of erroneous interpretation of experiments with
cultured cells. [Seiler 1995 and 2004] Moreover, it is also possible that polyamine metabolism
can occur via an alternative oxidation systems, such as with cytochrome P450. [Vujcic et. al.
2003, Bergeron et. al. 1995] Aminoguanidine (Fig. 4 on page 34) is the most widely used
inhibitor of DAO whereas pargyline (N-Benzyl-N-methylprop-2-yn-1-amine, Fig. 4) inhibits
MAO. [Seiler 2003a and 2004]
2.2.3  Uptake and excretion of polyamines
In addition to biosynthesis, polyamines can be taken up in cells from external sources.
Polyamines, which are partly absorbed to circulation in the gastrointestinal tract from bacterial
and also of dietary origin, as well as polyamines liberated from other cells, may be transported
into the cells. However, the process of polyamine transport in mammalian cells is not fully
understood, as the identity of the mammalian polyamine transporter(s) is still lacking. [Seiler et.
al. 1996] In mammals, functional studies have shown 15 different transport systems for
polyamine movement across cell surfaces. However, very recently some evidence have appeared
that one of the human membrane glycoprotein CCC9 splice variants can behave as a polyamine
carrier system in HEK-293 cells. [Daigle et. al. 2009]
Two models have been suggested for polyamine uptake in mammalian cells. In the first model
the uptake is most likely initiated by a plasma membrane carrier or channel, and this is rapidly
followed by accumulation of the substrate into acidic polyamine-sequestering vesicles. [Soulet et.
al. 2004] The other, endocytic mechanism proposes that polyamines first bind glypican-1 at the
exofacial side of the plasma membrane, and this complex is then internalized via caveolation, and
delivery of the polyamine to the cytosol occurs via an unknown mechanism. [Belting et. al. 2003]
It is known that the polyamine uptake is generally low, but increases in response to proliferative
stimuli such as growth factors, hormones and decreased levels of intracellular polyamines. This
compensation for diminished polyamine formation is in most cases one of the reasons for the
failure of polyamine biosynthesis inhibitors to inhibit cell growth in tumours. Overaccumulation
of polyamines is prevented by regulation system involving AZ. This feedback control of ODC
and uptake can be mimicked by structural analogues of the natural polyamines. Polyamine
transport is also affected by numerous Ca2+ mediated reactions. [Seiler et. al. 1996, Mitchell et.
al. 2007]
In general, the specificity of polyamine transporter is not stringent. In addition to the natural
polyamines, polyamine transport systems are capable of transporting a significant range of
polyamine analogues, such as derivatives with alkyl substituents on the primary amino groups or
substituted carbon chains. Even compounds with a relatively poor structural resemblance to the
natural polyamines may utilize polyamine transport system in some cell lines. For this reason, the
polyamine transport system has been evaluated as a drug delivery vehicle for various toxic,
fluorescent or growth-regulatory agents. Increased polyamine uptake in tumour cells may also
achieve more selectivity. [Seiler et. al. 1996, Mitchell et. al. 2007, Reguera et. al. 2005]
Charge has shown to be critical to polyamine transport and recognition. The affinity of
polyamine transporter appears to increase with the number of positive charges from PUT to
SPM, [Seiler et. al. 1996] and polyamines are better substrates for uptake than acetylpolyamines.
[Sakata et al. 2000] Physiologically tetra-cationic N1,N12-diethylspermine DESPM (Fig. 5 on
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page 36)  can be concentrated to millimolar levels intracellularly, whereas di-cationic N1,N12-
bis(2,2,2-trifluoroethyl)spermine is only poorly transported. If polyamines are vectored to other
molecules, the charge of these cargoes is also important. Neutral or positively charged cargos are
imported effectively, whereas negatively charged cargoes are poorly transported into the cell
through the polyamine transporter system. However, negatively charged cargos can be masked
e.g. to esterase labile esters. [Bergeron et. al. 2005a] In addition, the separation of charges, the
degree of N-alkylation and the spacer unit connecting the N-terminus to the different arylcargoes
have been studied to be key contributors to optimal delivery via the polyamine transporter.
[Phanstiel et. al. 2007, Kaur et. al. 2008, Wang et. al. 2008] It has also presumed that bis-benzyl
polyamine analogues do not utilize the polyamine uptake system, but use some other carrier-
mediated uptake system. [Byers et. al. 1990] Furthermore, cationization of peptides and proteins
by modifying them covalently with di- and polyamines, enables the transport of these large
molecules through the blood brain barrier, and the use of these compounds in
neuropharmaceutical applications. [Hervé et. al. 2008]
The polyamine export in mammalian cells is still poorly understood, but the polyamine uptake
and release are believed to be functions of two different transport systems. [Seiler et. al. 1996]
With respect to the export mechanisms, only the diamine exporter, which catalyzes the export of
PUT and acetylpolyamines via arginine exchange activity, has been identified and characterized
from animal cells. [Uemura et. al. 2008] It has also been demonstrated that PUT and SPD may be
excreted as such, but only traces of SPM are excreted by healthy cells. However, mostly SPD and
SPM are excreted from cells as their acetylated forms, and are first transported to the blood and
then to the kidney for urine excretion. [Seiler et. al. 1996] AZ has been found to stimulate
polyamine and acetylpolyamine excretion in mouse cells. [Sakata et al. 2000] In addition to
acetylated polyamines, also terminal degradation products are normally excreted from the cell.
[Seiler 2004]
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2.3  PAO AND SMO – TWO KEY ENZYMES IN POLYAMINE CATABOLISM
PAO and SMO are two of the key enzymes in polyamine catabolism. The redox cofactor in both
enzymes is flavin-adenine dinucleotide (FAD) which is non-covalently bound to the protein.
Generally flavin amine oxidases catalyze the oxidation of amines via an oxidative cleavage of the
?–CH bond of the substrate to form an imine product with the concomitant reduction of the
flavin cofactor. The imine product is then hydrolyzed to the corresponding aldehyde and
ammonia or amine, depending on the protein and substrate. The reduced flavin coenzyme reacts
with oxygen to form hydrogen peroxide and the oxidized form of the flavin to complete the
catalytic  cycle.  [Binda  et.  al.  2002,  Royo  &  Fitzpatrick  2005]  A  variety  of   mechanisms  have
been proposed for amine oxidation by flavoproteins, including direct hydride transfer from the
neutral amine to the flavin, nucleophilic addition of the amine to the flavin, single electron
transfer reactions, and formation of a substrate carbanion by loss of a proton. However, most
recent data for flavin amine oxidases support the mechanism of direct hydride transfer.
[Fitzpatrick 2007]
Figure 3. General amine oxidation by flavin amine oxidases with direct hydride transfer (Mechanism as in
reference [Fitzpatrick 2007])
No crystal structures of a mammalian PAO or SMO have been described to date, but some
comparable enzyme structures are available. The structure of maize PAO has been described in
oxidized and reduced state, and in a complex with several inhibitors. [Binda et. al. 1999 and
2001] The active site of maize PAO consists of a 30 ångström long U-shaped catalytic tunnel,
whose innermost part is located in front of the flavin ring. [Binda et. al. 1999] However, as the
plant enzymes prefer SPM and SPD as substrates instead of acetylated polyamines, plant PAOs
are rather spermine oxidases than polyamine oxidases. [Royo & Fitzpatrick 2005] True
polyamine oxidases, which prefer acetylated polyamines as substrates include enzymes from
humans [Vujcic et. al. 2003], mice [Wu et. al. 2003], and yeast, [Landry & Sternglanz 2003]
from which crystal structures are available only for yeast spermine oxidase (Fms1). [Huang et. al.
2005a]   The  Fms1  active  site  is  in  a  long  tunnel  with  two  entrances,  and  it  is  located  at  the
interface  of  the  FAD  binding  domain  and  the  substrate  binding  domain.  The  two  ends  of  the
tunnel are hydrophilic, while the middle part is hydrophobic, establishing hydrophobic and
cation-? interactions with active site ligands. Overall, the substrate-binding site of Fms1 is more
hydrophobic than that of maize PAO. [Huang et. al. 2005a, Binda et. al. 2001] However, as Fms1
also oxidizes SPM but not SPD, it may also be considered as a spermine oxidase, thus Fms1
represents also the first SMO whose crystal structure has been determined. [Huang et. al. 2005a]
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In addition, analysis of molecular models of murine PAO and SMO indicates a significant
reduction of the hydrophobic pocket located in maize PAO at the wider catalytic tunnel opening.
[Bianchi et. al. 2006, Cona et. al. 2004] Furthermore, the active site of human lysine-specific
demethylase 1 (LSD1) is highly homologous to that of human SMO and SMO5 (see chapter
2.3.2). However, LSD1 has been found to possess little oxidase activity on the polyamines, but it
can act on mono- and dimethylated lysine 4 of histone H3 through an oxidase reaction almost
identical to the activity of SMO. Similarly to SMO, LSD1 also functions in the nucleus, and
utilizes FAD as a cofactor. [Shi et. al. 2004, Chen et. al. 2006, Murray-Stewart et. al. 2008]
However, as the substrate specificity between PAO and SMO in mammals, and the site of
substrate oxidation between the plant and animal enzymes is known to differ, and the structures
of mammalian PAO and SMO are not available, it has to be stated that little is known of the
structural reasons for these differences. This means that designing of inhibitors and substrates for
human PAO and SMO relies on mainly ligand based methods. Fortunately, cloning of both the
human PAO and human SMO enzymes has made them readily available for recombinant protein
production that has facilitated further testing of their binding and substrate properties. [Wang et.
al. 2003 and 2005a, Vujcic et. al. 2003, Järvinen et. al. 2006a] Recently, also 3D structures of
murine PAO and SMO have been modelled using the crystal structure of maize PAO. [Bianchi
et. al. 2006]
2.3.1  PAO
2.3.1.1 Distribution and biological relevance in mammalian cells
PAO was first characterized in 1977 when Hölttä purified rat liver PAO enzyme. [Hölttä 1977]
Subsequently, PAO has been purified from a few other sources [e.g. Tsukada et. al. 1988, Libby
& Porter 1987, Wu et. al. 2003] and the human enzyme was cloned in 2003. [Vujcic et. al. 2003]
cDNAs corresponding to 12 splice variants of human PAO have been identified later. [Wang et.
al. 2005a] Human PAO is a protein with 511 amino acids with molecular mass of 55.5 kDa.
[Vujcic et. al. 2003]
PAO catalyses the oxidation of the secondary amino groups of polyamines, but the exact nature
of the reduction product depends on the source of the enzyme. Mammalian PAO oxidizes
preferentially N1-AcSPD and N1-AcSPM at the exo-side of N4 nitrogen (Fig. 24 on page 118) into
PUT and SPD, respectively, and in addition 3-acetamidopropionaldehyde and H2O2 is formed.
Conversely, plant, bacterial, and protozoan PAO generally acts on the other side of the secondary
amino group (endo-side of the N4-nitrogen) oxidizing SPD and SPM to 4-aminobutyraldehyde
and 3-(aminopropyl)-4-aminobutyraldehyde, respectively, and in addition 1,3-diaminopropane
and H2O2 are formed. [Tabor & Tabor, 1984] The optimal pH for PAO catalytic activity is shown
to be close to pH 10 [Hölttä 1977, Henderson Pozzi et. al. 2009, Seiler 1995, Vujcic et. al. 2002]
In vertebrates PAO is found to be abundantly expressed in all tissues, and has been shown to be
subcellularly located in both cytoplasm and peroxisomes. [Seiler 1995, Hölttä 1977, Libby &
Porter 1987, Tsukada et. al. 1988, Vujcic et. al. 2003] PAO has a slow turnover rate with a
biological half life of several days. Its expression was found to be inducible by polyamine
analogues and it thus may contribute to the inhibition of cell growth. [Vujcic et. al. 2003]
Moreover, PAO activity has been reported to be lower in certain tumours relative to normal
tissue, suggesting that PAO activity may decrease during tumourigenesis. This may be due to
hypoxia in the cells, where inadequate O2 supply diminishes the O2 dependent oxidation reaction.
[Seiler 2004] However, PAO mediated H2O2 and 3-aminopropanal liberation have also been
proposed to have an impact on apoptotic responses to polyamine analogues. [Ha et. al. 1997]
PAO may also be one of the regulatory enzymes in the production of polyamine cross-links,
which are believed to be involved in skin formation and psoriasis. [Lentini et. al. 2007]
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2.3.1.2 Substrates of mammalian PAO
PAO prefers acetylated polyamines over non-acetylated polyamines, and its natural substrate
ranking is found to be N1-AcSPM ? N1-AcSPD > N1,N12-DiAcSPM >>SPM. [Vujcic et. al. 2003,
Wu et. al. 2003, Seiler 1995, Wang et. al. 2005a] Human recombinant PAO (hPAO-1) oxidizes
most efficiently N1-AcSPD and has very high affinity for N1-AcSPM. N8-AcSPD, SPD, and SPM
were not found to be efficiently oxidized, thereby demonstrating a significant difference in
substrate specificity from the human spermine oxidase SMO. The kinetic values for human PAO
are given in Table 3. [Wang et. al. 2005a, Järvinen et. al. 2006a] Moreover, the recent pH
dependence studies conducted with the mouse PAO and several polyamine analogues proposed
that mammalian PAO requires that nitrogen next to the site of C?H bond cleavage is
unprotonated in order for C?H bond cleavage to occur, and the monoprotonated forms of
substrates are required for catalysis. The requirement for the monoprotonated substrate provides
a potential mechanism of discrimination against SPM by PAO. In addition, the kcat/Kamine values
were essentially identical at pH 10 for the two natural substrates N1-AcSPM and N1-AcSPD, but
at the physiological pH in peroxisomes of approximately 8.2, N1-AcSPM was found to be a better
substrate. [Henderson Pozzi et. al. 2009]
 Table 3. Kinetic parameters for human recombinant PAO
Substrate Km (µM) kcat (1/s) pH Reference
N1-AcSPD 2.1 15.0 8.0 Wang et. al. 2005a
14 8.5 9.5 Järvinen et. al. 2006a
N1 AcSPM 0.85 31.7 8.0 Wang et. al. 2005a
1.1 17 9.5 Järvinen et. al. 2006a
SPM 47 0.4 9.5 Järvinen et. al. 2006a
In addition to the natural polyamines, some terminally N-alkylated, and other polyamine
analogues are degraded by cellular oxidases, including PAO. [Wang et. al. 2005a, Wu et. al.
2003, Vujcic et. al. 2003, Seiler et. al. 2000, Bitonti et. al. 1990, Lawson et. al. 2002, Takao et.
al. 2008 and 2007, Bolkenius & Seiler 1989] It has been clearly shown that human and murine
recombinant PAO is capable of metabolizing DENSPM (Fig. 5 on page 36) [Wu et. al. 2003,
Vujcic et. al. 2003]. However, there is a controversy related to the degradation pathways of the
diethylated SPM analogues. [Wu et. al. 2003] Two metabolic pathways are described in the
literature. One suggests that in mice and dogs, DENSPM and DEHSPM (Fig. 5 on page 36) are
metabolized by deethylation by PAO, followed by step-wise spermidine/spermine-N1-
acetyltransferase (SSAT)/PAO mediated further degradation. [Bergeron et. al. 1995 and 1996]
The other indicates that DENSPM, DEHSPM and DESPM are catabolized like diacetylated
polyamines by human recombinant PAO. [Vujcic et. al. 2003] The rank order of substrate
preference of N-ethylated polyamines by human recombinant PAO was found to be
monoethylspermine  >  DENSPM  >  DESPM  >  DEHSPM.  [Vujcic  et.  al.  2003]  Furthermore,
dibenzyl polyamine derivatives have also been shown to serve as substrates for PAO. Rat liver
PAO is capable of oxidatively cleaving the terminal benzyl groups to form polyamine analogues
with free terminal amines, and this debenzylation is shown to be necessary for the antimalarial
activity in mice. [Bitonti et. al. 1990] In addition, since pig liver PAO in known to mediate
oxidative dealkylation of N-alkyldiaminoalkanes, N-alkylated diamines have been suggested as a
possible prodrug approach for aldehydes. [Bolkenius & Seiler 1989] In addition, some
unsymmetrically N-substituted norspermine analogues, CPENSPM, CHENSPM, and IPENSPM
(Fig.  6  on  page  36),  have  been  demonstrated  to  be  substrates  of  human  PAO,  [Wang  et.  al.
2005a, Lawson et. al. 2002] but further analysis will be required to confirm the identity of the
formed catabolic products. [Wang et. al. 2005a] Finally, also some of the otherwise metabolically
stable, chiral polyamine analogues (Fig. 8) are catabolized by human PAO when certain
aldehydes are present in the reaction mixture. However, the mechanism of the change in the
substrate specificity of PAO due to aldehyde treatment still remains to be elucidated. [Järvinen et.
al. 2006a and 2005] Thus, substrate properties of PAO, as well as the mechanisms of N-alkylated
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polyamine analogue catabolism with PAO, are not entirely clear at present. Moreover, the ability
of PAO to oxidize several polyamine analogues suggests that the oxidase activity of PAO could
have a significant effect on drug sensitivity to these or similar agents. Clarification of PAO
mediated polyamine catabolism might offer invaluable information also for other novel
applications, e.g. for the development of novel inhibitors for PAO, new kinds of prodrug
structures or efficient biocatalytical tools to prepare enantiomerically pure chemicals.
2.3.1.3 Inhibitors of mammalian PAO
An enzyme-activable, irreversible binding PAO inhibitor MDL 72527 (N1,N4-bis(2,3-
butadienyl)putrescine, Fig. 4 on page 34) and some closely related structures were synthesised in
1985. [Bey et. al. 1985] MDL 72527 was found to inactivate, at micromolar concentrations and
time-dependently, the enzyme in cells, as well as in all organs of experimental animals. At
present, it is the only PAO inactivator in use [Seiler et. al. 2002]. Human recombinant PAO
enzyme was inhibited with MDL 72527 with an IC50 < 0.1µM. [Wang et. al. 2005a] Murine PAO
was inhibited with MDL 72527 having a Ki value of 21 µM for N1-AcSPM oxidation [Bianchi et.
al. 2006] or Ki = 1.1 µM for N1-AcSPD oxidation [Wu et. al. 2005] The difference in Ki values
for murine PAO inhibition by MDL 72527 was explained to be due to the N1-AcSPD substrate
used, which has lower affinity for murine PAO, and thus lowers the apparent Ki value. [Bianchi
et. al. 2006] Prolonged incubation (> 10 s) with MDL 72527 results in the formation of a
covalent adduct and an irreversible loss of enzyme activity. [Bianchi et. al. 2006, Wu et. al. 2005]
Certain oligoamine analogues are also potent inhibitors of human PAO. [Wang et. al. 2005a]
Wang et. al. examined a wide range of compounds and noted that three oligoamine analogues,
SL-11144, SL-11150, and SL-11158 (Fig. 7 on page 37), were inhibitors of the recombinant
human PAO enzyme, with SL-11150 and SL-11158 completely inhibiting human PAO activity at
the concentration of 10 µM tested. [Wang et. al. 2005a] Interestingly, 1,12-diaminododecane
behave as specific inhibitors of murine PAO, having a Ki value  of  8.0  µM  for N1-AcSPM
oxidation. This value is markedly lower than for murine SMO (Ki = >10-3 M for SPM oxidation)
indicating the occurrence of basic differences in the ligand binding mode of the two murine
enzymes. Other murine PAO inhibitors found were N-prenylagmatine, and guazatine (Ki =  0.8
µM and 0.45 µM for N1-AcSPM oxidation, respectively). [Bianchi et. al. 2006]
2.3.2  SMO
2.3.2.1 Distribution and biological relevance in mammalian cells
Several groups have reported the cloning and characterization of mammalian spermine oxidase
(SMO), [Wang et. al. 2001 and 2003, Vujcic et. al. 2002, Cervelli et. al. 2003] and human SMO
(also known as PAOh1), which was initially described as PAO, was cloned and characterized in
2001 [Wang et. al. 2001]. A sequence comparison has indicated 39% identity between human
SMO and PAO proteins, the major difference being a 31 amino acid fragment in the middle of
the SMO protein, which is lacking in PAO. [Vujcic et. al. 2003] The human SMO is slightly
heavier than PAO with 555 amino acids and molecular mass of ~62 kDa [Wang et. al. 2001,
Vujcic et. al. 2002]. Three additional splice variants of human SMO were detected later,
[Murray-Stewart et. al. 2002] but the purified recombinant proteins of these variants failed to
exhibit significant oxidase activity on the natural polyamines. However, the possibility does exist
that the SMO splice variants that do not oxidize SPM may oxidize other, as yet undefined,
substrates. Recently a second catalytically active splice variant of SMO, called SMO5 (65kDa),
was described. [Murray-Stewart et. al. 2008] Both active human SMO isoforms exist in the
cytoplasm as well as in nucleus. [Murray-Stewart et. al. 2008] Optimal pH for SMO activity
using SPM as the substrate was measured to be 9.5. [Vujcic et. al. 2002]
Generally,  SMO activity  is  very  low in  cells.  However,  exposure  of  cells  to  inducers  of  SSAT
evokes an increase in the activity of SMO [Vujcic et al. 2002, Wang et al. 2001] Also in cancer
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cells, where polyamine levels are frequently increased, SMO activity has been shown to be
inducible by antitumour polyamine analogues, leading to generation of reactive oxygen species,
lethal DNA damage and the apoptotic type of cell death. [Pledgie et. al. 2005, Devereux et. al.
2003] Furthermore, SMO has been shown to be over-expressed in certain human tumour cells.
This, together with nuclear localization and inducibility with polyamine analogues, increases the
production of H2O2 near to DNA and the potential for oxidative DNA damage in a more selective
manner in tumour cells. The decrease in nuclear SPM levels may also alter the DNA protective
role of SPM. [Murray-Stewart et. al. 2008] However, it is still unclear the extent to which these
effects are due to reactive oxygen species production by oxidative metabolism, or to the
depletion of SPM as a reactive oxygen species scavenger and DNA shielding molecule.
[Amendola et. al. 2009]
2.3.2.2 Substrates of mammalian SMO
SMO possesses very different substrate specificities for the natural polyamines as compared with
PAO. This enzyme prefers non-acetylated polyamines, efficiently oxidizing SPM, less efficiently
N1-AcSPM, and does not use SPD as a substrate. [Wang et. al. 2003] SMO and SMO5 have very
similar  affinities  for  SPM,  and  for N1-AcSPM as  shown  in  Table  4.  A  kcat value  of  SMO  was
found to be approximately 2.4-fold that of SMO5 with either of the substrates. With both
isoforms of SMO, the kcat value of SPM is approximately 27-fold that of N1-AcSPM. [Murray-
Stewart et. al. 2008] Moreover, studies with SMO have revealed that many of the investigated
polyamine analogues have affinity to the enzyme and many of them have been shown to be
inhibitors, but not substrates [Wang et. al. 2003, Vujcic et. al. 2002]. Only monoethylspermine
has shown to be as efficient a substrate as SPM, producing mainly SPD. [Vujcic et. al. 2002]
Table 4. Kinetic parameters for human recombinant SMO and SMO5 [Murray-Stewart et. al. 2008]
SMO SMO5
Substrate Km (µM) kcat (1/s) Km (µM) kcat (1/s)
SPM 0.6 7.55 0.5 3.11
N1-AcSPM 3.0 0.28 3.0 0.12
* Kinetic parameters were determined as described in [Wang et al. 2003]
2.3.2.3 Inhibitors of mammalian SMO
Irreversible PAO inhibitor MDL 72527 inhibits also both human SMO (44% [Vujcic et. al.
2002]) and SMO5 (99% [Murray-Stewart et. al. 2008] as well as murine SMO (Ki = 63 µM for
SPM oxidation with murine SMO). [Bianchi et. al. 2006, Wu et. al. 2005, Bellelli et. al. 2004]
Also several polyamine analogues have also been evaluated as inhibitors [Wang et. al. 2003,
Vujcic et. al. 2002] and of these conformationally restricted oligoamine analogues (SL-11144,
SL-11150, SL-11158 in Fig. 7 on page 37) were found to be potent inhibitors of human SMO
activity. Both SL-11144 and SL-11150 demonstrated an IC50 < 0.1 µM, and were 100 times more
potent than MDL 72527. [Wang et. al. 2003] The same analogues were later found to be also
inhibitors of human PAO. [Wang et. al. 2005a] Murine SMO inhibitors found are N-
prenylagmatine (Ki = 46 µM), and guazatine (Ki = 0.4 µM) for SPM oxidation. [Bianchi et.  al.
2006]
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2.4  POLYAMINE ANALOGUES
Polyamine metabolic pathways have been found to exhibit important interspecies differences
among eukaryotic cells, plants and some bacteria and protozoa. For example, some parasitic
organisms have additional enzymes that are not present in the host cell. Moreover, polyamine
metabolism differs also within the same individual, from cell type to cell type, and changes with
the physiological and pathological situation. Thus, compounds interfering with polyamine
biosynthesis or function provide a target for the design of specific drugs, for example against
parasitic infections, cancer and several other diseases.
A number of specific, single enzyme inhibitors have been developed to block the polyamine
pathway. These have proved to be extremely useful as research tools to elucidate the cellular
functions of the naturally occurring polyamines. In addition, some of the biosynthesis inhibitors
have already yielded clinically useful drugs, particularly for the treatment of parasitic diseases.
Some of these inhibitors are shown in Fig 4. Most of these agents cause a loss of two out of the
three polyamines. For example, DFMO decreases the intracellular content of PUT and SPD, but
has no effect on SPM content. MGBG decreases intracellular SPD and SPM, but increases PUT.
However, inhibition of specific enzymes by single enzyme inhibitors alone has mostly had only
limited clinical success due to disapearance of therapeutic effects due to increased uptake of
extracellular polyamines, or unacceptable toxicity. In addition, some organisms may not
synthesise their own polyamines and are thus resistant to biosynthesis inhibitors. Nonetheless, it
has been proposed that a combination of single enzyme inhibitors with other drugs would present
a more promising approach. [Marton & Pegg 1995, Seiler 2003a, Wallace 2007a]
Figure 4. Enzyme inhibitors for polyamine biosynthesis and catabolism: DFMO-ODC; AdoDATO-SpdSyn;
MGBG-AdoMetDC; AdoDATAD-SpmSyn; MDL72527-PAO and SMO; L-2-amino-4-methoxy-cis-but-3-enoic
acid – AdoMet synthase; Aminoguanidine-DAO; Pargyline-MAO
In addition to single enzyme inhibitors, cellular polyamine metabolism can be influenced by
treatment with polyamine analogues, which are sufficiently similar for the natural polyamines to
allow their recognition and uptake. The advantage of the analogues is that they can target more
than one reaction in the polyamine pathway. For example they can mediate the negative feedback
on polyamine biosynthesis enzymes ODC and AdoMetDC, inhibit the uptake of the natural
polyamines into the cell, and in some cases they can upregulate SSAT. They can also bind to
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intracellular sites, but usually polyamine analogues cannot as effectively replace the other
biological functions of their natural counterparts. Since polyamine analogues can influence
several stages of polyamine metabolism, they can be considered as multi-site inhibitors.
Numerous structural analogues of the polyamines have been synthesised and some of the N-
alkylated polyamine analogues have already shown promising results in various model systems
of chemotherapy. However, the exact mechanisms involved in their cytotoxicity have not been
fully elucidated. Several explanations have been proposed, for example catalysis of polyamines
through analogue-induced SSAT and PAO activities produces H2O2 as a byproduct, and
analogue-induced apoptosis may be in part due to oxidative stress resulting from H2O2
production. However, some analogues, like CHENSPM (Fig. 6 on page 36) do not induce SSAT,
but still induce significant apoptotic cell death in tumour cells. [Casero & Woster 2001, Seiler
2003b, Huang et. al. 2005b, Wallace & Niiranen 2007, Wallace 2007a, Casero & Marton 2007]
According to [Casero & Marton 2007] “The ideal analogue might use the polyamine transporter
to gain entry into the cell, thus competing with the natural polyamines for uptake; downregulate
multiple polyamine biosynthetic enzymes, preventing potential increases in untargeted enzymes;
upregulate polyamine catabolism, resulting in greater intracellular polyamine depletion than
would be afforded by simply decreasing synthesis; reduce all three natural polyamines; Not
substitute for the natural polyamines in growth-related functions; and exhibit tumour-selective
activity.” Some analogues can meet several of these criteria, but it is known that relatively
modest structural modifications in the polyamine backbone or incorporation of terminal N-alkyl
substituent(s) may evoke significant differences in their chemical and biological behaviour.
[Bergeron, et. al. 1997, 2001a and 2005a, Byers et. al. 1990, Seiler 2005]
The precise mechanism(s) by which different polyamine analogues induce cell death is unclear.
However, due to above mentioned differences, polyamine analogues can be divided into two
main categories based on their ability to change the polyamine pool size. Compounds that mimic
regulatory properties of the natural polyamines, induce catabolic processes, suppress biosynthetic
reactions, and thus deplete the pools of PUT, SPD and SPM, are polyamine mimetics.
Polyamines, which prevent cells from growing without depleting polyamine pools to such an
extent as necessary to prevent cell growth, are polyamine antagonists. The mechanism of action
of polyamine antagonists is not well understood, but it is believed that they prevent the natural
polyamines from functioning due to binding to the functionally important polyamine binding
sites. [Seiler 2003b] In addition, some polyamine analogues have been demonstrated to interact
with specific enzymes, such as SMO, being neither exclusively polyamine mimetics, nor
exclusively polyamine antagonists. [Amendola et. al. 2009]
2.4.1  Symmetrically N-alkylated analogues
The first analogues were symmetrically alkylated polyamines (See examples in Fig. 5). Their
synthesis is relatively straightforward and thus several structures containing different kinds of
alkyl substituents, carbon skeletons and length have been prepared. [Woster 2006, Casero &
Woster 2001] For example, N-ethyl substituted polyamines, like DESPM, DEHSPM, and
particularly DENSPM, have displayed a variety of therapeutic effects, like cytotoxic activity. For
example DENSPM competes with natural polyamines for uptake, stabilizes SSAT at RNA and
protein level, activates SSAT (enhances SSAT mRNA productive splicing [Hyvönen et. al.
2006]) and SMO expression, inhibits ODC, down regulates cell growth and induces apoptotic
cell death in tumour cells, and thus depletes intracellular polyamine content. Although initial
studies with DENSPM for anticancer therapy were promising, the clinical trials have not yet
revealed its efficacy as a single agent. [Amendola et. al. 2009] However, recently the combined
use of N-alkylated polyamine analogues with ‘conventional’ non-polyamine based cytotoxic
drugs have shown increased therapeutic potential in comparison with single agent therapy.
[Carew et. al. 2008, Hector et. al. 2004 and 2008]
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Also symmetrical polyamines with properties other than antitumour activity have been prepared.
For example N1,N12-diisopropylspermine (DIPSPM) and related derivatives of SPM are potential
antidiarrheals [Bergeron et al. 2001a and 2001b] and bis-benzyl derivatives have shown promise
as effective drugs against chloroquine-resistant malaria parasites [Bitonti et. al. 1989, Edwards et.
al. 1991a], and activity against several other micro-organisms, like the protozoans Leishmania
donovani [Baumann et. al. 1990], Trypanosoma cruzi [Majumber & Kierszenbaum 1993], the
filarial parasite Brugia pahangi [Müller et. al. 1991] as well as pneumonia causing Pneumocystis
carinii. [Merali et. al. 2000]
Figure 5. Some symmetrically N-alkylated polyamine analogues
2.4.2  Unsymmetrically N-alkylated analogues
The second generation of polyamine analogues are unsymmetrically substituted analogues, some
of which have exhibited more cell type specific responses than their symmetrical counterparts.
However, their synthesis is more complicated, because it requires selective protection and
deprotection of the secondary and primary nitrogens. Some unsymmetrically alkylated polyamine
analogues are shown in Fig. 6. Structure activity studies have revealed that optimal cytotoxic
Figure 6. Some unsymmetrically alkylated polyamine analogues
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activity can be obtained from molecules that possess secondary terminal nitrogens, and at least
one of the two terminal nitrogens of the backbone need to be substituted with a small alkyl group.
In addition, structurally similar compounds, like CPENSPM and CHENSPM, which differ only
in the number of carbons in the cycloalkyl substituents, appear to inhibit cell growth by
completely different mechanisms. [Woster 2006, Casero & Woster 2001] IPENSPM competes
with natural polyamines for uptake, induces both SMO and SSAT (and in that way differs from
CHENSPM), and it can also block the cell cycle at G2/M cell via altered tubulin polymerization,
thus being cytotoxic to tumour cell lines. [Amendola et. al. 2009]
2.4.3  Conformationally restricted N-alkylated analogues
The third group of N-alkylated polyamine analogues include structures in which the rotation of
the central chain is restricted. These include polyamines with inserted cis and trans double
bond(s), triple bond(s) and amines with one or more internal cyclic structures like cis- and trans-
cyclopropyl or cyclobutyl ring and disubstituted aromatic ring. [Woster 2006, Huang et. al.
2005b] These compounds have also shown some antiproliferative effects in human tumour cells.
However, due to their polyamine backbone, they may possess other mechanisms of action than
simply polyamine depletion or replacement, i.e. altering the expression of oestrogen receptor-?,
or DNA aggregation [Casero & Marton 2007, Wallace 2007a] Examples of conformationally
restricted polyamine analogues are shown in Fig. 7. For example, there are currently clinical
trials involving CGC-11093 and CGC-11047 tested as potential antitumour agents and CGC-
11047 as a cure for macular degeneration. SL-11047 has also shown efficacy in a mouse model
as a treatment for Cryptosporidium parvum (intracellular protozoan parasite causing enteric
infection and diarrheal). [Waters et. al. 2000] For example CGC-11047 competes with natural
polyamines for uptake, induces both SMO and SSAT, and thus may exert a positive effect in
several human tumour models in vivo. It also depletes intracellular polyamine content, and has
been claimed to have antiangiogenic activity in macular degeneration in an in vivo model.
[Amendola et. al. 2009]
Figure 7. Some conformationally restricted polyamine analogues
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2.4.4  C-alkylated analogues
In addition to N-alkylated polyamines, also several backbone C-alkylated polyamine analogues
have been prepared. If only one of the hydrogens is substituted, the polyamine backbone
becomes chiral. Both racemic, and enantiomerically pure derivatives, as well as gem-alkylated
derivatives have been synthesised, with the ?-methylated polyamine analogues probably being
the most extensively studied. In contrast to N-alkylated analogues, ?-methylated compounds
seem to fulfill many of the cellular functions of the natural polyamines. However, ?-methylation
prevents the N-acetylation by SSAT, rendering the analogues metabolically more stable than
their natural counterparts. These features mean that ?-methylated analogues are valuable
experimental tools in investigating polyamine metabolism. In addition, some metabolically stable
polyamine analogues have been claimed to represent novel ways to treat acute human
pancreatitis, a disease for which no specific cure is currently available. Furthermore, aldehyde
guided stereospecific catabolism of these chiral compounds with PAO, or possibly a similar
approach with other enzymes, may represent a valuable tool to enable the enzymatic synthesis of
enantiomerically pure compounds. [Keinänen et. al. 2007, Khomutov et. al. 2009]
Figure 8. Some C-alkylated polyamine analogues
2.4.5  Other polyamine analogues
In addition to the analogues described above, a number of other terminally and internally
alkylated and acylated spermidines, spermines, and their analogues, as well as backbone
structures containing different heteroatoms have been prepared for several purposes. These
include several ion channel blockers [Strømgaard & Mellor 2004, Kashiwagi et. al. 2007,
Melchiorre et. al. 2003] and drug candidates for neurodegenerative diseases, like Alzheimer’s
disease [Bolognesi et. al. 2009], neuroprotective agents after the induction of various types of
neurotrauma, like ischemia, [Li et. al. 2007] potential antitumour agents [Casero & Woster 2001,
Seiler 2003b, Huang et. al. 2005b, Woster 2006, Casero & Marton 2007] vectors for drug and
gene delivery [Blagbrough et. al. 2003, Seiler 2003b, Casero & Marton 2007] drugs for parasitic
diseases, e.g. malaria and African trypanosomiasis [Boncher et. al. 2007, Bacchi & Yarlett 2002,
Casero & Woster 2001] bacterial and virus infections [Liang et. al. 2006, Yingyongnarongkul et.
al. 2008] as well as antiarrhythmics and antidiarrheal compounds. [Bergeron et. al. 1998, 2001a
and 2001b] Some chemically subdivided examples of these polyamine derivatives are presented
in the following chapters.
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2.4.5.1 Polyamine conjugates
Lipid-polyamine conjugates, typically long alkyl, alkenyl or steroid covalently attached to
branched, linear or cyclic polyamines, can be used as non-viral vectors for plasmid DNA and
siRNA delivery. [Blagbrough et. al. 2003, Ghonaim et. al. 2009, Unciti-Broceta et. al. 2008,
Huang et. al. 2008] Oligonucleotide and nucleoside-polyamine conjugates have also been studied
as potential carriers of nucleosides and modified oligonucleotides into the cell. [Winkler et. al.
2009, Wu et. al. 2007b] When polyamines are conjugated to cytotoxic drugs this increases their
DNA binding and cytotoxicity, as well as facilitating selective uptake of these antitumour agents
by the tumour via the polyamine uptake system [Barret et. al. 2008]
2.4.5.2 Polyamines containing heteroatoms
Several polyamines have been synthesised, which contain also other heteroatoms in addition to
nitrogen. As an example, boron-containing polyamines have been developed as potential agents
for neutron capture therapy. Oxapolyamines, polyamines bearing an aminooxy group have
demonstrated cytotoxic and bacteriostatic properties and are useful tools in generating further
information on the role of polyamines in biological systems. A peptide polyamine conjugate
containing the phosphinate group in the polyamine chain was found to be a potent inhibitor of
one of the key enzyme in trypanothione biosynthesis. Dimethylsilane tetramines were originally
considered as candidates for antineoplastic therapy, but they have not been very successful.
Polyamines with a thiophene component in the chain have been used in the elucidation of the
physiological significance of polyamine regulatory site of the NMDA receptor complex. [Kuksa
et. al. 2000, Seiler 2003b]
2.4.5.3 Polyamine based complexes and macrocyclic polyamines
Polyamines can also be utilized in complexes. For example, polyamine platinum complexes are
potential cytotoxic drugs. [Hegmans et. al. 2008, Seiler 2003b] Polyamine vectored iron chelators
have beed developed for iron dependent diseases, like hereditary anemia, and Parkinson’s disease
[Bergeron et. al. 2005a] Technetium polyamine analogues have been claimed to have potential in
tumour imaging purposes [Wan et. al. 2008] Macrocyclic polyamines with a large number of
donors and cavities of appropriate shape and dimension are superior ligands for transition metal
ions and lanthanides. These cyclic chelates and free cyclic amines have several medical
applications, for example as agents with anti-viral (e.g. HIV) or antitumour activity, and contrast
agents for magnetic resonance imaging (MRI). [Liang et. al. 2006, Cohen 1998] A reticular,
cyclic polyamine based polymer has also been studied as a gene delivery vector in DNA
transfection [Zhou et. al. 2009]
2.4.5.4 Labelled polyamines
Isotopic polyamine derivatives have particular value in dissecting the physiological significance
of the compounds. They enable the application of 13C- and 15N-NMR and mass spectrometry in
the study of the polyamines in intact cells and in their association with large structures and
molecules. [Cohen 1998] The isotope labelled polyamines, their use and labelling techniques will
be reviewed in more detail in chapter 2.6.
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2.5  SYNTHESIS OF POLYAMINES AND THEIR ANALOGUES
Various protocols have been developed for the synthesis of polyamine analogues and conjugates.
A number of N-alkylation methods and reduction of nitriles, azides, imines or amides have been
applied in solution-phase synthesis, and the majority of these transformations are also used in
solid phase synthesis as well. However, in all cases, the selective functionalization of multiple
amines in polyamine backbone and purification of the highly hydrophilic products is challenging.
Generally, the methods can be divided into two groups: One can attempt selective
fuctionalization/protection of the amino groups in polyamine backbone or alternatively there are
fragment based synthesis protocols to build up the molecule. The latter offers greater flexibility,
as the polyamine skeleton can be obtained at the appropriate length with the desired number of
differently protected amines and other possible labels and substituents in the chain. These types
of compounds can be subsequently used in selective reactions.  Solid phase procedures enable the
synthesis of the polyamine moiety either by a linear strategy or alternatively by constructing the
polyamine backbone from the centre, thus allowing modifications at either end of the polyamine.
[Bradshaw et.al. 1992, Karigiannis & Papaioannou 2000, Kuksa et. al. 2000, Salvatore et. al.
2001, Olsen et. al. 2005]
2.5.1  Methods utilizing selective functionalization
Direct selective protection of primary amine groups in polyamines has been achieved using
various groups, like phthalyl (Pht), benzyloxycarbonyl (Cbz), and tert-butyl carbamate (Boc)
(See Fig. 9). Potassium phthalimide is convenient reagent to have terminal amine from halogen
compounds, as hydrazine hydrate cleavage of the Pht group leads to the primary amine. Selective
bis-acylation has been achieved with a variety of activated carboxylic acids. Indirect
functionalization of primary amines is obtained by protecting all amine groups e.g. first with
sulfonyl chlorides like toluenesulfonylchloride (TsCl), mesitylenesulfonylchloride (MtsCl), and
2-nitrobenzenesulfonylchloride (NsCl), or a Boc group followed by alkylation with alkyl halides.
Subsequent removal of the protection groups yields bis-alkylated polyamines. However, steric
hindrance of the protection groups may prevent the reaction of secondary and tertiary alkyl
halides. Protection of secondary amino groups may be performed using temporary protection of
primary amines, or directly utilizing metal complexes. Also secondary amines separated from
another amine with propylene moieties can be protected using a reaction either with
formaldehyde, benzaldehyde or other aldehydes leading to corresponding hexahydropyrimidine
derivatives. [Bradshaw et. al. 1992, Karigiannis & Papaioannou 2000, Kuksa et.al. 2000]. Several
other protection groups for amines are available. [Theodoridis 2000, Greene & Wuts 1991]
Figure 9. Examples of some protection groups used in polyamine synthesis
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2.5.2  Fragment based polyamine backbone elongation
2.5.2.1 Michael addition
One of the oldest and very frequently used methods to extend the polyamine chain is the Michael
addition of diamines to acrylonitrile (see Scheme 1). The subsequent reduction of the nitrile
group produces aminopropyl moieties in one or both amines in the diamine. The method allows
the variation of the tetramethylene chain in the natural polyamines, like SPD and SPM, and also
stepwise chain elongation with several aminopropyl moieties. Unfortunately Michael addition
reaction involving unprotected primary amines can sometimes lead to mixtures of mono- and bis-
cyanoalkylated amines. However, this ability to bis-alkylation has also been utilized in the
synthesis of linear and branched polyamines. For example N-alkyl-bis(3-aminopropyl)amines are
prepared by bisconjugate addition of alkylamines to acrylonitrile and subsequent catalytic
hydrogenation. [Denton et. al. 2007] Also Michael addition of amines with or without catalyst
using several ?,?-unsaturated carboxylic esters, ketones, nitriles and amides in aqueous medium
have been studied, which may be utilized in polyamine synthesis. [Ranu & Banerjee 2007,
Polshettiwar & Varma 2007] C-methylated polyamine analogues are obtained using e.g.
crotononitrile as the Michael acceptor. Also the Michael reaction between protected diamine and
methyl vinyl ketone gives the diketone, which can be subsequently converted to the dioxime and
then reduced and deprotected to the C-methylated tetramine. [Bradshaw et. al. 1992, Kuksa et. al.
2000, Karigiannis & Papaioannou 2000]
Scheme 1. Examples of Michael addition
2.5.2.2 Direct N-alkylation of primary amines
Direct N-alkylation is the most common and straightforward route to prepare secondary amines.
However, treatment of primary amines with alkyl halides is of limited value due to
overalkylations, which lead to the mixture of primary, secondary and tertiary amines, as well as
quaternary ammonium salts. However, polyamines have been prepared by treatment of an alkyl
halide with a large excess of primary diamine, which may prefer the secondary amine formation.
In addition, other reaction parameter optimisations, like reaction temperature, time and used
additives, as well as steric hindrance near the amine nitrogen may prevent overalkylation.
Moreover, also other reagents like bromo- or chloronitriles, N-(bromoalkyl)phthalimides,
alcohols with metal catalysts and masked alcohols, such as sulfonates, oxiranes, alkyl phosphates
and alkyl phosphites can be used to alkylate suitable amines. Due to the poor selectivity of direct
alkylation, the amines can also be protected with applicable protecting group(s) prior alkylation.
[Salvatore et. al. 2001, Karigiannis & Papaioannou 2000, Kuksa et. al. 2000]
2.5.2.3 Fukuama sulfonamide alkylation and Mitsunobu conditions
The alkylation of sulfonamides, like Fukuyama alkylation (Scheme 2) [Fukuyama et. al. 1995], is
an efficient method to prepare secondary amines both in solution-phase and on the solid-phase.
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 Scheme 2. An example of the Fukuyama alkylation and the subsequent sulfonamide deprotection
Sulfonamides of Ts, Mts, and trifluoromethanesulfonamides, 2-nitrobenzenesulfonamides
(NsNH-), 4-nitrobenzenesulfonamides, and 2,4-dinitrobenzenesulfonamides can be alkylated
with either alkyl halides under basic conditions, or with alcohols under Mitsunobu conditions,
[Mitsunobu 1981] that is the condensation between an acidic proton, as is present in sulfonamide,
and a primary or secondary alcohol in the presence of diethylazodicarboxylate (DEAD) and
triphenylphosphine (PPh3). Also other Mitsunobu reagents can be used, including N,N,N’,N’-
tetramethylazodicarboxamide, 1,1’-(azodicarbonyl)dipiperidine (ADDP) and
tetraisopropylazodicarboxamides. The product is a tertiary sulfonamide, which can be
deprotected under relatively mild conditions using thiol and base, yielding the corresponding
secondary amines. [Salvatore et. al. 2001] Mitsunobu conditions are also utilized to prepare
chiral C-alkylated polyamines, with the subsequent sulfonyl groups being removed also without
loss of chirality. [Bradshaw et. al. 1992]
On resin Fukuyama-Mitsunobu coupling has been used to synthesise polyamine derivatives by
loading the symmetrical triamine onto the resin, treating with NsCl and alkylating the resulting
terminal secondary sulfonamide with N-Fmoc-4-aminoalcohol using DEAD-PPh3. The piperidine
treatment released the terminal primary amine to be further derivatized. Asymmetric polyamines
have been synthesised on the solid phase using the Tsunoda redox pair (ADDP-PBu3). [Olsen et.
al. 2005]
2.5.2.4 Reductive alkylation and reduction of Schiff’s base
Condensation between a primary amine and a carbonyl compound yields the imine, called a
Schiff’s base, which can be reduced to substituted amine. Schiff’s bases may also be formed via
an aza-Wittig reaction, where an azide is reacted with triphenylphosphine followed by the
addition of the aldehyde giving the corresponding imine, which can then be reduced to the amine
(Scheme 3). However, due to imine instability, difficulties may be faced when trying to obtain
pure imines. If the amine is treated with an aldehyde or ketone in the presence of reducing agent,
the method is called reductive alkylation. The possible overalkylation can be minimized using
less than one equivalent of the carbonyl group. Mono-N-alkylation of amines by reductive
alkylation can also be performed on the solid phase. The most commonly used reducing agent is
NaBH4, and its derivatives, like NaBH3CN and NaB(OAc)3H), or hydrogenation with 5% Pd on
carbon. [Kuksa et. al. 2000, Salvatore et. al. 2001]
Scheme 3. A) Formation and reduction of Schiff´s base (R´= H, alkyl, aryl, etc.). B) Schiff´s base formation
via Aza-Wittig reaction
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2.5.2.5 Reducion of amides, nitriles, atzides and nitro group
The reduction of amides, nitriles and azides provides a simple method for incorporating amines
into polyamine backbone. Polyamine chain elongation may be performed by acylation of suitable
amines with activated carboxylic acids and reduction of the obtained amides to the corresponding
amines. The most widely used reducing agents for this task are LiAlH4 and  BH3-THF.
[Karigiannis & Papaioannou 2000] Resin bound chiral polyamines have been obtained by
reducing peptide libraries with BH3-THF and dissociation of the intermediate polyamine-borane
complexes with piperidine. [Olsen et. al. 2005]
Reduction of the nitrile group to amine is commonly carried out with catalytic hydrogenation
using various catalysts, like PtO2 or Raney Ni, or with metal hydrides like LiAlH4. Byproduct
formation during hydrogenation is prevented by addition of ammonia and inorganic bases, such
as sodium hydroxide or lithium hydroxide, to the solution containing the nitrile. Also direct
acylation of the product primary amine with acetic anhydride or by protonation with acids has
been utilized. In addition, a large molar excess of LiAlH4 may be needed to minimize secondary
and tertiary amine byproduct formation. [Denton et. al. 2007] Optically active C-alkylated
polyamines have been performed using chiral nitriles as starting materials. [Grigorenko et. al.
2005]
Azides can function as masked amino functionalities in the reactions. Reduction of azides
normally involves mild reaction conditions, like hydrogenation with Lindlar catalyst, Raney Ni
or Pd, or reduction with BH3-THF. Another possibility is the Staudinger reaction (PPh3 and
water). However, the toxic and explosive nature limits the use of azides. [Carboni et. al. 1993,
Carrington et. al. 1999] Certain C-alkylated polyamines have also been prepared using nitro
compounds as amino group sources by reducing the nitro group with NaBH4-Ni2B. [Nagarajan &
Ganem 1986]
2.5.2.6 Other methods for polyamine synthesis
The reaction between an azide and an alkyl dichloroborane has been used for the synthesis of
symmetrical di- and tetramines. (Scheme 4A) [Carboni et. al. 1993] C-alkylation in polyamine
chain extension has been performed by alkylation of 3-trimethylsilyl-N-butoxycarbonylprop-2-
ynylamine with N-Boc-protected alkyl iodide in the presence of an excess of strong base
(Scheme 4B). [Casara et. al. 1985] 1- and 2-alkylputrescines are synthesised starting from 2- and
3-alkylpyrroles, respectively, [Garrido et. al. 1988] and substituted furans have been used as
starting materials to prepare several aminomethyl and/or hydroxymethyl substituted putrescines.
[Frydman & Ojeze 1998] Ring opening of epoxides has been used in the synthesis of
hydroxylated, and other polyamine derivatives (Scheme 4C). [Edwards et. al. 1991b, Bergeron et.
al. 2005b] Recently a direct access to nonsymmetrical alkyl polyamines was introduced, where
symmetrical secondary diamines are incorporated into the four-component Ugi reaction (Scheme
4D). In this reaction, one of the diamine nitrogens undergoes acylation and the other is subjected
to alkylation. [Pirali et. al. 2008] Also chemoselective N-acylation via condensations of N-
(benzoyloxy)amines and ?-ketophosphonic acids under aqueous conditions may be utilized later
in the polyamine synthesis (Scheme 4E). [Arora et. al. 2008]
Merja Häkkinen: N-Alkylated Polyamine Analogues – Deuterium Labelling, LC-MS/MS Analysis and Catabolism…
44 Kuopio Univ. Publ. C. Nat. and Environ. Sci. 263: 1-145 (2009)
A
B
R1 N3
C
D
TMS
NHBoc
I R
TMS
NHBoc
R
NH2
R
BuLi
TMEDA
i) MeONa/MeOH
ii) HCl/Et2O
B R2
Cl
Cl
N
B
R1 N2
R2
Cl
Cl
N B
Cl
Cl
R2
R1
NH
R2
R1
-N2
O
R1 H2N
R3
R2
R1
N
R3
OH R2
R1
H
N
R3
NH2
R1
N
R3
O R2
R1
H
N
R3
CXY
X, Y = H,H/
H,Cl/ H,CH3
E O
H
N
R1
O
P
R2 R2
O
R3
O
t-BuOH/H2O NH R
3
O
R1
Ph N
H
N
H
Ph R1
O
H R2 NC R
3 HN
OH
O
O
R3
H
N
N
H
N
H
H
N
R2
i) N-split Ugi
ii) Reduction and Hydrogenolysis
Scheme 4. Some unusual methods for polyamine chain elongation A) Reductive alkylation of an azide by
alkyl dichloroborane B) An example of C-alkylaton in polyamine chain extension C) Ring opening of
epoxides in the synthesis of polyamine derivatives D) Four-component Ugi reaction in the synthesis of
nonsymmetrical polyamines E) Amide formation with N-benzoyloxyamines and ?-ketophosphonic acids
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2.6  STABLE ISOTOPE LABELLED MOLECULES
Stable isotope labelled compounds have been utilized widely in chemical and biomedical
research. They are widely used as internal standards in MS quantification (see chapter 2.9.6), and
they are also valuable in verifying the proposed MS fragmentation pathways as well as
establishing the mechanism of organic reactions. Stable isotope labelled analogues are also useful
in analysis of the metabolism of drugs and toxic substances and structure of their metabolites.
They represent invaluable tools in studying the mechanisms of enzymes, the site of drug binding
and biotransformation, complex metabolic pathways, and metabolism-mediated toxicities. When
combined with the innovations in the MS and NMR technologies stable isotope labelled
compounds are now being utilized in a number of fields including adsorption, distribution,
metabolism and excretion (ADME) studies. Deuterium labelling plays also a critical role in the
examination of the secondary and tertiary structures, and dynamics of biomolecules.  [Mutlib
2008, Kushner et. al. 1999, Gardner & Kay 1998, Leis et. al. 1998, Cleland 1982, Haskins 1982]
2.6.1  Methods for deuterium labelling
Basically, two strategies are followed for the synthesis of isotopically labelled compounds. One
can either start from commercially available, stable isotopically labelled precursors, or one can
attempt to label the target molecule or an intermediate in the synthesis by different methods.
Deuterium remains the most useful nucleus to obtain stable isotope labelled compounds. In many
applications, several labels are necessary, and deuterium is the most widely accessible stable
isotope, since it is available at low cost and high isotopic purity, and it is often synthetically
straightforward to incorporate more than one deuterium atom into the molecule.
Several methods can be used for the introduction of one or more deuterium atoms into molecules.
One of the oldest techniques is the acid-or base-catalyzed H-D exchange to an activated
positions, like ?-hydrogens in carbonyl containing compounds, ?-hydrogens in ???-unsaturated
ketones and related species. However, the reverse exchange of deuterium for hydrogen can take
place, so further chemical steps are often necessary to achieve stable compounds. In addition,
H/D-exchange reactions without the addition of acids and bases to the acidic CH position, are
possible simply by the use of deuterium oxide, which can act as either an acid or a base due to its
ampholytic nature. Exchange reactions can also be carried out in the presence of homogenous or
heterogenous metal catalysts. For example, soluble catalyst complexes, like cationic iridium,
platinum, rhodium and ruthenium complexes, offer mild reaction conditions and a high degree of
tolerance towards a number of functional groups. Also a high efficiency for H/D exchange has
been found with heterogenous palladium, platinum, rhodium, nickel, and cobalt catalysts with
gaseous deuterium, D2O and deuterated protic solvents as deuterium sources. The advantage of
heterogeneous over the soluble catalyte is the possibility to remove the catalyst by simple
filtration at the end of the reaction. Moreover, deuterolysis of an organometallic compound,
isotope-exchange reactions with treated support-bound reagents, such as zeolites or sulfated
zirconium dioxide, polymer bound acids and other solid phase catalysts, may be utilized in the
deuteration. In addition, base catalysed supercritical and near-critical exchange methods and
different microwave techniques have led to new methods for H-D exchange. [Atzrodt et. al.
2007, Junk & Catallo 1997]
In addition to H-D exchange techniques, deuterium can also be inserted into a molecule by
halogen/deuterium exchange utilizing the methods of metal-mediated hydrodehalogenation of
organic halides, where the most important chemical methods are catalytic hydrogenation,
reduction with metals or low-valent metal compounds, reduction with metal hydrides or complex
metal hydrides, and reduction with some strong nucleophilic neutral or anionic species. The ease
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of reductive hydrodehalogenation of organic halides follows the general order I > Br > Cl >> F,
and the cleavage of the carbon-halogen bond is favored in the order aliphatic < aromatic < vinylic
< allylic < benzylic. [Alonso et. al. 2002]
A variety of reductive hydrogenation methods are available [Hudlický 1984, Blaser et. al. 2003,
Zassinovich et. al. 1992, Johnstone et. al. 1985, Brown & Krishnamurthy 1979], and several of
these reactions can also be applied for deuteration as well. Catalytic deuteration of different
unsaturated functionalities with deuterium gas (D2) is probably the most widely used deuteration
method. For example, D2 mediated reduction of unsaturated compounds, like double and triple
bonds,  using distinct catalysts, like 5% palladium-on-carbon, nickel acetate or Wilkinson’s
catalyst (RhCl(PPh3)3), have been frequently used. [Leis et. al. 1998] Also catalytic transfer
deuteration methods are common. For example, the SmI2/D2O system,  which  can  been  used  to
deuterate double and triple bonds, [Concellón et. al. 2004 and 2002] as well as in the
transformation of epoxyesters to 2,3-dideuteroesters. [Concellón et. al. 2003] Microwave-
enhanced double bond deuteration has been performed using RhCl3 and DCOOK in D2O as the
deuterium source. [Chappelle et. al. 2002] The most widely used metal deuteride reductions
include reduction with NaBD4,  and LiAlD4, but also other methods, like reduction with lithium
perhydro-9b-boraphenylallyl hydride, NaBD4 in the presence of Pd(II)Cl2 and inorganic
deuterated hydrazine hydrate have been reported. [Leis et. al. 1998] For example, some optically
active deuterated primary amines have been synthesised by enantioselective reduction of
aldimines with NaBD4 and catalyzed by optically active cobolt complexes. [Miyazaki et. al.
2003] Furthermore, also labelled reagents for the opening of chiral epoxide have been utilized in
deuteration. [Shattuck & Meinwald 1997]
In addition to the many chemical methods, also enzymatic methods can be utilized in the
syntheses of chirally pure isotopically labelled compounds. Biosynthetic routes may offer the
possibility to readily obtain even complex biomolecules and metabolites in a suitable labelled
form. [Junk & Catallo 1997, Leis et. al. 1998, Winkler et. al. 1995]
2.6.2  Isotope-labelled polyamines
The atoms in polyamines which could be labelled are H, N and C, and also more than one type of
labels have been incorporated into the one molecule. The simplest way to prepare deuterium
labelled polyamines is the N-deuteration by simply mixing the amines with D2O, but the products
are not stable.Various stable, backbone deuterated analogues of DAP, PUT, and other diamines
as well as SPD and SPM have been prepared by catalytic deuteration of nitriles with D2 using
transition metal catalytes (PtO2, Pt). [Smith & Daves 1978, Shipe et. al. 1979, Van den Berg et.
al. 1984, Callery et. al. 1992, Dorhout et. al. 1997] Also acid- and base catalysed exchange of
carbonyl containing compounds has been utilized in the deuteration of propane-1,3-diamine.
[Jentgens et. al. 1997] Catalytic cis-deuteration of 5,6-dihydro-2H-pyran-2-one using
Wilkinson’s catalyst is used to prepare diastereospecifically deuterated SPD. [Maryoshi et. al.
2004] Triple bonds can also be reduced using this same catalyst in order to prepare deuterated
diaminohexane. [Moser et. al. 2007] Chirally deuterated spermidines are synthesised using
chirally deuterated amino acids and enzyme catalysed alkyl transfer. [Orr et. al. 1988] Deuterium
labelled SPD, N1-AcSPM and N1-AcSPD are prepared starting from [1,1,3,3-D4]-DAP. [Gawandi
& Fitzpatrick 2007] Cyclic SPM derivative D8-(S)-dihydroxyverbacine, was synthesised starting
from [1,1,2,2,3,3,4,4-D8]-butane-1,4-diol. [Nezbedova et. al. 2000] Nitrosation of the secondary
amino groups of 1,4,7-triazacyclononane has enabled a straightforward perdeuteration of the
macrocycle by H/D exchange in alkaline solution, and the subsequent denitrosation by reduction
with Ni/Al alloy produced the labelled cyclic polyamine. [Pacchioni et. al. 2002]. Tritiated
analogues have been prepared for example by reducing nitriles with NaBT4/CoCl2 complex,
[Khomutov et. al. 1996] or catalytic tritiation with 3H2 and  PtO2,  [Fischer  1975]  as  well  as
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catalytic tritiation of triple bond with 3H2 and Pd/BaSO4 or Pd/C. [Shevchenco et. al. 1995,
Fischer 1975]
Symmetrically 13C labelled SPM and PUT, as well as several SPD derivatives, have been
synthesised using K13CN as the 13C source [Samejima et. al. 1995, Geneste & Hesse 1998],
whereas 14C  labelled  SPD  and  SPM  have  been  obtained  by  using  1-14C-acrylonitrile or 1-14C-
PUT as the starting material. [Jackson & Rosenthal 1960] 11C-labelled polyamine analogues can
be prepared by labelling phenolic alkyl groups with [11C]methyl iodide. [Sasaki et. al. 2004]
15N enriched PUT, SPD and SPM are obtained using labelled potassium phthalimide or
ammonium sulfate as a 15N source,[Samejima et. al. 1984] and 15N labelled acylpentamines have
been prepared using 15N-benzylamine on a solid phase.[Manov et. al. 2004] 15N together with 13C
labelled polyamines were prepared using K13CN and potassium [15N]phthalimide [Hara et. al.
2000] or K13C15N as isotope sources, [Xu et. al. 2002] and 15N together with deuterium labelled
[15N2,D4]PUT,  [15N2,D4]SPD  and  [15N2,D4]SPM were prepared starting from [1,1,4,4-D4]1,4-
dibromobutane using the same methods [Samejima et. al. 2007]. 15N and  D labelled PUT and
DAP have also been synthesised via Hofmann degradation of [15N2,D8]-adipic acid diamine or by
Gabriel synthesis from 1,3-dichloropropane and 15N-phthalimide, respectively [Scherer &
Limbach 1994]
Very recently, deuterated as well as D together with 13C labelled SPDs were prepared utilizing
several labelling methods, like catalytic cis-deuteration of the unsaturated lactame or lactone with
Wilkinson’s catalyst, reduction of ester with LiAlD4, and base catalysed exchange of carbonyl
and/or nitrile containing compounds. 13C was achieved from K13CN or from bromoacetic-2-13C
acid. [Maryoshi et. al. 2009]
2.6.3  Deuterium isotope effects
The difference in mass between deuterium and protium causes the vibrational frequencies of C-D
bonds to be lower than for the corresponding C-H bonds. This means, that bonds involving
deuterium are stronger and have shorter length than the corresponding bonds in hydrogen. These
differences may be enough to confer significant changes, called isotope effects, in biological and
chemical reactions. The deuterated forms of drugs may have different pharmacological effects
than the protonated forms due to several reasons. Some deuterated drugs show altered transport
or penetration properties. More often deuteration leads to increased metabolic stability. In
particular, the modifications mediated by cytochrome P450 systems have been studied.
Deuteration may also change the pathway of drug metabolism, so called “metabolic switching”.
Altered metabolism may lead to increased duration of action and lower toxicity. It may also lead
to lower activity, if the drug is normally metabolized to the active form in vivo. [Kushner et. al.
1999, Nelson & Trager 2003, Haskins 1982]
Conventional deuterium isotope effects include changes in the rate of cleavage of covalent bonds
to deuterium, or to an atom located adjacent to deuterium, in a reactant molecule compared to a
non-labelled molecule. These effects are known as primary and secondary isotope effects,
respectively, and can be used for example as tools for determining enzymatic mechanisms.
[Cleland 1982] Tenfold difference in the rates of cleavage between C-protonated and deuterated
compounds are common, but secondary isotope effects are usually small. [Kushner et. al. 1999,
Haskins 1982] However, using a series of otherwise symmetrical diamines, but bis-deuterated on
the one of the methylenes alpha to the amino group, have shown 1.45-10.5-fold preference of
diamine oxidase for deamination reaction at the unlabelled methylene amine end. [Callery et. al.
1992]
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In addition, a deuterium isotope effect on non-covalent interactions between molecules can also
be considerable.  For example, deuteration may result in a more polar molecule, which may cause
differences in the retention times in chromatographic columns for deuterated and unlabelled
compounds. This effect on polarity may become more pronounced as the number of deuteriums
in the molecule increases. If the deuterated molecule also contains heteroatoms (e.g. N, O, S),
this polarity increase (or decrease), will depend on the position of deuterium substitution with
respect to the location of heteroatoms in the molecule. The site of isotopic modification can also
affect the other physicochemical properties of the molecule, such as ionisation, solubility, and
molecular geometry. Thus, the changes in these properties can have considerable influence on the
molecule’s distribution, binding affinity to transport proteins and enzymology, as well as other
data interpretation from experiments involving deuterium labelled compounds. [Wade 1999]
For example, introduction of a deuterium nucleus into the molecule induces small changes in
chemical shifts in the 1H and 13C NMR spectra. In the 1H NMR spectra, the deuterium exchanged
proton signals in the molecule disappear and because proton-deuterium coupling constants are
small, the remaining coupling patterns are simplified. In addition, substitution of hydrogen by
deuterium causes changes in the chemical shift of nearby protons or carbon atoms. These close
range effects are typically around 0.01 ppm for 1H or 0.2-1.33 ppm for 13C. Moreover, when the
protons are replaced by deuterium, the spin-lattice relaxation time (T1) for the deuterated carbon
may be more than one order of magnitude greater than that of the comparable protonated carbon.
This may mean that with normal recycle delay for carbon measurements (D = 3 s) deuterated
carbons may either not show up or appear with much reduced intensity. Thus, usually the
intensity of the deuterated carbon signal in the 13C NMR spectra appears as a low intensity signal,
closely upfield to the corresponding non-deuterated carbon. In addition, since deuterium is a spin
1 nucleus, the signal will be split into a multiplet due to 13C–2H J coupling depending on how
many deuteriums are attached to the carbon (1:1:1 triplet for CD and 1:2:3:2:1 quintet for CD2).
[Akitt 1987] Also IR vibrations may be changed due to deuteration. According to the literature,
the range for C–D stretches is 2200–2080 cm-1, while C-H stretches appear around 3000-2800
cm-1. [Pretsch et. al. 2000]
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2.7  IN VITRO METABOLIC STUDIES
In vitro metabolic studies play a critical role in the drug discovery, development and approval
stages of a new therapeutic agent. During the pre-clinical phase of drug development, these kinds
of studies include the evaluation of metabolic stability, the identication of specific enzyme(s)
involved in metabolism, the identification and structural determination of the metabolic end
products, assessment of the site(s) and rate of metabolism, as well as detection of drug interaction
issues related to enzyme inhibition and induction. The possible in vitro systems for these studies
include the incubation of the studied compound with recombinant enzymes, cell cultures from
transgenic and a number of other different cell lines, subcellular fractions, (like liver microsomes
and cytosols), cellular organelles (such as hepatocytes), or with precision cut liver slices. Pure
recombinant enzymes and transgenic cell lines are excellent tools as they allow the study of
single enzyme reactions and kinetics. It is possible to elucidate the influence of one isoenzyme or
a combination of a number of isoenzymes on the biotransformation and for example to screen for
differences in cytotoxicities of the metabolites. Pure enzymes can also be used to generate
metabolites for structure elucidation and pharmacological characterization and to assess the
potential drug–drug interactions at the metabolic level. [Ekins et. al. 2000, Hariparsad et. al.
2006]
A variety of techniques including NMR, radioimmunoassay (RIA), gas chromatography/mass
spectrometry (GC/MS), and LC with UV, fluorescence, radioactivity and MS detection, are
employed in the identification and quantification of drugs and their metabolites. If the
concentrations of the metabolites are very low, highly specific and sensitive analytical methods,
like LC-MS/MS (see chapter 2.9) are then desirable. [Kostiainen et. al. 2003, Prakash et. al.
2007, Hol?apek 2008]
50 Kuopio Univ. Publ. C. Nat. and Environ. Sci. 263: 1-145 (2009)
2.8  METHODS FOR POLYAMINE ANALYSIS
Analysis of biogenic amines is a subject of increasing interest in biological sciences and food
chemistry. For example, as polyamine concentrations may change drastically in many
pathological conditions, such as in cancer, their measurements in biological fluids and tissues
may have clinical relevance. Determination of extracellular polyamines may be useful for
estimation of therapy efficacy, and monitoring of disease progression and recurrence. Different
polyamine analogues have potential use as therapeutic agents for several diseases, and thus their
mechanisms of action and metabolism in the host need to be defined. Polyamines and other
biogenic amines are analyzed from foods as indicators of the degree of freshness or spoilage. In
addition, fundamental aspects of amine biochemistry and physiology still need elucidation in
animals, plants and micro-oganisms. [Teti et. al. 2002, Gugliucci 2004, Khuhawar & Qureshi
2001, Moinard et. al. 2005, Önal 2007, Bouchereau et. al. 2000]
Due to this widespread interest in the polyamines and their derivatives and metabolites, several
assay methods have been developed, utilizing virtually all separation methods connected to all
available detection methods. [Seiler 1986, Muskiet et. al. 1995, Khuhawar & Qureshi 2001, Teti
et. al. 2002, Molnár-Perl 2003] Generally, methods for polyamine analysis must include
procedures to extract, and sometimes concentrate, the polyamines, to separate them from other
amino-containing compounds (like amino acids and from each other), to identify them and then
to make quantitative measurements [Morgan 1998] Due to the poorly volatile and non-
fluorescent nature of the polyamine backbone, most of the existing methods are based on the
analysis of different derivatives. However, the development of the direct methods, which do not
need derivatization, is desirable to avoid pitfalls e.g. diverse reactivities of the analytes, and
instability of the derivatization products. Thus, new methods are still being developed to improve
the determination of the presence and the amounts of amines in various sources. An ideal method
is comprehensive, precise, accurate and reliable, and at the same time simple and rapid.
2.8.1  Separation and detection methods
Since polyamines have similar structural features with each other, as well as with frequently
occurring interfering compounds in biological samples, a good separation is usually necessary
before the analysis. Paper and thin-layer chromatography are the oldest and the simplest
techniques used, but the results obtained tend to be merely semi-quantitative. Thus paper and
thin-layer electrophoretic methods are nowadays rarely used for amine analysis.  More advanced
techniques include LC, GC, and capillary electrophoretic (CE) methods. [Seiler 1986,
Bouchereau et. al. 2000, Khuhawar & Qureshi 2001, Teti et. al. 2002] In addition, techniques like
NMR can be used to characterize an unknown molecule and different reaction products. [Bacchi
et. al. 2009] However, NMR requires relatively large quantities of analytes and is not practical
for complex mixtures.
LC remains the most widely used technique for polyamine assay, and can be divided into ion-
exchange (IC), ion-pair reversed phase or reversed phase (RP) methods. Most applications to
separate free charged amines are based on the utilization of either ion-pairing reagents (See
chapter 2.9.3) or cationic exchange resins, with the basic fraction eluted with 6M HCl or acetic
acid, but also strong anion exchange resins have produced good results. [Bouchereau et. al. 2000,
Seiler 1986, Molnár-Perl 2003] Detection in LC based polyamine quantifications is traditionally
performed with UV-Vis detection combined with the use of different derivatization methods (see
chapter 2.8.2). Unfortunately the LC-UV assays suffer from lack of sensitivity and specificity, as
the analysis relies on retention time, peak area and UV spectral characteristics. In addition to
UV-Vis detection, LC methods have been combined with fluorescence detection, electron
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capture detection, pulsed amperometric detection (PAD), integrated pulsed amperometer (IPAD),
integrated voltameter (IVD), integrated square wave (ISWD), condensation nucleation light
scattering (CNLSD), chemiluminescence, radiometric and MS detection. [Teti et. al. 2002,
Bouchereau et. al. 2000]
GC of free amines is more time-consuming as the compounds to be analysed have to be in a
volatile form, which leads to the need for derivatizable, salt-free extracts from biological fluids.
GC can be combined with flame ionization detection, electron capture detection, nitrogen-
phosphorus detection and MS. [Teti  et.  al.  2002,  Muskiet  et.  al.  1995]  CE methods are  usually
less sensitive than GC and LC [Teti et. al. 2002], and reproducibility of CE has not been as good
as with the LC techniques. [Chiu et.al. 2006] CE separations include capillary zone
electrophoresis (CZE), micellar electrokinetic capillary chromatography, capillary
electrochromatography, capillary isoelectric focusing, capillary gel electrophoresis and capillary
isotachophoresis. [Teti et. al. 2002] CE can be combined with a variety of detection systems
including diode laser-induced fluorescence detection, [Chiu et. al. 2006, Fu et. al. 2007] UV-Vis
absorption, electrochemiluminescence (ECL) detection, and MS. There are also a few alternative,
immunochemical methods which can be used to analyse polyamines, like RIA and ELISA.
However, due to possible cross-reactivity, their specificity is only modest. [Teti et. al. 2002,
Cohen 1998] Modified amino acid analyzers and enzymatic methods have also been used.
[Muskiet et. al. 1995]
In order to avoid clogging of columns and capillaries, and to improve the selectivity, sensitivity
and reliability of analysis, proteins, salts and other interfering matrix compounds must be
removed from the sample before analysis. [Kostiainen & Kauppila 2009] The techniques used for
polyamine pre-clean-up, extraction and enrichment from several matrices include liquid-liquid
extraction and solid phase extraction. [Molins-Legua & Campins-Falcó 2005] For example high-
sulfonated polymeric support, C18-cartridges and strong cation-exchanger cartridges can be used
for amine analysis. [Boucherau et. al. 2000] The recently introduced single hollow fiber or
supported liquid membrane extraction methods [Dziarkowsk et. al. 2008] have also been used for
polyamines. One simple, but crude sample preparation method is protein precipitation with acid
or organic solvent, and subsequent centrifugation.
2.8.2  Derivatization
The polyamines are very polar and poorly volatile compounds, their backbone does not display
native fluorescence, and they absorb UV light at the same wavelength as many interfering
compounds. Thus, to avoid the separation problems of free amines and to improve the sensitivity
and/or applicability to different detection methods, the amine group(s) may need to be
derivatized with suitable agents. In the chromatographic separations, derivatives are usually
obtained either in the pre- or post-column mode. [Teti et. al. 2002]
The derivatization reactions should be rapid, single stage and give a maximum yield without side
products. As the functional group to be derivatised in polyamines is usually primary and/or
secondary amine(s) there are many possible reagents and different reaction methods which can
be used. The most common reactions used are acylation with acyl halides, anhydrides and other
activated carboxyl compunds, like N-hydroxysuccinimidyl esters; sulfonamide formation with
sulfonyl chlorides; carbamoylation with alkyl chloroformates; and pyrrole/isoindole formation
with O-phthalaldehyde. [Seiler 1986, Khuhawar & Qureshi 2001, Teti et. al. 2002] Table 5 lists
some of the derivatizing reagents used for polyamine analysis. Coloured derivatives have been
produced for paper and thin-layer chromatographic, or electrophoretic separations. UV absorbing
and fluorescent derivatives are useful for thin layer and column chromatographic and
electrophoretic separation. In particular, fluorescent reagents have become popular because of
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 Table 5. Some derivatizing reagents used in polyamine analysis
Structure Reagent name Product Reactiveamines
Dansyl chloride Sulfonylamide 1° and 2°
o-Phthalaldehyde
(OPA) Isoindole 1°
6-Aminoquinolyl-N-
hydroxysuccinimidyl
carbamate
(AQC)
Urea 1° and 2°
Fluorescein
isothiocyanate
(FITC)
Thiourea 1° and 2°
9-Fluorenylmethyl
chloroformate
(FMOC)
Carbamate 1° and 2°
Fluorescamine Pyrrolinone 1°
Heptafluorobutyric
anhydride Amide 1° and 2°
Succinimidylferro-
cenyl propionate
(SFP)
Amide 1° and 2°
4-(N,N-dimethylamino-
sulfonyl)-7-fluoro-
2,1,3-benzoxa-diazole
(DBD-F)
Aniline
(Alkyl) 1° and 2°
1-Phenylsulfonyl-3,3,3-
trifluoropropene
(PSTP) Alkyl 1°
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their superior sensitivity compared with those that introduce UV-Vis absorbing moieties.
[Muskiet et. al. 1995] Charged modified derivatives are utilized in CE, and stabilised or volatile
derivatives in GC separations. [Boucherau et. al. 2000] Fluorinated compounds can be
incorporated to introduce electron-capture properties and to improve the volatility of the
compounds. [Kataoka 1996] Other methods which include derivatization by more than one
reagent have been also studied for polyamine analysis [Paik et. al. 2006, Körös et. al. 2008]. By
selecting a proper derivatizating agent it is possible, at least in theory, to selectively derivatize
primary and secondary amines. [Zaikin & Halket 2006, Kataoka 1996]
2.8.2.1 Derivatization in MS analysis
Despite the high sensitivity and selectivity of MS detection, derivatization is sometimes used also
in MS based analysis to avoid the influence of the many contaminating ions present in the low
mass field, to enhance structure information, to increase retention to reversed phase column and
to increase the ionic intensity. Derivatization can also be used in order to distinguish primary,
secondary and tertiary amines, or to enable the analysis of otherwise positively charged amines in
the negative mode. [Zaikin & Halket 2006] Many derivatization reagents have been used for
polyamine analysis with LC-MS applications e.g.: dansyl chloride [Feistner 1994, de Agazio et.
al. 1996, Gaboriau et. al. 2003, Loukou & Zotou 2003, Geuns et. al. 2006] benzoyl chloride
[Feistner 1994] 2,4-dinitrofluorobenzene [Fuchslueger et. al. 1996] and 3,5-dinitrobenzoyl
chloride. [Kirschbaum et. al. 2000] Recently, also isobutyl chloroformate, [Byun et. al. 2008]
DBD-F (see Table 5.), [Sugiura et. al. 2008] and succinimidylferrocenyl propionate [Bomke et.
al. 2009] have been utilized. In GC-MS analysis, the most widely used derivatization methods
are perfluoroacetylation, alkylsilylation and alkoxycarbonylation. [Teti et. al. 2002]
Derivatization has also been used to enable the determination of polyamines using MS without
previous chromatographic or electrophoretic separation. For these purposes, polyamines have
been derivatized with dansyl chloride [Gaboriau et. al. 2003] or with heptafluorobutyric
anhydride. [Furuumi et. al. 1998, Xu et. al. 2002, Samejima et. al. 2007] However, when
choosing derivatizating agents for MS detection, one needs to take into account that reagents
which contain sulphur, such as tosyl and dansyl chloride, may cause problems due to the natural
isotopic peaks of sulfur (32S, 95.04 %; 33S, 0.76 %; 34S, 4.2 %). [Furuumi et. al. 1998]
2.8.3  Problems in methods involving derivatization
In addition to the benefits described above, there are also several drawbacks associated with
derivatization. The most apparent disadvantage is the prolonged analysis time due to additional
and tedious derivatization steps. Other problems can be the possible unstable reaction products,
side reactions and possible solubility problems of the derivatized compounds. For example,
dansylation yields light-sensitive derivatives, may form dansyl sulfonic acid and dansyl amide as
by-products, and tri- and tetra dansylated polyamine derivatives have poor water solubility. Also
OPA and fluorescamine have been reported to produce unstable reaction products. Some
analytes, like N-hydroxy compounds are base sensitive, which causes problems in derivatization
as most of the derivatization reactions need to be performed under basic conditions. Also
incomplete reaction with required functionalities, and side reactions with other functional groups
may cause artefacts. For example common acylating reagents used in derivatizations may form
derivatives with both primary and secondary amino groups, imidazole nitrogen, phenolic
hydroxyls and with some alcohols and thiols. Also interference and suppression of products from
excess derivatizing reagent might hamper the analysis. [Feistner 1994, Seiler 1986, Teti et. al.
2002] It is also possible that two or more fluorophores in a molecule cause fluorescence self-
quenching. [Nohta et. al. 2000, Sugiura et. al. 2008]
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2.8.4  Analysis without derivatization
In recent years there has been progress in developing analysis and detection systems for
polyamines that do not require derivatization; they would be preferred for their convenience and
simplicity. The detection systems of those applications mainly involve electrochemical detection
like amperometric, integrated pulsed or mass spectrometric methods. MS techniques utilizing
soft, atmospheric pressure ionization, mainly electrospray ionization (ESI) and atmospheric
pressure chemical ionization (APCI), are highly promising techniques for polyamine analysis
without derivatization. [Bouchereau et. al. 2000] Direct GC of alkylamines is difficult because
many column packing materials tend to absorb polar amines and this causes peak tailing, and
reduced sensitivity. The adsorption tendency is in the order primary > secondary > tertiary
amines, and aliphatic amines are generally more difficult to chromatograph than aromatic
amines. [Kataoka 1996] Table 6 lists the current methods for underivatized polyamine analysis.
However, the given sensitivity values may not be comparable, as the values have been calculated
using different acceptance criteria (See chapter 2.10.5 and 2.10.6), and there are also significant
differences between sample matrixes.
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2.9  LC-MS/MS METHOD DEVELOPMENT
2.9.1  ESI-MS
Detection and quantification utilizing LC/MS with either ESI or APCI are today important and
widely used methods in the analysis of metabolites. [Kostiainen et. al. 2003] ESI is the most
widely used technique for polar compounds, such as polyamines. In ESI, gas-phase ions are
formed from ionised analytes by spraying a sample solution through a small capillary at a high
potential with the aid of heat and/or pneumatics. Depending on the voltage polarity, the spray
creates small droplets carrying a positive or negative charge on the surface of the droplets. In
polyamine analysis, the positive ion ionisation mode is obvious due to the presence of several
amino groups, and hence the voltage polarity should be positive. Several mechanisms have been
proposed for the formation of the free gas phase ions from the initial droplets. According to one
proposed mechanism, the formed primary droplets, trapping the ionised analyte, become smaller
as the solvent molecules evaporate. At the same time, the charge density on the droplet surface
increases causing the droplet to become unstable, and eventually leading to its explosion when
repulsive forces between charges exceed the cohesive forces of the droplet. Smaller and smaller
droplets are formed, by repeating the process until gas phase ions are emitted from the formed
microdroplets. In addition to the ionised analytes, and other charged eluent species, also neutral
molecules may be ionised by ESI through gas-phase proton transfer reactions or through
electrochemical oxidation or reduction. The ionisation process is complex and is influenced by
several factors of solvents and additives, chemical and physical properties of the analyte and
operational parameters. Table 7 (page 57) lists some of the factors which may affect the signal
response and thereby the sensitivity of the method. [Cech & Enke 2001, Politi et. al. 2006,
Kostiainen & Kauppila 2009]
2.9.2  MS/MS detection and quantification
Since several compounds may have the same mass-to-charge (m/z), the isolated ion (termed
parent or precursor ion) of a compound formed in the ESI source is not a unique identifier, and
methods using only the first dimension MS quantification suffers from the lack of selectivity,
especially in very complex matrices, like biological samples. As a way to increase the selectivity,
the precursor ion may be selectively reacted to generate a set of product ions. One typical way is
the collision induced dissociation (CID), where the ions are collided with neutral gas molecules
(like nitrogen or argon). Fragmentation can be induced by increasing either the kinetic energy
(collision energy) of the precursor ion, or the gas pressure in the collision cell. As the precursor
ion fragmentation in the majority of cases provides a unique fragment, the most specific way to
perform MS quantification is by using a mass spectrometer capable of MS/MS fragmentation and
selective fragment ion detection, commonly with a triple quadrupole (QQQ) or ion trap mass
spectrometer. [Glish & Vachet 2003, Politi et. al. 2006, MS tutorial]
The MS/MS experiments use two sequential stages of independent mass analysis to select the
parent and product ion masses, and each stage of mass analysis can be made to define either a
fixed or a variable mass. By using the different combinations, four types of MS/MS experiments
have been widely utilized, termed reaction monitoring, parent, product, and neutral loss scan
modes. [Schwartz et. al. 1990] MS/MS quantifications are mostly performed using selected
reaction monitoring (SRM), where in addition to selectivity, also a relative increase in sensitivity
is achieved due to the dramatic reduction of the chemical noise. [Politi et. al. 2006] In SRM, both
mass analysers in the instrument are set on a specific mass, and the signal (or peak) obtained
represents the precursor-to-product ion transition for a specific ion pair. [Glish & Vachet 2003]
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Table 7. The factors influencing the ionisation process in ESI and thereby the signal response and
sensitivity of the method
Solvents and additives An example of the effect if the factor is changed
Volatility Increasing volatility increases solvent evaporation, and thus increases ion transmis-
sion to the gas phase
Organic content of the
solution
Increasing organic content reduces surface tension and increases solvent evapora-
tion from droplets
Surface tension Increasing surface tension decreases solvent evaporation
Viscosity Increasing viscosity decreases solvent evaporation, and thus decreases analyte
transportation  to the droplet surface
Conductivity Charge carrier important for the charge separation at the ESI needle tip, however if
too much, this evokes increases in spray current, impairs spray stability due to
electric discharge
Ion strength Too high ion strength causes discharges and unstable spray performance of the ESI
interface, which decreases analyte sensitivity
Dielectric constant Higher dielectic constant decreases ion escape from the droplets
Electrolyte concentration Addition of electrolytes (Na+ ,  Li+, NH4+ ) can be used to enhance ionization, but
high electrolyte concentrations (over ~10-5M) cause suppression
pH Affects the analyte ionization degree in the solution, and thus the sensitivity of ESI
Gas-phase ion-molecule
reactions
Possible neutral molecule ionisation, and possible increased adduct formation
Analyte properties An example of the effect if the factor is changed
Concentration Increasing analyte concentration linearly increases signal sensitivity up to ~10-5M
pKa Affects the ion formation in the solution
Hydrophobicity Increases analyte transportation to the droplet surface if increased
Surface activity Increases analyte transportation to the droplet surface if increased
Proton affinity (Gas-phase
basicity)
Molecule ionisation or ion neutralization
Operational parameters An example of the effect if the factor is changed
Flow rate ESI is concentration sensitive detector, and flow rate does not have much effect on
sensitivity. Decrease in the column diameter and flow rate increases analyte con-
centration in LC peak and thus increases S/N (micro- and nano-LC)
Temperature Solvent evaporation, analyte stability
ESI voltage Voltage value needs to be high enough to enable ionization, but not too high to
avoid discharge.
One typical property of the QQQ instrument is that the first quadrupole isolates the selected
precursor ion with a narrow isolation width, then the second quadrupole is used only for the
fragmentation of this ion by collision-induced dissociation and finally the third quadrupole is
programmed to detect the product ion with known m/z value. [Hol?apek et. al. 2008] The parent
ion has to dissociate to all the monitored product ions and the ratio of the product ions should
match a known value for the experimental conditions. [Glish & Vachet 2003] This combination
of the specific parent mass and the unique fragment ions is used to selectively monitor the
compounds to be quantified.
The optimization of the SRM method consists of three steps. First the precursor ion needs to be
isolated with the highest efficiency. This includes the selection of the voltage of the first mass
filter (orifice/fragmentor voltage). The second is the study of fragmentation of precursor ions and
the optimization of the collision cell voltage for each analyte. The third step is the selection of the
most sensitive and/or selective transition from the precursor ion to the selected product ion for
the quantification. It is good practice to avoid, if possible, product ions obtained by loss of a
water or ammonium molecule, as these fragmentations are not very selective. The monitoring of
other significant transitions (so called qualifier ions) may increase the selectivity of the method.
[Capote et. al. 2007] However other, instrument specific MS/MS parameters also need to be
optimised, like capillary voltage, nebulizer gas pressure, drying gas flow and temperature. All
these can be tested without chromatography by using flow injection analysis (FIA), where the LC
injector is connected directly to the ion source. [Politi et. al. 2006]
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2.9.3  Ion-pairing chromatography
Generally, extensive chromatographic separation for analytes is not necessary for the SRM
analysis since there is usually only a single peak for the analyte being detected in an entire
chromatographic run. However, the probability of observing multiple peaks due to the
endogenous compounds from the complex biological samples sharing the same SRM transition
for a given analyte is increased with small molecular weight compounds. Therefore, appropriate
chromatographic separation for very small molecules prior to mass spectrometric detection
becomes essential.
Traditional reversed phase separation of underivatized polyamines is challenging due to their low
column retention and susceptibility to undergo severe tailing. [Feistner 1994] Ion-pairing
chromatography utilizing lipophilic ions, termed ion-pairing reagents, as mobile phase additives
has been widely used as an effective way to obtain adequate retention of polar analytes. [Cecchi
2008] In addition to the better retention in LC separations of polar compounds, ion-pairing agents
are also used to decrease the secondary interactions between free silanol groups of the stationary
phase, resulting in decreased peak tailing and improved resolution. [Kostiainen & Kauppila
2009]
Ion-pairing reagent improves chromatographic retention on the hydrophobic stationary phase
through two mechanisms or their combination. The classical ion-pair model postulates that the
ion-pairing reagent and analyte ion are combined in the eluent to form an ion pair, which is then
able to partition into the hydrophobic stationary phase. According to the dynamic ion-exchange
model, the hydrophobic ions are first adsorbed onto the surface of the stationary phase and so
generated charge sites serve as exchange sites for analyte ions. [Cecchi 2008]
Conventionally, the polyamine separation has been performed with alkyl or aryl sulfonates as
anionic ion-pairing reagents. [Khuhawar & Qureshi 2001] However, these nonvolatile ion-
pairing reagents are not recommended for LC-MS as they cause ion source contamination,
increase background and cause strong signal suppression in MS. Volatile perfluorinated
carboxylic acids as ion-pairing reagents are normally adapted for LC/MS systems as they are
more compatible with the MS source. The most commonly used ion-pairing agents in LC-ESI-
MS analysis of polar basic compounds are trifluoroacetic acid (TFA), pentafluoropropionic acid
(PFPA) and heptafluorobutyric acid (HFBA). [Kostiainen & Kauppila 2009]
2.9.4  Ion suppression
Separations utilizing ion-pair LC, are mainly controlled by adjusting the ion-pairing reagent
concentration and the percentage of organic solvent in the mobile phase. However, the
composition of the eluent always has some impact not only on the chromatographic performance,
but also on the ionisation efficiency of the analytes in MS. The signal response in ESI tends to
increase with the amount of organic solvent, and it is advantageous if the retention of an analyte
to the stationary phase is increased so that the analyte is eluted with a higher content of organic
solvent. An ion-pairing reagent improves the retention but unfortunately it may have also a
negative influence on the MS sensitivity. Usually ESI can tolerate low additive concentrations (<
10 mM), but even smaller amounts may cause severe suppression. In particular, strong acids used
as ion-pairing reagents in LC are known to cause signal suppression when analysing basic
compounds with ESI-MS. For example, a sensitivity loss of ~30-80 % has been observed when
using fluorinated volatile acids like TFA, HFBA, or nonafluoroheptanoic acid as an additive,
compared to non-fluorinated additive containg buffers, such as formic acid [Gustavsson et. al.
2001] The signal reduction is believed to be due to either high conductivity and surface tension
of the aqueous eluent including the additive, or strong ion-pairing between the additive-ion and
the charged analyte. The ion-pairing process masks the charged analyte to neutral and thereby
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decreases the efficiency of the ESI droplet to transfer the charged analyte into the gas phase.
[Kostiainen & Kauppila 2009]
The suppressing effect of perfluorinated carboxylic acids has been partly eliminated by post-
columns addition of 500 mM formic acid in acetonitrile-water (95:5). [Petritis et. al. 2002] The
post-column addition of plain organic modifier may also help, providing that the increase in the
S/N ratio is not counterbalanced by an increase in flow rate. [Politi et. al. 2006] However, a
better way to decrease the suppression of fluorinated acids is the method called “TFA-fix”, where
a weak acid having the higher boiling point than perfluorinated additive, is added to the eluent
flow. It is postulated that the high concentration of weak acid compared the TFA protonates TFA
ions back to the neutral form. The protonated TFA, which is more volatile than a weak acid, is
evaporated more efficiently from the droplet. As the droplet shrinks, the ion pair is formed
between the analyte and the weak acid anion. This ion-pair is more reversible than an ion-pair
created with a stronger acid anion, and the ions are able to be ejected easier to the gas-phase,
resulting in decreased suppression. [Kuhlmann et. al. 1995, Apffel et. al. 1995] Two possible
ways have been demonstrated to conduct a “TFA-fix”. In the first method the weak acid, for
example propionic acid in 2-propanol (75:25 v/v) is added post-column to the eluent flow. In the
second method, the weak acid (for example 1 % propionic acid) is added directly to the mobile
phase. The post-column method is more efficient in signal reconstruction. However, the post-
column addition complicates the analysis and causes peak broadening and dilution. [Kuhlmann
et. al. 1995, Apffel et. al. 1995, Shou & Naidong 2005]. The eluent selection for LC-MS is thus
usually compromise between LC separation and ionisation efficiency and the concentration of
additives should be kept as low as possible. [Kostiainen & Kauppila 2009]
2.9.5  Matrix effect
The addition of ion-pairing reagents to the mobile phase is expected to retain not only polar
analytes, but also some of the polar endogenous components in biological samples. These
possible co-extracted and co-eluting substances may alter the amount of the charged analyte ions
reaching the gas-phase. This may either suppress or enhance the analyte signal, and though these
signal response changes may not be seen in the chromatography, they may have a negative
impact on the method’s sensitivity and selectivity. The phenomenon is called a matrix effect,
which is said to be the achilles heel of quantitative LC-MS/MS measurements. [Taylor 2005]
In addition to endogenous compounds, matrix effects can also be attributed to exogenous
materials, like polymers and other non-volatile or less volatile compounds in mobile phase, in the
current sample being injected or even in a previously injected sample. Also at high analyte
concentrations (>10-5 M) the linearity of the ESI response is often lost. This signal saturation at
high concentrations may be due to saturation of the droplet surface with the analyte, trapping the
rest inside the droplet and thus inhibiting gas phase ion formation. [Taylor 2005, Stahnke et. al.
2009, Cech & Enke 2001]
The exact mechanism of matrix formation is unknown, but several mechanisms have been
proposed.  As there  is  only a  limited amount  of  excess  charge available  on the ESI droplet,  too
high analyte amounts may not be able to ionise sufficiently. It is also possible that the saturation
of the droplet’s surface with analyte limits the ejection of ions trapped inside the droplets. Matrix
components may also displace the analyte from obtaining a charge on the droplet surface.
Moreover, matrix compounds may increase the droplet’s surface tension, and the droplets may be
enclosed in micelle-like structures. These effects may also slow down the solvent evaporation
and thus reduce the formation of gas-phase ions. Also the droplet’s viscosity may be altered, so
the analyte transportation to the droplet surface may be changed. In addition, analyte ions can be
neutralized in the gas phase with other substances, and non-volatile materials can decrease the
droplet formation efficiency due to co-precipitation with the analyte. The matrix may also
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generate different adduct ions, which are not recognized by SRM analysis. [Eeckhaut et. al. 2009,
Stahnke et. al. 2009]
The matrix effect can be assessed either by the post-column infusion method [Bonfiglio et. al.
1999] or by the post-extraction addition method. [Matuszewski et. al. 2003] In the post-extraction
addition method, the MS/MS response of sample extracts, when the analyte is added after
extraction, are compared with the MS/MS response of pure solutions prepared in the mobile
phase containing equivalent amounts of the same analyte. In the post-column infusion method, a
constant flow of analyte (concentration in the analytical range) is delivered into the LC eluent
after the chromatographic column but before MS detection using an infusion pump. A sample
extract free of added analyte is then injected to the column and run at the desired
chromatographic conditions. The response from the infused analyte and the matrix effect is
investigated over the entire chromatographic run in the SRM mode. The post-column infusion
method may make it easier to evaluate the influence of different sample extraction techniques
and mobile phase additives on matrix effects and response, and to study the appropriate
analytical column, where the matrix effect occur and are absent during a chromatographic run.
Usually the majority of matrix effects occur in the solvent front of the chromatographic run. In
contrast, the post-extraction addition method offers the possibility to measure the whole process
efficiency (the combination of matrix effect and recovery of the analyte from the matrix by the
used sample extraction process) by comparing the MS/MS response of the analyte added pre-
extraction with the MS/MS response of pure solutions. [Taylor 2005]
The deleterious matrix effects may be minimized by modification and improvement of the
sample extraction methodology and chromatographic separation. For example, solid phase or
liquid-liquid extractions and on-line two-dimensional chromatography using a column-switching
device may be considered. [Taylor 2005] Evaluating and changing the LC-MS interface and the
mechanism of ionisation of analytes may also help, since the matrix effect may be different
between different ion sources, such as ESI and APCI. Recently, it was proposed that the extent of
matrix effects is influenced more by the properties of the matrix components eluting at the same
time rather than by the physicochemical properties of the analytes. This was suggested to offer
the opportunity to compensate for matrix effects by investigating matrix effect profiles
determined by the post-column infusion data. [Stahnke et. al. 2009]
One technique that can be used to compensate for matrix effects is the application of internal
standards (See chapter 2.9.6). In particular, the use of stable isotope-labelled analogues as
internal standards is recommended, as matrix effect should not affect the relative efficiency of
ionisation of the analyte and its co-eluting stable isotope labelled IS. However, the elimination of
the co-eluting compounds is still advisable, since their presence will reduce the method
sensitivity, and may lead to false negative results for low concentrated samples. [Matuszewski et.
al. 2003, Eeckhaut et. al. 2009]
2.9.6  The internal standard and isotope dilution LC-MS
When performing MS quantification, an internal standard (IS) is added to the sample to be
measured to enhance the reliability of the method.  An appropriate IS will control for the
ionisation variability, which may happen in the MS detection, as well as for any losses occurring
during extraction and sample preparation if added at the beginning of the sample work-up. The
added amount of the IS should be well above the limit of quantification LLOQ (see chapter
2.10.6) but not so high as to suppress the ionisation of the analyte. Usually the amount is target to
the lower 1/3 of the working standard curve. An IS should be added at the same level in every
sample including the standards, but it is not necessary to know the exact concentration of IS. The
analytes and IS are then extracted, purified, sometimes derivatized, separated by LC, and finally
analyzed by MS. The quantification is achieved by comparing the peak area ratios of the analyte
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ions and IS ions, with the peak area ratios of the calibrators used in preparing a standard curve.
When the IS used is a stable-isotope labelled analogue of the analyte, the above described
quantitative method is called isotope dilution LC-MS method. [MS tutorial]
An ideal IS has a similar extraction recovery, ionisation response in ESI mass spectrometry, and
a similar chromatographic retention time. The ideal IS is an isotopically labelled version of the
molecule to be quantified, since the physicochemical properties of an isotopically labelled
analogue are virtually identical with those of the analyte, but it has a different m/z value in MS.
Other possibilities for an IS are structural analogues of the analyte. However, it should be noted
that if the analyte and the structural analogue differ in their functional groups, the IS is less likely
to be appropriate than when the difference is in the carbon backbone of the molecule. Also
substitution or rearrangement of heteroatoms is more likely to result in altered charge distribution
of the molecule than to changes to carbon-hydrogen groups. [Hol?apek et. al. 2008, Taylor 2006]
In contrast, isotope labelled analogues may suffer from ion suppression or enhancement by the
analyte at high concentrations and vice versa. This may have a great impact on the accuracy of
other measurements in the same chromatographic run, if only one IS is used for several analytes.
In addition, due to the other possible differences in the matrix profile, an IS may be required for
each analyte, if more than one compound is determined in the same analytical method. However,
this  may not  always be possible,  thus if  limited number of  ISs is  available,  the use of  the dual
quantification based on different ISs may be feasible. [Kronstrand & Josefsson 2006]
When choosing IS, it has to be ensured that the chosen compound is not present in the analyte
mixture and if there is a large number of carbon atoms in the analyte molecule, the molecular
mass of the stable isotope labelled IS should preferably be at least three mass units higher to
avoid interference by natural isotopes of the analyte at the m/z value of the labelled compound.
Thus, more than one isotope atom is needed in the stable isotope labelled IS.
The stable isotopes most commonly used in MS analyses are D, 13C, and 15N. The most popular
isotope of these is deuterium (see chapter 2.6). Usually deuterated analogues have no observable
differences in their chromatographic retention approximately up to six deuterium atoms, but with
molecules containing multiple deuteriums, a very small retention shift can occur [Hol?apek et. al.
2008, Stokvis et. al. 2005] This effect is due to the isotope effects, (See chapter 2.6.3) and may
be detrimental if a different degree of matrix effects exists around the analyte and IS, and the
possible existence of the phenomenon needs to be studied during method development. [Wang et.
al. 2007] However, changing the mobile phase from neutral pH to acidic [Stokvis et. al. 2005] or
another type of stationary phase may prefer co-elution. [Takegawa et. al. 2008]
In addition, if one is using deuterated ISs, it is important to establish their stability in solution and
through all the phases of the method. The best way is to use standards, which are deuterated in
stable positions and are not prone to deuterium exchange reactions. Finally, in addition to being
used as ISs in MS studies, deuterated analogues are also valuable in verifying of the proposed
fragmentation pathways. [Smith & Daves 1978]
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2.10  METHOD VALIDATION
High quality data can only be derived from reliable analytical methods, and every new method
requires careful method development. Suitable sample preparation, proper chromatographic
conditions and optimised MS parameters, as well as minimization of the possible ion suppression
and matrix effects and the selection of an appropriate IS(s) are important issues to be addressed
in LC-ESI-MS method development. Nonetheless, though the quality of an analytical method
largely is based on method development, but also the method validation is an important part to be
performed, as only validation can objectively demonstrate the inherent quality of an analytical
method and minimum acceptance criteria to be fulfilled thus to prove the method applicability for
a certain purpose. There are various different international organisations which offer guidelines
on method validation, such as the United States Food and Drug Administration (FDA), and the
International Conference on Harmonization (ICH). Several review articles and books have been
also published on the topic of analytical method validation. [Peters 2006 and 2007, Rozet et. al.
2007] A general validation guideline is currently not available, but for quantitative bioanalytical
procedures at least the following validation parameters should be evaluated: Selectivity,
calibration model, accuracy, precision, stability and the lower limit of quantification (LLOQ).
Additional parameters, which may be relevant, are for example limit of detection (LOD), upper
limit of quantification (ULOQ), extraction recovery, reproducibility, and ruggedness (robustness)
[Peters et. al. 2007] In addition, proper system suitability tests should be used to verify that the
instrument is suitable for the intended analysis.
2.10.1  Selectivity and specificity
The selectivity is the ability to measure the analyte in a complex mixture without interference
from other components. When the selectivity reaches 100 %, the method is called specific, and
there is no interference at all. The term specific generally refers to a method that produces a
response for a single analyte only. In contrast, the term selective refers to a method that provides
responses for more than one compound, which may or may not be distinguished from each other.
If the response is distinguished from all other responses, the method is selective.
The method selectivity must be demonstrated by providing data to show the absence of
interference peaks with regard to degradation products, synthetic impurities and the matrix. There
are several experimental approaches which can be used to assess selectivity. One approach is to
prove the lack of response in a blank matrix by comparison of the chromatograms obtained after
injection of blank samples with and without the analytes or IS. Selectivity should be ensured at
the lower limit of quantification (LLOQ, see chapter 2.10.6). For example, the selected stable
isotope labelled IS may contain the non-labelled compound as an impurity or its mass spectra
may contain fragment ions with the same m/z as the monitored target analyte ion. In such cases,
the analyte peak area would be over-estimated. Thus the absence of interferences caused by the
IS can be checked by analysing blank samples spiked with the IS, so-called zero samples. Also
the analyte might interfere with a stable-isotope labelled IS. This may be a problem with
deuterated standards when analysing higher molecular weight molecules, if the number of
deuteriums of the analogue or one of its monitored fragments is three or less. The absence of
such interferences can be checked with blank samples spiked with the analyte at the upper limit
of the calibration range, but without IS. [Peters et. al. 2007]
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2.10.2  Calibration curve
The calibration curve for LC-MS/MS method is measured as a relationship between the response
(area ratio of analyte versus IS) and a known concentration of the analyte, and it should be
generated for each measured analyte in the method. Calibrator concentrations must cover the
whole calibration range, and according to FDA guidelines, a calibration curve should consist of a
blank sample (matrix without IS), a zero sample (matrix with IS) and six to eight non-zero
samples including LLOQ. [FDA 2001]
The standard curve fitting is determined by applying the simplest model using appropriate
weighting and statistical test for goodness of fit. Models for calibration curve fitting can be either
a straight line or a curved line (e.g. a quadratic fit). Usually linear models are preferable, however
quadratic fits may be necessary for MS, which displays a reduced response at high
concentrations.  With  ESI,  the  upper  end  of  the  linear  range  is  known  to  be  limited  to
approximately 10 ?M. [Cech & Enke 2001] At higher concentrations, the saturation effects
cannot be avoided even with deuterated IS, and calibration curves tend to be best fitted by non-
linear equations. However, quadratic calibration functions may affect the precision in the upper
range, as the change in response is small compared with the change in concentration. [Kronstrand
& Josefsson 2006] In addition, it is common that the signal variances across the concentration
range are heterogenous, and the weighting may improve significantly the accuracy of the results,
particularly at low concentration levels. The weighting factors 1/x and 1/x2 are by far the most
widely used [Rozet et. al. 2007, Peters 2006] FDA guidelines acceptance criteria for calibration
curve is that a minimum of 75 % of standard calibration samples, when back calculated, should
fall within ?15 %, except for LLOQ, which should be within ?20 % of the nominal value.  [FDA
2001] In addition, the so-called accuracy profile as a decision tool may be used to find the most
appropriate standard curve model. [Rozet et. al. 2007]
2.10.3  Accuracy
According to FDA guidelines, [FDA 2001] the accuracy is the closeness of mean test results
obtained by the method to the true value (concentration) of the analyte. As the detection response
may vary non-linearly, accuracy should be tested over the whole calibration range by replicate
analysis of quality control (QC) samples containing known amounts of the analyte. The FDA
guideline suggests evaluating the accuracy by measuring a minimum of three concentration
levels (one within 3x LLOQ, medium and high concentrations) prepared in five replicates in the
range of expected concentrations. The acceptance criteria for accuracy are mean value within ?
15 % of the nominal value, except for LLOQ, which can be within ? 20 %.
2.10.4  Precision
Precision is defined as the closeness of individual measures of an analyte (degree of scatter)
between a series of measurements obtained from multiple sampling of the same homogenous
sample under the prescribed conditions. Precision should also be measured using a minimum of
five determinations per each of three concentration levels spread out over the calibration range.
Precision is expressed as relative standard deviation (RSD), which has to be within 15 %, except
for LLOQ where 20 % is acceptable. Precision is further subdivided into different precision
levels. The FDA guidelines distinguishes the intra-day precision, which assesses the precision
during a single analytical run, and inter-day precision, which measures precision in time, and
may involve different equipment, reagents, analysts, even laboratories. [FDA 2001]
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2.10.5  Sensitivity and limit of detection (LOD)
Limit of detection (LOD) is defined as the lowest concentration of an analyte that can be reliably
differentiated from the background noise. Due to different procedures available, LOD can be
defined using different approaches, like visual evaluation, methods based on signal-to-noise ratio
and methods based on standard deviation of the response and the slope (Rozet et. al. 2007,
Araujo 2008, Peters 2006) However, each of these approaches may provide a different value,
which is highly problematic as then it is not possible to compare the values of different
laboratories using the same analytical procedure. [Rozet et. al. 2007]
2.10.6  Lower limit of quantification LLOQ and upper limit of quantification ULOQ
According to FDA guidelines, LLOQ is defined as the lowest concentration of an analyte that can
be quantitatively determined with an acceptable accuracy and precision. Below the LLOQ, a
method can produce only semi-quantitative or qualitative data. The LLOQ is measured using at
least five samples independent of standards. [FDA 2001] However, similarly to LOD, also LLOQ
may be evaluated by using other approaches.
The highest standard defines the upper limit of quantification (ULOQ). It is known that with ESI,
the upper end of linear range is limited to approximately 10 ?M.  [Cech  &  Enke  2001]  In
quantification, the analyte amount in the sample has to be within the LLOQ and ULOQ values
(in the calibration or dynamic range)
2.10.7  Stability
The stability of the analytes and ISs during the whole analytical procedure is a prerequisite to
obtain reliable and reproducible results. Therefore the stability in the various stages of analysis
must be determined by comparing the response with that of freshly prepared solutions.
The stability time of the analytes and IS in the matrix and in the stock solutions during storage
conditions should be determined, at least as long as the original samples and stock solutions are
expected to be stored. These so-called long-term and stock solution stability studies include also
defining of the storage vessels and the storage temperature (frozen or in refrigerator). If samples
are frozen and thawed for example for re-analysis, the freeze/thaw stability should be evaluated
through a minimum of three freeze and thaw cycles. Also short-term temperature stability at
room temperature based on the expected duration that samples will be maintained at room
temperature in the intended study, and the stability time of processed samples in the autosampler
over the anticipated run time needs to be studied. Special care should be taken with potential
binding of polyamines to the walls of glass apparatus or plastic material used in extraction and
subsequent procedures. [FDA 2001, Bouchereau et. al. 2000]
2.10.8  Recovery
If the method includes sample extraction or processing, such as derivatization, the efficiency of
these procedures should be evaluated. Recovery is reported as a percentage of the known amount
of analyte carried through the sample extraction and processing steps. For traditional polyamine
analysis, 1,7-heptanediamine (DAH) is often added as an internal standard for estimating the
percentage of recovery. [Morgan 1998]. In LC-MS/MS analysis, part of the change in the
response in prepared samples in comparison to the respective standard solutions might be due to
a matrix effect. Therefore it is appropriate to perform the recovery experiments together with
matrix effect experiments by measuring the response from the post-extraction addition and the
pre-extraction addition in comparison with the pure solutions. (See chapter 2.9.5)
Kuopio Univ. Publ. C. Nat. and Environ. Sci. 263: 1-145 (2009) 65
3.  AIMS OF THE STUDY
Metabolic studies are a part of the basic knowledge required prior to clinical drug use since they
provide information of the drug safety and efficacy, and may prevent unnecessary expenditures
in drug development as unsuitable projects can be interrupted as quickly as possible. Since N-
alkylated polyamines are being developed as drugs for several diseases, and because it is
conceivable that some of the polyamine analogue metabolites will contribute to the effect elicited
by the parent analogue, or even account for their main mode of action, it is necessary to
understand their metabolic behaviour thoroughly. In addition, as most of the clinical trials so far
have failed due to apparent toxicity and/or low efficacy of the studied compounds, it is necessary
to study to what extent it is possible that the reason for low cell response to polyamine analogues
would  be  due  to  the  catabolism  of  the  active  drugs  by  different  oxidases.  In  view  of  these
considerations, the aims of this work were:
1.  To study the sites of metabolism of bis-N-alkylated spermines and their predicted
metabolites N-alkylated spermines, spermidines and diaminopropanes, with human PAO
and SMO in vitro with purified human recombinant enzymes as well as in DU145 cell
culture experiments (IV)
2.  To measure the enzyme kinetic parameters Km,  Vmax and kcat for the observed substrates
using purified human recombinant enzymes (IV)
3.  To identify differences between the catabolism of analogues with different alkyl
substituents in order to study the potential to affect to the cleavage site with different
kinds of alkyl substituents (IV)
4. To evaluate differences between the two polyamine oxidase PAO and SMO towards these
N-alkylated analogues (IV)
5.  To develop and validate a selective and sensitive quantitative method to analyse
polyamines, their  analogues  and metabolites using LC-MS/MS without derivatization, in
order to avoid possible derivatization problems and to achieve better sensitivity and more
specific identification of the metabolites, than with traditional LC-UV system (I and II)
6.  To synthesise proper N-alkylated substrates and their potential metabolites for the
quantitative metabolic study (III)
7.  To devise a method to synthesise deuterium labelled derivatives to be used as internal
standards in quantitative polyamine analysis with LC-MS/MS, as well as potential
biochemical probes in future studies (III)
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4.  LC-MS/MS METHOD DEVELOPMENT FOR POLYAMINE ANALYSIS
Adapted/modified  from Journal of Pharmaceutical and Biomedical Analysis, Vol. 45, Häkkinen M. R., Keinänen T. A.,
Vepsäläinen J., Khomutov A. R., Alhonen L., Jänne J., Auriola S. Analysis of underivatized polyamines by reversed phase
liquid chromatography with electrospray tandem mass spectrometry, Pages No. 625-634, Copyright (2007), with
permission from Elsevier.
The aim of this work was to find the optimal LC-MS/MS conditions for polyamine analysis. In
order to avoid the many derivatization problems, separation and analysis were studied without
derivatization and with minimal sample preliminary preparation. Five volatile acids: formic acid
(FA), acetic acid (AcOH), butyric acid (BA) trifluoriacetic acid (TFA), pentafluoropropionic acid
(PFPA), and heptafluorobutyric acid (HFBA), were compared as ion-pairing reagents in
chromatographic separation of polyamines, acetylated polyamines and N-alkylated polyamine
analogues. In addition, the effects of these mobile phase additives were tested on the relative
signal intensities of some of the studied polyamines. Moreover, two different methods utilizing
propionic acid (PrA) were evaluated in order to reduce ion suppression caused by the studied
ionpairing reagents. The final method was tested in the identification of metabolites of DESPM
which was used as a substrate for recombinant human polyamine oxidase (hPAO).
4.1 RESULTS AND DISCUSSION
4.1.1 Mass spectrometry analysis
Structures, molecular masses, measured precursor ions and MS/MS data for the compounds
studied are summarized in Table 8. All polyamines produced protonated [M+H]+ molecules and
no adduct formation was observed. The diamines PUT, CAD and DAH resulted in higher
precursor ion abundance with lower fragmentor voltage values compared to the other analytes.
The product ion spectra for each polyamine were obtained, and presumable product ions formed
for EtDAP, EtSPD and EtSPM as examples are shown in Fig. 10 A–C. The MS/MS spectra of
the studied polyamines displayed typical neutral loss of ammonia. The main fragment ions in the
CAD and DAH MS/MS spectrum, at m/z 86 and 114, respectively, are probably similar types of
ring structures as described before for PUT [Feistner 1994, Bigler & Hesse 1995], but also linear
product ion structures are possible. [Gosetti et. al. 2007] The diamines PUT and CAD had no
other major fragment ions, but DAH had another fragment m/z 55. N1-AcSPD and N8-AcSPD had
similar precursor ions, but MS/MS spectrum showed different behaviour in the collision cell and
this made it possible to select divergent product ions, m/z 100 and 114, respectively, for SRM
analysis.
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4.1.2 The effect of different solvent compositions to relative signal intensity
The results for the effect of different acid additives (FA, AA, BA, TFA, PFPA and HFBA) in the
solvent system used with respect to the relative signal intensities of five selected polyamines
(PUT, N1-AcSPD, SPM, DESPM and EtSPM) are shown in Fig. 11. Common signal suppression
for basic compounds was observed when the solvent system contained strong acids like TFA,
PFPA and HFBA but not with weaker acids like AA and BA. On the other hand, it was found
that SPM, DESPM and EtSPM could not be analyzed using solvent systems containing FA, AA
or BA as the acid. These analytes were adsorbed onto the mass spectrometer tubing, and they
emerged later as broad peaks. One possible explanation for this phenomenon is the weak ion pair
that forms between the sample and the weak acid anion, which allows a sample interaction with
carbonyl groups which are present in the polyetheretherketone, material of which the tubing is
made. It was also noted that relative signal intensities varied between the different analytes. This
means that stable isotope analogues rather than structural homologues should be used in
quantitative analysis, because the response of the labelled standards would be virtually the same
as for the analytes.
Figure 11. Relative signal intensity for analytes in different solvent compositions. Five parallel FIA of five
polyamines were carried out in the SRM mode using 0.1% acid in water and 0.1% acid in ACN in a ratio
1:1 as a solvent. SPM, DESPM and EtSPM could not be detected accurately using FA, AA or BA as an
acid. The influence of the addition of 2% (v/v) PrA to the HFBA containing solvent system is shown in
right. Error bars illustrate the standard deviation.
4.1.3 Analytical chromatography
Retention times for all polyamines in different solvent compositions are shown in Table 9, and
the retention factor k for five selected analytes (PUT, N1-AcSPD, SPM, DESPM and EtSPM) in
different solvent compositions are shown in Fig. 12. The results reveal that complete
chromatographic separation of the eight polyamine standards (PUT, CAD, DAH, N1-AcSPD, N8-
AcSPD, SPD, N1-AcSPM and SPM) and four alkylated polyamine analogues (DESPM, EtSPM,
EtSPD and EtDAP) was achieved using HFBA as an acid. In addition, PFPA was able to retain
polyamines in the column to some extent. When using PFPA as an ionpairing agent instead of
HFBA, it was noted that SPM and SPD eluted faster than the other analytes (see Table 9). Other
acids were not able to retain polyamines sufficiently in the reversed phase material. Furthermore,
weaker acids were not able to decrease the interaction of polyamines with the free silanol groups
in the column material, and severe peak tailing was observed with some of the polyamines. This
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interaction was greatly reduced by using stronger acids. The solvents used for sample dilution
were also found to influence the chromatographic separations. When studying the relative signal
intensity and retention times, the injection volume was 1 µL. When the injection volume was
increased to 10 µL, the samples had to be diluted with 0.1% HFBA instead of plain water prior to
chromatography. With water, some of the compounds were not retained completely by the
column, probably because of the insufficient replacement of the polyamine chloride ions with
solvent acid ions. When 0.1% HFBA was used for dilution, all the compounds were retained.
Figure 12. The effect of solvent composition on the retention factor k.  RP-LC-MS/MS separations were
performed by linear gradient elution of 0-50% B in 10 minutes (Solvent A: 0.1% (v/v) acid in water, solvent
B: 0.1% (v/v) acid in ACN) at flow rate of 0.2mL/min. Injection volume of the 100  µM sample was 1 µL.
Polyamines were not retained properly to the column using FA, AA, BA or TFA as an ion-pairing acid. The
influence of the addition of 2% (v/v) PrA to the HFBA containing solvent system is shown in right.
 Table 9. Retention times for studied polyamines under different solvent compositions.
Compound FA AA BA TFA PFPA HFBA HFBA + PrA
PUT 0.43 0.43 0.43 0.55 0.82 2.49 1.69
CAD 0.43 0.43 0.43 0.56 0.87 2.97 1.88
EtDAP 0.43 0.42 0.42 0.56 0.97 3.62 2.23
N1-AcSPD 0.43 0.43 0.43 0.62 1.33 4.52 3.24
N8-AcSPD 0.43 0.43 0.43 0.67 1.58 4.81 3.72
DAH 0.43 0.43 0.43 0.68 1.85 5.02 4.03
SPD 0.43 0.43* 0.44* 0.54 1.28 5.97 4.99
EtSPD 0.43 0.44* 0.44* 0.57 1.98 6.37 5.73
N1-AcSPM 0.43 0.44* 0.51* 0.63 2.89 6.44 5.93
SPM 0.44* 0.46* 0.46* 0.54 2.68 7.19 6.83
EtSPM 0.45* 0.70* 0.48* 0.57 4.25 7.36 7.06
DESPM 0.45* 0.48* 0.47* 0.64 4.92 7.53 7.28
A linear gradient elution of 0-50% B in 10 minutes was performed at flow rate 0.2 mL/min. Solvent A was 0.1% (v/v)
acid in water and solvent B was 0.1% (v/v) acid in ACN. The acids tested were formic- (FA), acetic- (AA), butyric-
(BA), trifluoroacetic- (TFA), pentafluoroacetic- (PFPA) and heptafluoroacetic (HFBA) acids. Polyamines are in the
order they appeared with the HFBA containing solvent system. The influence of the addition of 2% (v/v) PrA to the
HFBA containing solvent system is shown as HFBA+PrA. Severe tailing was observed for compounds marked with *.
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4.1.4 Signal suppression and enhancement
When volatile strong acids were used as ion-pairing reagents in the reversed phase LC, this
causes  signal  suppression  for  basic  compounds  in  the  ESI-MS  analysis.  This  was  also  noted
when relative signal intensity measurements with different ion-pairing reagents were compared
with each other (see Fig. 11.) Kuhlmann et al. [1995] have proposed a practical method to
enhance the signal for most basic analytes by employing post-column addition of a solution of
75% PrA and 25% IPA in a ratio 1:2 to the column flow. We also studied the influence of this
method on the relative signal intensity (see Fig. 11). The results revealed that addition of 2% PrA
to the solvent system increased relative signal intensity slightly, up to ~3 times depending on the
measured molecule. The influence of PrA addition on the retention times was on the contrary
unfavourable, because it was noted that peaks started to fail to be retained as compared with the
result without PrA (see Fig. 12). Due to the undesirable effect on the retention times, isocratic
post-column addition of a solution of 75% PrA in IPA was done through a PEEK mixing tee in a
ratio 1:2 to the column flow as in [Kuhlmann et. al. 1995]. The influence of the PEEK mixing tee
and post-column flow on the peak shape and retention times was studied. Number of theoretical
plates N, were calculated for four of the analytes (PUT, SPD, SPM and N1-AcSPD) from the
three chromatographic separations performed. These three values for each four analytes are
shown in Table 8. The results indicate that the column efficiency was decreased because of the
PEEK mixing tee volume. The post-column addition of 75% PrA in IPA had no significant
additional effect on N, but increased the relative signal intensity 4–10 times depending on the
analyte (see Fig. 13). As the best results were achieved with HFBA as the ion pairing agent
together with the post-column addition of 75% PrA in IPA, these were selected for further
method development.
Figure 13. The effect of the post-column addition of 75% PrA in IPA on relative signal intensity. RP-LC-
MS/MS separation of eight polyamines was carried out by linear gradient elution of 0-50% B in 10 minutes
(Solvent A: 0.1% (v/v) HFBA in water, solvent B: 0.1% (v/v) HFBA in ACN) at flow rate of 0.2 mL/min.
Injection volume of the 100 µM sample was 1 µL. Sample was diluted with water. Isocratic post-column
addition of a solution of 75% PrA and 25% IPA in a ratio 1:2 was performed through a PEEK mixing tee at
0.1 mL/min into the column flow. Experiments were performed in triplicate and the error bars show the
standard deviation.
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4.1.5 Metabolic studies of DESPM
The positive ion LC–MS/MS SRM chromatograms of the mixture of eight polyamine standards
are shown in Fig. 14, the mixture of four N-alkylated polyamine analogues in Fig. 15., and SRM
chromatograms of three different DESPM incubation experiments are shown in Fig. 16 (a = 0
min, b = 30 min and c = 60 min). The metabolites formed in the catabolism of DESPM included
EtSPM, EtSPD, SPD and EtDAP. DESPM was used as the substrate. However it is known to
contain traces of EtSPM (see Fig. 16A). Nonetheless, one can see clear increases in the amount
of EtSPM in the chromatograms after the incubation with hPAO, which could not be due to the
presence of these trace impurities in the substrate (see Fig. 16B and C). Due to the fact that
relative signal intensities are greatly dependent on the analyte being measured, the determination
of the quantitative amounts of metabolites requires the use of labelled (e.g. deuterated) analogues
as internal standards. The degradation products originated from DESPM by hPAO, which were
found after MS analysis, are clear evidence of enzymatic de-ethylation of DESPM to EtSPM
[Bergeron et. al. 1995], and the appearance of EtSPD support the belief that DESPM can be
degraded like diacetylated spermine by PAO [Vujcic et. al. 2003]. Furthermore, we detected both
SPD and EtDAP. SPD may be derived from EtSPD [Vujcic et. al. 2003], but interestingly EtDAP
should be derived from endo-cleavage that has not been shown to occur with mammalian PAO.
However, plant, bacterial and protozoan PAOs are known to be responsible for the endo-cleavage
(or terminal catabolism) of polyamines [Cona et. al. 2004]. PUT was not detected from the
metabolic studies of DESPM, suggesting that EtSPD is not recognized as a mimic of N1-AcSPD
by hPAO. A schematic representation of the possible catabolic pathways of DESPM is shown in
Fig. 17. These results suggest that hPAO-mediated degradation is more complicated than shown
before.
4. LC-MS/MS method development
Kuopio Univ. Publ. C. Nat. and Environ. Sci. 263: 1-145 (2009) 73
Figure 14. Positive-ion RP-LC/MS/MS SRM chromatogram of mixture of eight polyamines, 100 µM each
with injection volume of 10 µL. Elution order: 1. PUT, 2. CAD, 3. N1-AcSPD, 4. N8-AcSPD, 5. DAH, 6.
SPD, 7. N1-AcSPM, 8. SPM.
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Figure 15. Positive ion RP-LC/MS/MS SRM chromatogram of mixture of four N-alkylated polyamine
analogues, 100 µM each with injection volume of 10 µL. 1. EtDAP, 2. EtSPD, 3. EtSPM, 4. DESPM.
Figure 16. Positive ion LC-MS/MS SRM chromatograms of three different incubation experiments carried
out with DESPM as the substrate of hPAO (a = 0min, b = 30min and c = 60min.) Chromatographic
separation and MS identification of DESPM metabolites was performed using the final LC-MS/MS
conditions described in detail in the experimental section.
4. LC-MS/MS method development
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Figure 17. Possible catabolic pathways of DESPM catalyzed by hPAO. (a) De-ethylation of DESPM to
EtSPM [Bergeron et. al. 1995], (b) Exo-cleavage of DESPM to EtSPD, mimicking the catabolism of N1,N12-
DiAcSPM [Vujcic et. al. 2003], (c, d and e) Endo-cleavage of DESPM to EtDAP, (f) SPD derived from
EtSPM [Vujcic et. al. 2003], (g) De-ethylation of EtSPD to SPD, and (h) Exo-cleavage of EtSPM to EtSPD.
4.2 CONCLUSIONS
All polyamines in the study (PUT, CAD, DAH, N1-AcSPD, N8-AcSPD, SPD, N1-AcSPM, SPM
and four N-alkylated polyamine analogues DESPM, EtSPM, EtSPD and EtDAP) were separated
and detected without any derivatization using the developed LC–MS/MS method. Five volatile
acids were tested as ion-pairing reagents, of which HFBA proved to yield the best
chromatographic separation of the analytes with good symmetrical peak shapes. Even the closely
related N1-AcSPD and N8-AcSPD were separated from each other. Some of the tested acids were
not able to prevent adsorption of underivatized polyamines to instrument capillaries during MS
analysis and tailing of the peaks during LC gradient, but these were greatly reduced by using a
stronger acid like HFBA as the ion-pairing additive. The common problem of signal suppression
in ESI-MS for basic compounds by strong acids was prevented using post-column addition of
PrA to column flow. In comparison with conventional methods for polyamine analysis, this novel
LC–MS/MS technique is easier to use and is substantially faster since there is minimal sample
pre-treatment and rapid chromatographic separation. Moreover, the method allows unambiguous
identification of the products by the highly sensitive MS technique and the possibility to
eliminate interfering peaks arising from the matrix by selective MS/MS. The developed method
was successfully applied to identify metabolites of DESPM as a substrate for recombinant hPAO.
Metabolites formed in the hPAO reaction included EtSPM, EtSPD, SPD and EtDAP, suggesting
that hPAO-mediated degradation is more complicated than believed earlier.
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4.3  EXPERIMENTAL
4.3.1 Instrumentation
LC separations, MS detection and analysis of the compounds were achieved with Agilent 6410
Triple Quad LC/MS equipped with Agilent 1200 Series Binary Pump SL pumping system and
Agilent 1200 Autosampler. Data acquisition and analysis were performed using Agilent
MassHunterWorkstation software. The chromatographic separations were carried out using
Phenomenex Gemini reversed phase C18 column (3 µm, 30 mm×2 mm, 110 Å ). Ultrapure water
was prepared using a Milli-Q Gradient system (Millipore, Milford, MA, USA).
4.3.2 Reagents
Butane-1,4-diamine dihydrochloride (PUT), pentane-1,5-diamine dihydrochloride (CAD), and
heptane-1,7-diamine (DAH) were from ICN Biomedicals Inc. N1-(3-Aminopropyl)butane-1,4-
diamine trihydrochloride (SPD), N-[3-(4-aminobutylamino)propyl]acetamide dihydrochloride
(N1-AcSPD), N-[4-(3-aminopropylamino)butyl]acetamide dihydrochloride (N8-AcSPD), N,N’-
bis(3-aminopropyl)butane-1,4-diamine tetrahydrochloride (SPM) and N-{3-[4-(3-
aminopropylamino)-butylamino]propyl}acetamide trihydrochloride (N1-AcSPM) were from
Aldrich. N,N’-Bis(3-ethylaminopropyl)butane-1,4-diamine (DESPM) was synthesized essentially
as described earlier [Rehse et. al. 1990]. Preparation methods for N1-ethylpropane-1,3-diamine
dihydrochloride (EtDAP), N1-(3-ethylaminopropyl)butane-1,4-diamine trihydrochloride (EtSDP)
and N-(3-aminopropyl)-N’-(3-ethylaminopropyl)butane-1,4-diamine tetrahydrochloride (EtSPM),
see Chapter 6. Stock solutions of the standards were prepared by dissolving an appropriate
amount in ultrapure water to yield a concentration of 1 mM. All solutions were passed through a
0.22 µm filter, stored at ?20°C and used after dilution to the required concentration. Ultra
gradient HPLC-grade acetonitrile (ACN) was purchased from J.T. Baker. Trifluoroacetic acid
(TFA, 99+%), pentafluoropropionic acid (PFPA, 97%) and heptafluorobutyric acid (HFBA,
99%) from Aldrich. Butyric acid (BA, >99.5%), acetic acid (AA, >99.8%), propionic acid (PrA,
>99.5%) and isopropanol (IPA> 99.8%) from Fluka, and formic acid (FA, 99%) from Riedel-
deHaën. Recombinant human polyamine oxidase (hPAO) was produced as described earlier
[Järvinen et. al. 2005]. All other reagents were from Sigma.
4.3.3 Mass spectrometer conditions
Flow injection analysis (FIA) was used to optimize the fragmentor and source parameters. The
drying gas temperature was varied between 300 and 350 °C, drying gas flow between 6 and 10
L/min and capillary voltage between 3500 and 4500V. The optimized source parameters for MS
analysis were as follows: drying gas temperature 300 °C and gas flow 8 L/min, nebulizer gas
pressure 40 psi and capillary voltage 4000V. Fragmentor voltage values were tested between 0
and 120V for each polyamine to obtain the highest precursor ion abundance, and the optimized
values are shown in Table 8. After optimization, positive-ion mass spectra for each polyamine
were generated by FIA in full scan mode at the mass range m/z 50–400. MS/MS experiments
were based on collisionally activated dissociation occurring in the collision cell (quadrupole 2) of
the triple quadrupoles, with a nitrogen collision gas. In order to determine the characteristic mass
fragments for selected reaction monitoring (SRM) analysis, the product spectra of each
polyamine were recorded in full scan mode by varying the offset voltage between 5 and 20 eV.
The characteristic product ion was selected and the optimal collision energy value chosen to
obtain the highest selected product ion abundance. Precursor ions, chosen product ions and
collision energy values for all analytes used in the following SRM analysis are given in Table 8.
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4.3.4 Relative signal intensity studies
The relative signal intensity for different solvent compositions was measured by comparing the
relative peak area obtained from FIA of five polyamines (PUT, N1-AcSPD, SPM, DESPM and
EtSPM). Five parallel injections were carried out and analyzed in the multiple reaction
monitoring mode (SRM) using the chosen fragmentation and optimized fragmentor and collision
energy values described in Table 8. Dwell time was adjusted to 200 ms, injection volume of the
100 µM sample was 1 µL and the delay between injections was 30 s. The sample was diluted
with water. Solvent system consisted of 0.1% acid in water (solvent A) and 0.1% acid in ACN
(solvent B) in a ratio 1:1. Acids tested were FA, AA, BA, TFA, PFPA and HFBA. The influence
of propionic acid to the relative signal intensity was carried out using the conditions mentioned
above, where the solvent A was 0.1% (v/v) HFBA and 2% (v/v) PrA in water, and solvent B was
0.1% (v/v) HFBA and 2% (v/v) PrA in ACN.
4.3.5 Chromatographic conditions
Chromatographic separations were carried out by an analytical LC–MS/MS using a gradient
solvent system at flow rate of 0.2 mL/min. A gradient of 0.1% (v/v) acid in water (solvent A) and
0.1% (v/v) acid in ACN (solvent B) was used. Gradient was increased from 0 to 50% B over 10
min. Reversed phase column was thermostated to 25 °C. MS/MS detection of the eluted analytes
were carried out in the SRM mode using precursor ions, chosen product ions and optimized
fragmentor and collision energy values as described in Table 8. Dwell time for all was adjusted
to 50 ms. Two samples were used in the studies, one containing a mixture of eight polyamine
standards (PUT, CAD, DAH, N1-AcSPD, N8-AcSPD, SPD, N1-AcSPM and SPM) and the other
including a mixture of four N-alkylated polyamine analogues (DESPM, EtSPM, EtSPD and
EtDAP). In the retention time studies, two samples were diluted with water to a concentration of
100 µM and the injection volume of the sample was 1 µL. Acids studied in the solvent system
were FA, AA, BA, TFA, PFPA and HFBA. Reliability was checked by at least two injections,
except for FA, where only one injection was performed with each of the two polyamine mixtures.
The effect of propionic acid on the retention times was checked using the LC–MS/MS conditions
mentioned above, where the solvent A was 0.1% (v/v) HFBA and 2% (v/v) PrA in water, and
solvent  B was 0.1% (v/v)  HFBA and 2% (v/v)  PrA in ACN. The injection volumes of  the two
samples were 1 µL, and the dilution to 100 µM was done with water. The retention factor k for
each solvent composition was calculated using the equation k =  (tR? ?t0)/t0, where tR is the
retention time and t0 is the solvent front (0.42).
4.3.6 The effect of post-column addition of PrA to relative signal intensity and retention times
The post-column addition of a solution of 75% PrA and 25% IPA was performed through a
PEEK mixing tee (VICI Jour Research AB, Sweden) at 0.1 mL/min into the column flow. Other
LC–MS/MS conditions were as before, where the solvent A was 0.1% (v/v) HFBA in water and
solvent B was 0.1% (v/v) HFBA in ACN. The influences of the PEEK mixing tee and the post-
column flow on the peak shape and retention times were studied under the following conditions:
Three different chromatographic separations were performed and each of them was repeated
three times: one without the PEEK mixing tee, the other with the tee but without the postcolumn
flow and the third with the tee and the post-column flow. The injection volume of the sample
containing a mixture of eight polyamine standards (PUT, CAD, DAH, N1-AcSPD, N8-AcSPD,
SPD, N1-AcSPM and SPM) was 1 µL in each run, with the dilution to 100 µM being made with
water. The number of theoretical plates N, was then calculated for four of the analytes (PUT,
SPD,  SPM  and N1-AcSPD) from the three chromatographic separations performed, using the
equation N = 5.54(tR/W1/2)2. The relative signal intensity was measured by comparing the relative
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peak areas obtained from the LC–MS/MS run with the tee but without the post-column flow, and
the LC–MS/MS run with the tee and the post-column flow.
4.3.7 The final LC–MS/MS conditions for DESPM metabolic studies
A gradient solvent system at flow rate of 0.2 mL/min. A gradient of 0.1% (v/v) HFBA in water
(solvent A) and 0.1% (v/v) HFBA in ACN. The gradient was increased from 0 to 50% B over 10
min. Column temperature was adjusted to 25 °C. Isocratic post-column addition of a solution of
75% PrA and 25% IPA was performed through a PEEK mixing tee at 0.1 mL/min to the column
flow. MS/MS detection of the eluted analytes were carried out in the SRM mode using precursor
ions, product ions and optimized fragmentor and collision energy values described in Table 8.
Dwell time for all was adjusted to 50 ms. LC–MS/MS conditions were tested prior to the
DESPM metabolic studies by investigating two samples, one containing a mixture of eight
polyamine standards (PUT, CAD, DAH, N1-AcSPD, N8-AcSPD, SPD, N1-AcSPM and SPM) and
the other including four N-alkylated polyamine analogues (DESPM, EtSPM, EtSPD and EtDAP).
The injection volume of the 100 µM sample was 10 µL and the sample was diluted with 0.1%
HFBA in water. Reproducibility was checked with two injections.
4.3.8 Metabolic studies of DESPM
Enzymatic degradation of DESPM was performed with recombinant hPAO. Reactions were
carried out in a total volume of 360 µL including 100 mM glycine–NaOH buffer pH 9.5, 1 mM
DESPM and 1 µg hPAO. The reactions were allowed to proceed for the indicated time at +37 °C
before the addition of 40 µL of 50% formic acid in water. The first of the incubations was
stopped immediately (incubating time 0 min), the second after 30 min of incubation and the third
after 60 min of incubation. All solutions were passed through 0.22 µm filter and stored at ?20 °C.
Prior to LC–MS/MS analysis, samples were diluted 1:10 with 0.1% HFBA in water. The final
LC–MS/MS conditions described above were used to analyze the samples. The injection volume
of the diluted sample was 10 µL. The reproducibility was checked with two injections.
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5.  LC-MS/MS METHOD VALIDATION FOR POLYAMINE ANALYSIS
Adapted/Modified from Journal of Pharmaceutical and Biomedical Analysis, Vol. 48, Häkkinen M. R., Keinänen T. A.,
Vepsäläinen J., Khomutov A. R., Alhonen L., Jänne J., Auriola S. Quantitative determination of underivatized polyamines
by using isotope dilution RP-LC–ESI-MS/MS, Pages No. 414-421, Copyright (2008), with permission from Elsevier.
In this study, a fast and sensitive quantitative method was developed and validated to separate
and analyze five polyamines (DESPM, EtSPM, EtSPD, SPD and EtDAP) by LC-MS/MS using
HFBA as an ion-pairing reagent in chromatographic separation and stable, deuterium labelled
reference compounds as internal standards (ISs) in quantification. The matrix ionisation
suppression effect for the proposed ion-pairing LC-ESI-MS/MS systems was investigated using
the post-column infusion technique. Unlike conventional methods of polyamine analysis,
separation and quantitative analysis were carried out without any derivatization and after
straightforward sample preparation. The developed method was successfully applied to the
quantification of metabolites of DESPM as a substrate for hPAO.
5.1  RESULTS AND DISCUSSION
5.1.1  LC–MS/MS optimization
Analyses  were  performed  by  RP-LC  followed  by  ESI  in  the  positive  ion  mode  and  MS/MS
detection. The structures, molecular masses, retention times, measured precursor ions and
MS/MS data for quantification of the compounds studied are summarized in Table 10. All
studied polyamines produced protonated [M+H]+ molecules and no adduct formation was
observed. In order to determine the optimal conditions for SRM analysis, the positive ion product
spectra of each polyamine were recorded as described in Chapter 4. The fragment ions in the IS
and STD MS/MS spectra are presumably similar type ring structures as described before
[Feistner 1994, Bigler & Hesse 1995, McLuckey et. al. 2000, de Maaijer-Gilbert et. al. 1999],
although product ions with linear structures are also possible [Gosetti et al. 2007, Zhang et. al.
1998]. An excellent chromatographic separation of the quantified analytes with good
symmetrical peak shapes was achieved in 10 min using volatile HFBA as the ion-pairing agent
essentially as reported in Chapter 4, with few exceptions. The gradient was increased from 2 to
50% organic and no post-column addition of propionic acid (PrA) was used to prevent
suppression. HFBA is known to suppress ionization in the MS, and the addition of PrA has been
demonstrated to compensate for this suppression to some extent [Kuhlmann et. al. 1995, Apffel
et. al. 1995, Shou & Naidong 2005] Postcolumn addition of IPA/PrA was shown to increase
polyamine signal in electrospray by 4–10-fold (see Chapter 4.) However, addition of IPA/PrA
results in severe background in certain studied MS/MS channels, especially concerning EtSPM
ion transition m/z 231–157. Since the PrA addition was not beneficial for all analytes, and to keep
the chromatography as simple as possible, no post-column addition was used in this study. In the
experimental conditions, the retention times for each compound did not exhibit any significant
changes (R.S.D. <0.12%, n = 175) as shown in Table 10. for each compound. However, a high
carry-over (approx. 0.1%) after concentrated samples was noted during chromatographic method
validation. In particular, traces of DESPM and EtSPM remained in the system after several blank
injections. One possible source for the contamination is the injector valve. Standards and QC
samples were analyzed before the samples within each analysis batch, and reasonable numbers of
blank injections were performed before the samples to minimize any carry-over effects. The
interference  arising  from  IS  in  the  STD  MS/MS  channels  ranged  from  0  to  0.2%,  and  the
interference from the STD solution in the IS MS/MS channels ranged from 0.04 to 0.5%. No ion
suppression arising from the matrix was found to affect to the sensitivity of the method.
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5.1.2  Sample preparation
The solvent used for sample dilution can influence the chromatographic separations, since the
compounds are not retained completely by the column without using 0.1% HFBA for dilution,
probably because of the insufficient replacement of the polyamine chloride ions with solvent acid
ions as shown in Chapter 4. For this reason all the samples, standards and QC samples were
prepared to a final concentration of 0.1% HFBA. Metabolic studies of DESPM were carried out
using 100 mM Gly–NaOH buffer pH 9.5, and incubations were stopped with 50% FA resulting
in the sample matrix solution to be 90 mM in concentration of Gly–NaOH and 5% of FA. All the
standards and QC samples were prepared to have the same matrix to ensure that accuracy,
precision, selectivity and sensitivity would not be affected when any samples originally above the
upper limit of the standard curve were diluted with the 90 mMGly–NaOH–FA buffer. To
compensate for any possible bias in accuracy originating from the sample preparation, all the
samples, standards and QC samples were prepared similarly by adding IS solution and HFBA
solution to the sample.
5.1.3  Linearity of calibration curves and lower limit of quantification (LLOQ)
The method was linear for DESPM, EtSPD, SPD and EtDAP over the range 0.03–60 µM (0.012–
24 µM in the injected solution) and for EtSPM over the range 0.03–30 µM (0.012–12 µM in the
injected solution). The mean equations of the calibration curves (n = 4) with standard deviations
are shown in Table 11. X is the concentration of each analyte in the sample before sample
preparation (µM) and Y is the peak-area ratios of each analyte to its deuterated analogue. The
correlation coefficients (R2) were always >0.995 for all analytes. The mean correlation
coefficients are shown in Table 11. The LLOQ for determination of DESPM, EtSPM, EtSPD,
SPD and EtDAP,was 0.03 µM (0.012 µM in the injected solution) for all, which is equivalent to
49 pg of DESPM, 45 pg of EtSPM, 34 pg of EtSPD, 31 pg of SPD and 21 pg of EtDAP as their
hydrochloride salts injected on-column. LC–MS/MS SRM chromatograms of SPD (the common
endogenous polyamine) in the zero, LLOQ and 60 min incubation sample as an example, are
shown in Fig. 18a–c.
Table 11. The mean equations of the calibration curves (n = 4) with standard deviations shown in
parentheses. *
Compound Regression equation R2
DESPM Y = 1.2738 (0.0339)X + 0.0012 (0.0061) 0.9998 (0.0001)
EtSPM Y = 1.2555 (0.0346)X + 0.0027 (0.0008) 0.9980 (0.0007)
EtSPD Y = 0.9628 (0.0133)X + 0.0008 (0.0010) 0.9994 (0.0002)
SPD Y = 1.1087 (0.0186)X + 0.0032 (0.0013) 0.9966 (0.0013)
EtDAP Y = 1.1863 (0.0391)X + 0.0191 (0.0021) 0.9993 (0.0006)
* X is the concentration of each analyte in the sample (µM), Y is the peak-area ratios of each analyte to its
deuterated analogue, and R2 is the mean correlation coefficient.
5.1.4  Assay precision and accuracy
For all QC levels the intra-day precision ranged from 0.2 to 9.7% (R.S.D.) and accuracy ranged
between 87.6 and 109.8%. The interday precision of the overall method ranged between 0.9 and
6.8%, and the inter-day accuracy of the assay ranged between 89.6 and 106.6%. The results for
LLOQ and QC are shown in Table 12.
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Figure 18. Positive ion SRM chromatograms of SPD in the mixture of five studied polyamines and their
deuterated analogues as an IS. a) Zero sample, corresponding  to buffer, 0.4 µM IS and 0.1% HFBA in
the sample vial with injection volume of 10 µL. b) LLOQ (0.03 µM ) sample, corresponding to 0.012 µM
STD, 0.4 µM IS and 0.1% HFBA in the sample vial with injection volume of 10 µL. c) 60 min incubation
sample. QT = Quantifier transition, QL = Qualifier transition, IS = deuterated analogue as an internal
standard.
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5.1.5  Stability of the analytes
Stock solutions of polyamines and their deuterated analogues were stable for at least 18 h at room
temperature, 1 week in a refrigerator, and at least 1 week in a freezer. Working standard solutions
were stable in polypropylene tubes for at least 1 week. Analytes were also found to be stable after
three freeze–thaw cycles and no degradation was seen during post-preparative storage in the
instrument autosampler. Glass tubes were noted to adsorb the analytes in low concentration
samples when stored at 10 °C for 24 h, so all the solutions should be stored in polypropylene
containers. However, analytes were stable and no significant adsorption was observed when the
samples containing 0.1% HFBA were stored in Agilent glass vial inserts, Agilent deactivated
glass vial inserts or Agilent polypropylene vial inserts in the instrument autosampler at 10 °C for
24 h.
5.1.6  Application of the method to metabolic studies of DESPM
Enzymatic degradation of DESPM was performed with hPAO. Positive ion LC-MS/MS SRM
chromatograms of a 60 min incubation experiment, as an example, are shown in Fig. 19.
Quantitative results for measured samples, with 95% confidence intervals (n = 3) in parenthesis,
are shown in Table 13. No interference was arising from the enzyme addition to the sample in the
IS or STD MS/MS channels (data not shown). Metabolites formed in the catabolism of DESPM
included EtSPM, EtSPD, SPD and EtDAP as already reported in Chapter 4. Unlike before, in this
study DESPM, used as an enzyme substrate, contained no traces of EtSPM. During the studies,
concentrations of four DESPM metabolites were 0.03–60 µM, after dilution of the samples to
1:10 with the buffer, which did not alter the matrix composition. When assessing the results
shown in Table 13, it can be concluded the major metabolite was EtSPD (82%), indicating that
DESPM is catabolized in a similar manner as diacetylated spermine (N1,N12-AcSPM). [Vujcic et.
al. 2003] However, also EtSPM (11%) and EtDAP (6%) were detected, pointing to minor
catabolic pathways such as de-ethylation, [Bergeron et. al. 1995] and the previously shown endo-
cleavage (see Chapter 4.) Comparing the 30 min and 60 min incubation results, it can be seen
that after 60 min incubation, the amounts of EtSPD and EtDAP are 1.87 and 1.84 times greater
than the amounts resulting after the 30 min incubation, respectively. Thus, the formation of
EtSPD and EtDAP is linear in time within 95% confidence intervals. However, the amounts of
EtSPM and SPD after 60 min incubation were 1.66 and 3.53 times greater than the amounts
resulting after the 30 min incubation, respectively. In conclusion, EtSPM appears to be further
metabolized to SPD, mimicking the catabolism of N1-AcSPD by PAO. [Vujcic et. al. 2003]
Table 13. Quantitative results (µM) of DESPM reactions with hPAO. Mean values from triplicate incubation
samples, with 95% confidence intervals (n = 3) in parenthesis. ND = Not detectable
Sample DESPM EtSPM EtSPM SPD EtDAP
without hPaO 94.24 (4.76) ND ND ND ND
0 min 94.29 (4.96) 0.03 (0.01) 0.07 (0.02) ND ND
30 min 86.64 (1.18) 1.13 (0.03) 7.79 (0.51) 0.072 (0.003) 0.56 (0.06)
60 min 78.49 (3.48) 1.87 (0.08) 14.56 (3.47) 0.254 (0.030) 1.03 (0.18)
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Figure 19. Positive ion SRM chromatograms of a 60min incubation experiment carried out with DESPM
as the substrate of hPAO. QT = Quantifier transition, QL = Qualifier transition, IS = deuterated analogue
as an internal standard.
5.2 CONCLUSIONS
All  polyamines  in  the  study  (DESPM,  EtSPM,  EtSPD,  SPD  and  EtDAP)  were  separated  and
quantified without any derivatization using the developed LC-MS/MS method. Stable isotope
reference compounds of the studied molecules were included as internal standards to the method.
HFBA  as  an  additive  in  the  LC  separations  has  two  important  functions  in  the  analysis  of
polyamines. It enables the chromatographic separation of the highly polar analytes, giving them
good symmetrical peak shapes and prevents the unwanted interaction of these basic analytes to
free silanol groups in the column and to capillaries in the instrument. The sensitivity of the LC-
MS/MS method was about 30 times better than the previously used LC fluorescense system
[Porter et. al. 1985]. Moreover, the analysis time could be further decreased by using higher
eluent flow rates. In comparison to conventional methods of polyamine analysis, the developed
LC-MS/MS is easier to use and is substantially faster due to minimal sample pre-treatment and
rapid chromatographic separation. Moreover, the method allows clear identification of the
products by highly sensitive MS and the possibility to eliminate interfering peaks arising from
the matrix by selective MS/MS. The developed method was successfully applied to quantify
metabolites of DESPM as a substrate for hPAO. During the studies, concentrations of four
DESPM metabolites were between 0.03 and 60µM after dilution of the samples to 1:10 with the
buffer, which did not alter the matrix composition. Quantitative analysis of the DESPM
metabolites indicates that hPAO mediated degradation is more complicated than believed earlier.
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5.3  EXPERIMENTAL
5.3.1  Reagents
SPD was from Aldrich. The preparation methods for EtDAP, N1-ethyl-3,3-2H2-propane-1,3-
diamine dihydrochloride (EtDAP-2D), N1-(1,1-2H2-(3-amino)propyl)butane-1,4-diamine
trihydrochloride (SPD-2D), EtSPD, N1-(1,1-2H2-(3-ethylamino)propyl)-butane-1,4-diamine
trihydrochloride (EtSPD-2D), EtSPM, N-(3-aminopropyl)-N’-(1,1-2H2-(3-ethylamino)propyl)-
butane-1,4-diamine tetrahydrochloride (EtSPM-2D), DESPM and N, N’-bis(1,1-2H2-(3-
ethylamino)propyl)-butane-1,4-diamine (DESPM-4D) see III (Chapter 6). Ultra gradient HPLC-
grade acetonitrile (ACN) was purchased from J.T. Baker, and heptafluorobutyric acid (HFBA,
>99%) from Fluka. Sterile filtered deuterium oxide (>99%) was from Spectra Stable Isotopes,
USA. Sodium 3-(trimethylsilyl)-1-propionic acid (TSP, 99.8% atom D) was from Euriso-top,
France. All other reagents were from Sigma. Ultrapure water was prepared using a Milli-Q
Gradient system (Millipore, Milford, MA, USA). Recombinant human polyamine oxidase was
produced as described earlier [Järvinen et. al. 2005].
5.3.2  LC–MS/MS instrumentation and analytical conditions
LC separations, MS/MS detection and analysis of the compounds were achieved with Agilent
6410 Triple Quad LC/MS equipped with Agilent 1200 Series Binary Pump SL pumping system
and Agilent 1200 Autosampler. Data acquisition and analysis were performed using an Agilent
MassHunter Workstation software (Agilent Corporation, MA, USA).
The chromatographic separations were carried out using a Phenomenex Gemini reversed phase
C18 column (3 µm, 30 mm ×2 mm, 110 Å) protected with a Phenomenex C18 guard column (4
mm×2 mm). The column was thermostated to 25 °C and the autosampler tray temperature was
set at 10 °C. The injection volume was 10 µL and the injection was performed using 10 s needle
wash with 50% ACN. A gradient solvent system consisting of 0.1% (v/v) HFBA in water
(solvent A) and 0.1% (v/v) HFBA in ACN (solvent B) was used and the gradient was increased
from 2 to 50% B over 10 min at a flow rate of 0.2 mL min?1.
Ionization was achieved using electrospray ionization (ESI) in the positive mode with the
capillary voltage 4000 V. Nitrogen was used as nebulizer gas and nebulizer pressure was set at
40 psi. Drying gas (nitrogen) temperature was 300 °C and gas flow was 8 L/min. Fragmentor
voltage value was set to 90V for all analytes to obtain the highest precursor ion abundance.
MS/MS experiments were based on selected reaction monitoring (SRM) analysis, with high
purity nitrogen as collision gas. The product spectra of each polyamine were recorded similarly
as described earlier (see Chapter 4). Precursor ions, selected product ions for quantification and
qualification, and collision energy values for all analytes used in the following quantitative SRM
analysis are given in Table 10. Both resolving quadrupoles were maintained at unit resolution
(0.7 amu) during SRM analysis. Dwell time for allwas adjusted to 50 ms, and electron multiplier
voltage was 1400 V.
5.3.3  Preparation of standards
Stock solutions of five calibration standards and five internal standards were prepared by
dissolving an appropriate amount in 0.5 or 1 mL D2O to yield a concentration of approximately
100 mM. Weighing of the analytes was done with a calibrated analytical balance (Ohaus GA 200
D, England). All solutions were also analyzed by NMR (Bruker Avance (Bruker, Rheinstetter,
Germany) spectrometer operating at 500.13 MHz to ensure the actual concentration of the stock
solutions and the purity of the analytes. Quantitative NMR-spectra were measured from each
stock solution diluted to 1:1 TSP (100 mM) as an internal reference and collecting 32 scans using
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a 90º  pulse  angle,  and a  60 s  relaxation time.  Stock solutions were stored in  a  refrigerator  at  a
temperature between 1 and 9 °C. One millimolar stock solution of five polyamines in 90 mM
Gly-NaOH-FA buffer was prepared by pipetting 100 µl of 10 mM mixture of five polyamines in
water, 100 µl 50 % formic acid, 90 µl 1M glycine-NaOH buffer pH 9.5 and 710 µl water.
Standard working solutions (STD) were then prepared by diluting this 1 mM stock solution with
90 mM Gly-NaOH-FA buffer (90 mM Glycine-NaOH buffer, pH = 9.5, to which 50 % FA has
been added to yield 5 % v/v FA) to achieve STD concentrations of 0.03, 0.1, 0.3, 1, 3, 10, 30 and
60 µM. Working solutions for quality control (QC) samples were prepared from a separate stock
solution by diluting with the same 90 mM Gly-NaOH-FA buffer to achieve concentrations of
0.05, 0.2, 2 and 20 µM. Internal standard (IS) working solution containing 1 µM of each five
deuterated polyamine analogue was prepared from 100 mM stock solutions by diluting with
water. All the dilutions were made daily using volumetric pipettes and flasks. Each calibration
standard was prepared by pipetting 100 µl of each STD working solution, 100 µl of 1 µM IS
working solution and 50 µl 0.5 % HFBA in a polypropylene tube. Calibration curves were drawn
by having accurate concentration of working solution in X-axis, and peak area ratio sample vs.
internal standard in y-axis. Final concentrations in the sample vials were 0.012, 0.04, 0.12, 0.4,
1.2, 4, 12 and 24 µM, and an IS concentration of 0.4 µM. After vortexing, samples were
transferred into Agilent glass vial inserts (Borosilicate glass, part number 5181-3377) for the LC-
MS/MS analysis.
5.3.4 Metabolic studies of DESPM
Enzymatic degradation of DESPM was performed with hPAO. Reactions were carried out in a
total volume of 360 µL including 100 mM glycine-NaOH buffer pH 9.5, 1 mM DESPM and 1 µg
hPAO. The reactions were allowed to proceed for the indicated time at + 37 ºC and then stopped
by the addition of 40 µL of 50 % formic acid in water. The incubation at time 0 min was stopped
immediately, with the second incubation lasting 30 min and the third one for 60 min. In addition,
a sample containing only hPAO and no DESPM was included to ensure that no interference in
the IS or STD MS/MS channels was arising from the enzyme addition. Parallel samples not
containing hPAO were also studied to ensure that all metabolites were arising only from the
reaction with hPAO. All reactions were carried out in triplicate and stored at -20 ºC.
5.3.5 Sample preparation
Prior to LC-MS/MS analysis, samples were diluted to 1:10 with 90 mM Gly-NaOH-FA buffer
and passed through a 0.22 µm filter. Dilution with the buffer did not alter the sample matrix.
Samples were prepared by pipetting 100 µl of diluted sample solution, 100 µl of IS working
solution and 50 µl 0.5% HFBA in a polypropylene tube. After vortexing, samples were moved in
Agilent glass vial inserts for the LC-MS/MS analysis. QC samples were prepared similarly as the
standards and the incubation samples by pipetting 100 µl of each QC working solution, 100 µl of
1 µM IS working solution and 50 µl 0.5% HFBA in a polypropylene tube. Final QC
concentrations in the sample vials were: 0.02, 0.08, 0.8 and 8 µM, and IS concentration of 0.4
µM. The calibration curve included a blank sample (100 µl of 90 mM Gly-NaOH-FA buffer, 100
µl of water and 50 µl 0.5% HFBA) and a “zero” sample of 100 µl of 90 mM Gly-NaOH-FA
buffer, 100 µl of 1 µM IS working solution and 50 µl 0.5% HFBA.
5.3.6 Assay validation
Assay validation was performed according to the FDA guideline for bioanalytical method
validation [FDA 2001], with two exceptions. Recovery was not determined as the sample
preparation did not include sample extraction or processing steps. Inter-laboratory precision was
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not studied as all the samples were analyzed in the same laboratory using the same instruments.
Calibration standards were analysed before the samples within each analysis batch. Calibration
curves, ranging from 0.03-60 µM (in the original sample, 0.012 to 24 µM in the sample vial) of
the five analytes, were run on four separate days. Calibration included a blank sample and a
“zero” sample. Calibration curves were constructed from the peak area ratios of each analyte to
their deuterated analogues as an IS using a 1/x weighted linear least-squares regression model.
Five replicates of QC samples at four concentrations (0.05, 0.2, 2 and 20 µM in the original QC
sample, 0.02, 0.08, 0.8 and 8 µM in the QC sample vial) were included in each run to determine
the intra-day and inter-day precision and accuracy of the assay. Accurate concentrations of QC
working solutions were used in the method validation. RSD of the concentrations was used as an
index of precision. Accuracy was calculated by comparing the mean experimental concentrations
of assayed QC samples with their nominal values, and percentage values were used as the index.
The lower limit of quantification (LLOQ) for the method was defined as the lowest working
solution concentration analyzed with accuracy within 80-120% and precision better than 20%
RSD [FDA 2001]. The LLOQ was determined by calculating precision and accuracy for six
samples that were independent of the calibration curve. The system suitability was checked by
performing three replicate  injections of  2  µM QC sample (0.8 µM in the sample vial).  RSD of
peak areas of three injections was below 1.5 %. The stability of five deuterated polyamine
analogues in water and the level of interference to STD MS/MS channels were assessed by
analysing 100 µM IS stock solution after one week of storage in a refrigerator before sample
preparation. Final sample contained 50 µM IS in 0.1 % HFBA. The interference arising from the
STD solution to  IS MS/MS channels,  was assessed by analysing the sample containing 24 µM
STD  and  0.1%  HFBA  in  90  mM  Gly-NaOH-FA  buffer.  SRM  analysis  included  transitions  to
qualifier and quantifier product ions and also transitions to other product ions described in Table
10. The percentage level of interferences to STD MS/MS channels from IS solution was
calculated from the peak area ratios of each analyte to their deuterated analogues using the
equation Astd/AIS × 100 %, and the interference to IS MS/MS channels from STD solution was
calculated similarly (AIS/Astd × 100 %). The stability of five analytes in samples was assessed by
analysing 2 µM QC working solutions stored for 18 hours at room temperature (short-term
temperature stability), stored for 1 week in a refrigerator at a temperature between 1 and 9 °C
(long-term stability) and after going through three cycles of freezing at -20 ºC before sample
preparation and analysis. For the post-preparative stability study, the same sample was analysed
after the sample preparation and again after 20 h storage in the instrument autosampler. For the
stability studies of working solutions in glass containers, 2 µM QC working solution was stored
in a glass container at 10 °C for 24 h before the sample preparation and analysis. Results were
compared to 2 µM QC working solution stored in polypropylene tube at the same conditions.
Three different container systems for the samples were evaluated by analysing three different
samples; One which was transferred after sample preparation into Agilent glass vial inserts (part
number 5181-3377), the other in Agilent deactivated vial insert (part number 5183-2086) and the
third in Agilent polypropylene insert (part number 5182-0549) for the LC-MS/MS analysis.
These three post-preparative samples were analyzed after the sample preparation and again after
20 h storage in the instrument autosampler. The effect of the filtration through 0.22 µm filtter to
the sample concentration was evaluated by analysing 2 µM QC working solution sample filtered
through 0.22 µm filter before sample preparation and comparing the results to the unfiltered
samples. A post-column infusion experiment was performed to evaluate the matrix effect after
sample injection. The infusion setup consisted of a post-column PEEK mixing tee (VICI Jour
Research AB, Sweden) and syringe pump (801 Syringe pump, Univentor, Malta) as previously
reported  [Souverain  et.  al.  2004].  A constant  flow of  1  µM stock  solution  of  all  five  standards
and  five  IS  in  water  containing  0.1  %  HFBA  was  delivered  via  the  PEEK  mixing  tee  to  the
mobile phase at flow rate 6 µL/min. All quantifier and qualifier product ions listed in Table 10
were monitored after the injection and gradient elution of the blank sample.
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6.  SYNTHESIS OF DEUTERATED POLYAMINES
Adapted/modified from Tetrahedron Vol. 65, Häkkinen M. R., Keinänen T. A., Khomutov A. R., Auriola S., Weisell J.,
Alhonen L., Jänne J., Vepsäläinen J. Synthesis of novel deuterium labelled derivatives of N-alkylated polyamines, Pages
No. 547-562, Copyright (2009), with permission from Elsevier.
The aim of this study was to develop a simple and straightforward method to synthesize N-
alkylated polyamines 1–4, in which R = H, Et, iPr, Bn or c-Hex,  and  X,  Y,  X1 and  Y1 are
deuterium labelling positions, in order to use these compounds as standards in quantitative
analysis of polyamines by LC-MS/MS, as well as biochemical probes to study the metabolism of
polyamines in future studies. The same synthesis methods were also used to prepare the
corresponding unlabelled N-alkylated substrates and their potential metabolites for the
quantitative metabolic studies (paper IV).
6.1  RESULTS AND DISCUSSION
6.1.1  Syntheses
Synthetic strategies to deuterated polyamine analogues 1–4 were based on the methods described
in chapters 2.5 and 2.6. As shown in Scheme 5, the starting compound was acrylonitrile (5), since
it allows not only the introduction of the desired N-alkyl group to the double bond, but also the
deuterium labelling of either X or Y positions, or both. The key intermediate 1, after sufficient
protection, can undergo chain elongation to yield the corresponding deuterium labelled SPD and
SPM derivatives. The structures of prepared target compounds 1–4, their overall yields and the
isotopic purities of the deuterated compounds are summarized in Tables 14-16.
Scheme 5. (i) R–NH2 (R = Et, iPr, c-Hex, Bn), MeOH, reflux; (ii) Method A: LiAlH4 or LiAlD4, THF, reflux,
Method B: H2/PtO2, EtOH, HCl; (iii) 0.1 M NaOD, D2O, EtOD; X and Y = H or D.
Preparation of polyamines 1–4 was started from acrylonitrile (5) and the appropriate N-
alkylamine using the Michael addition to obtain the desired N-alkylamino-propionitriles 6a–d
with 79–91% yields. [Whitmore et. al 1944] In the next step, it was possible to exchange –
CH2CN protons with deuterium or to reduce the nitrile group to the CD2–NH2 or CH2–NH2 unit.
The base catalyzed hydrogen exchange reactions of the simple cyanoalkanes are much faster than
the corresponding hydrolysis to carboxylate ions, [Richard et. al. 1999] which enables labelling
at the ?-position. The deuteration stage achieved >97% for 6e,f after the exchange reaction was
repeated twice with a mixture of 0.1 M NaOD in D2O and EtOD by using dry diethylether as the
extraction solvent. Ethanol is of crucial importance for this reaction, since in its absence after the
first cycle, only about 82–84% hydrogen was exchanged, whereas with ethanol, the deuterium
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Table 14. Synthesized DAP derivatives, their overall yields and the isotopic purities of the deuterium labelled
compounds.
Compound Overal yield %a Isotopic purity %
DAP Intermediate
compound
Method
derivatives R X Y A B C
1a Et H H 6a 39 73 -
1b Et D H 6a 43 99
1c Et H D 6e 18 94
1d Et D D 6e 20 92
1e Bn H H 6d 62 56 -
1f Bn D H 6d 70 98
1g Bn D D 6f 49 98
1h Pri H H 6b 46 66 -
1i Pri D H 6b 47 99
1j c-Hex H H 6c 56 72 -
1k c-Hex D H 6c 60 98
1l H D H 1f 54 98
a Method A and method B, starting from alkylamine and acrylonitrile. Method A with LiAlH4 or LiAlD4, and Method B
with H2/PtO2. Method C, starting from aldehyde. Yields are for recrystallized compounds, and are not optimized.
Table 15. Synthesized SPD derivatives, their overall yields and the isotopic purities of the deuterium labelled
compounds.
Compound Overal yield %a Isotopic purity %
SPD Intermediate
compound
Method
derivatives R X Y A B C
2a Et H H 12a 25 46 -
2b Et D H 12b 21 99
2c Et D D 12c 15 93
2d Bn H H 12d 31 28 -
2e Bn D H 12e 39 97
2f Pri H H 12f 14 20 -
2g c-Hex H H 12g 19 25 -
2h H D H 2e 21 99
a Method A and method B, starting from alkylamine and acrylonitrile. Method C, starting from aldehyde. Yields are for
recrystallized compounds, and are not optimized.
Table 16. Synthesized SPM derivatives, their overall yields and the isotopic purities of the deuterium
labelled compounds.
Compound Overal yield %a Isotopic purity %
SPM Intermediate
compound
Method
derivatives R R1 X Y X1 Y1 A B C
3a Et H H H H H 13a 13 25 -
3b Et H D H H H 13b 15 97
3g Et H H H D D 4f 16 93
3c Bn H H H H H 13c 28 26 -
3d Bn H D D H H 13d 27 92
3e Pri H H H H H 13e 11 15 -
3f c-Hex  H H H H H 13f 12 16 -
4a Et Et H H H H 14a 16 30 -
4b Et Et D H D H 14b 14 97
4c Pri Pri H H H H 14c 10 15 -
4d c-Hex c-Hex  H H H H 14d 18 24 -
4e Et Bn H H H H 14e 21 40 -
4f Et Bn H H D D 14f 20 92
4g Et Bn D D D D 14g 10 87
4h H H D D H H 3d 22 92
a Method A and method B, starting from alkylamine and acrylonitrile. Method C, starting from aldehyde. Yields are for
recrystallized compounds, and are not optimized.
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stages were 92–95%. Moreover, chloroform was a poor extraction solvent, since both nitrogen
deuteriums and ?-deuteriums to nitrile were converted back to hydrogens to some extent, even
when the traces of water and ethanol (as a stabilizer in chloroform) were removed with P2O5.
[Iwasaki et. al. 1989]
The obtained nitriles 6a–f were reduced to the corresponding amines 1a–k either with LiAlD4
(method A, 43–88% yields) or with PtO2 catalysed hydrogenation (method B, 80–84% yields).
However, the latter method is not suitable for benzyl derivatives 1e–g, and as an example,
compound 1e was prepared from the commercially available Boc-protected amine 7 and
benzaldehyde via imine 8 using reductive amination (method C) as shown in Scheme 6.  Also the
chain elongation unit 10, which was used as a building block to the SPM derivatives 3a–g, was
prepared from 7 via protected 9. Previously, 10 (X = Br) was prepared from 9 and 1,4-
dibromobutane but we used 1-bromo-4-chlorobutane as an alkylating agent to avoid
dimerization. [Hidai et. al. 2000]
Scheme 6. (i) PhCHO, 3 Å molecular sieves, Et2O; (ii) (1) NaBH4, EtOH; (2) HCl, EtOH; (iii) NsCl, Et3N,
CH2Cl2; (iv) Br(CH2)4Cl, K2CO3, DMF; (v) NaI, acetone, reflux
Mono-N-alkylated SPD analogues were selectively prepared from propanediamines 1a–k after
protection as the o-nitrophenylsulfonyl (Ns) derivatives 11a–k (intermediate structures in Tables
20-23), since the only remaining NH group was readily alkylated with N-(4-
iodobutyl)phthalimide [Järvinen et. al. 2006b] to 12a–k under basic conditions with 81–95%
yields as shown in Scheme 7. It was notable that the protection of the sterically hindered N-
isopropyl and N-cyclohexyl derivatives to nosylated 11g–h required more robust reaction
conditions, chromatographic purification and yields (40–48%) were only half of that of those
obtained with the ethyl and benzyl derivatives. The target SPD hydrochlorides 2a–g were
obtained from 12a–k after deprotection and recrystallization from ethanol–water–EtOAc with
51–80% yields.
Scheme 7. (i) NsCl, Et3N, CH2Cl2; (ii) PhtN(CH2)4I, [Järvinen et. al. 2006b] K2CO3, DMF; (iii) (1) PhSH,
K2CO3,  DMF;  (2)  N2H4·H2O, EtOH, reflux; (3) HCl, 1,4-dioxane; (iv) 10b,  K2CO3,  DMF;  (v)  (1)  PhSH,
K2CO3, DMF; (2) HCl, 1,4-dioxane; (vi) I(CH2)4I,  K2CO3, DMF; (vii) Br(CH2)4Cl,  K2CO3, DMF; (viii) NaI,
acetone, reflux; (ix) 11, K2CO3, DMF
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Mono-N-alkylated SPM analogues 3a–f were also prepared from nosylated 11 via 13a–f using
10b (see Scheme 6) as an alkylating agent with 35–60% yields following the strategy having
been earlier developed for spermidines.[Järvinen et. al. 2006b, Grigorenko et. al. 2007] Using the
same approach and with 1,4-diiodobutane as the alkylating agent, the corresponding symmetric
di-N,N’-alkyl SPMs 4a–d were obtained via 14a–d with 32–69% yields. Surprisingly, the
purification of 14a–c was straightforward, since after addition of EtOAc and water to the reaction
mixtures, the products crystallized out. Thus, chromatographic purification was needed only for
the compound 14d.
Using this strategy it is also possible to prepare non-symmetric N,N’-dialkyl SPMs. In this case,
as shown in Scheme 7, we used 11a (R=Et, X=Y=H) or 11c (R=Et, X=Y=D) as starting materials
to prepare alkylating agents 15c and 15d, respectively. The compounds 11d (R=Bn, X=Y=H) or
11f (R=Bn, X=Y=D) were selected as the precursors of another three-carbon fragment of the
SPM molecule. The use of these benzyl derivatives not only allowed the preparation of mixed N-
ethyl-N-benzyl SPMs 4e–g, but also after the removal of benzyl group by catalytic
hydrogenation, it proved possible to obtain SPM derivatives labelled at the non-alkylated
terminus (see compound 3g in Table 16). The same strategy was used to prepare deuterated
propanediamine-d2 1l, spermidine-d2 2h and spermine-d4 4h starting from 1f, 2e and 3d,
respectively, as depicted in Scheme 8.
Scheme 8. (i) H2/10% Pd–C, EtOH–H2O
6.1.2   NMR, MS and IR studies
All of the compounds were identified by 1H and 13C NMR spectroscopy. The complicated 13C
NMR spectra were assigned based on 2D techniques and via the information obtained from
deuterated analogues. All the backbone carbons are quoted in Tables 17-19 (target compounds 1–
4) and in Tables 20-23 (intermediates). In the experimental part and in Tables 17-23, the
backbone carbons are assigned with a number and N-alkyl substituents by using Greek letters as
shown below.
During the syntheses, the overall deuterium contents were estimated from the 1H NMR spectra
and localizations were verified from the 13C NMR spectra. The presence of deuterium atoms in
the target compounds were identified without doubt, since in the 1H NMR spectra the exchanged
proton signals disappeared, remaining coupling patterns were simplified and in the 13C NMR
spectra, the low intensity CD2 quintets closely upfield to the corresponding CH2 signals were
observed as shown in Fig. 20. When the protons are replaced by deuterium the relaxation time
(T1) for the deuterated carbon may be more than an order of magnitude greater than that of the
comparable protonated carbon. This may mean that with normal recycle delay for carbon
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measurements (D1=3 s) deuterated carbons may either not show up or appear with much reduced
intensity. This was the reason to collect 13C NMR data over a long period of time with a longer
recycle delay (D1=10 s). In addition, the intensity of the carbon signal will be split into a
multiplet due to 13C–2H J coupling depending on how many deuterons are attached to the carbon
(1:1:1 triplet for CD and 1:2:3:2:1 quintet for CD2). Measured 13C–2H J couplings (1JCD ? 19–
22 Hz) for quintets are shown in Tables 17-20. However, 13C NMR spectra of the protected
intermediates were more complex due to dynamic effects caused by the neighbouring protecting
groups at room temperature and only multiplets were observed for the CD2 groups (Tables 21-
23). A typical example of the isotope effects generated by deuterium atoms is shown in Fig. 21.
Negative (upfield to the corresponding CH2) deuterium induced isotope shifts were observed
over one, two and three bonds, as can be estimated also from Tables 17-23. The isotopic shifts
are additive, since deuterated C-3 resonance is shifted more upfield when also C-2 is deuterated
(see Tables 17, 18, 21 and 22).  In some cases, 1H and 13C NMR chemical shifts for the known
compounds were re-evaluated, since the 13C NMR chemical shifts differences in the literature
compared to our shifts were 1–3 ppm (literature shifts measured in D2O without internal
standard) or in some cases chemical shifts were missing.
Table 17. 13C NMR Chemical shifts for DAP derivatives 1a-la-c
Compd
R C-1 C-2 1JCD C-3 1JCD
1a Et 46.8 26.6 39.5
1b Et 46.8 26.4 38.9* 22 Hz
1c Et 46.7 26.0* 20 Hz 39.3
1d Et 46.7 25.8* 20 Hz 38.8* 22 Hz
1e Bn 46.8 26.6 39.4
1f Bn 46.8 26.5 39.0* 22 Hz
1g Bn 46.6 25.7* 20 Hz 38.8* 22 Hz
1h iPr 44.5 26.9 39.5
1i iPr 44.5 26.6 39.0* 22 Hz
1j cHex 44.2 26.8 39.5
1k cHex 44.1 26.6 39.0* 22 Hz
1l H 39.4 27.5 38.9* 22 Hz
a NMR solvent was D2O with TSP, and products were measured as their HCl salts
b 13C NMR Chemical shifts for R are presented in Chapter 6.3.2
c  Shifts marked with * are for CD2 carbons, which were observed as 1:2:3:2:1 quintets
Table 18. 13C NMR Chemical shifts for SPD derivatives 2a-ha-c
Compd
R  C-1 C-2 1JCD C-3 1JCD C-5 C-6 C-7 C-8
2a Et  46.8 25.7 47.4 50.0 25.7 26.9 41.7
2b Et  46.7 25.4 46.8* 22 Hz 49.9 25.6 26.8 41.7
2c Et  46.6 24.7* 20 Hz 46.6* 22 Hz 49.9 25.6 26.7 41.7
2d Bn  46.8 25.6 47.4 50.0 25.7 26.8 41.7
2e Bn  46.7 25.3 46.8* 22 Hz 49.8 25.5 26.7 41.7
2f iPr  44.5 25.8 47.4 50.0 25.6 26.8 41.7
2g cHex  44.2 25.8 47.5 50.0 25.7 26.8 41.7
2h H  39.4 26.4 46.8* 22 Hz 49.9 25.6 26.7 41.7
a NMR solvent was D2O with TSP, and products were measured as their HCl salts
b 13C NMR Chemical shifts for R are presented in Chapter 6.3.2
c Shifts marked with * are for CD2 carbons, which were observed as quintets.
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Table 20. 13C NMR Chemical shifts for intermediates 6a-fa-c
Compd
R C-1 C-2 1JCD CN
6a Et 44.9 18.7 118.8
6e Et 44.7   18.3* 21 Hz 118.8
6d Bn 44.3 18.8 118.7
6f Bn 44.2   18.4* 21 Hz 118.7
6b iPr 42.6 19.1 118.8
6c cHex 42.2 19.2 118.9
a NMR solvent was CDCl3 with TMS
b 13C NMR Chemical shifts for R are presented in Chapter 6.3.2
c Shifts marked with * are for CD2 carbons, which were observed as quintets
Table 21. 13C NMR Chemical shifts for intermediate DAP derivatives 11a-ha-c
Compd
R C-1 C-2 C-3
11a Et 44.2 28.9 40.6
11b Et 44.1 28.7   40.1* (m)
11c Et 44.0   28.0* (m)   40.0* (m)
11d Bn 45.1 28.5 40.5
11e Bn 45.1 28.4   40.0* (m)
11f Bn 45.0   27.6* (m)   39.8* (m)
11g iPr 41.1 32.0 40.4
11h cHex 41.2 32.1 41.1
a NMR solvent was CDCl3 with TMS
b 13C NMR Chemical shifts for R and for protecting groups (Ns) are presented in Chapter 6.3.2
c Shifts marked with * are for CD2 carbons, which were observed as multiplets due to dynamic
 effects at room temperature
The isotopic distribution was estimated for all the deuterated target compounds. The isotopic
purity was 87% for 4g containing eight deuterium atoms, 91–97% for compounds with four
deuterium atoms and 94–99% for compounds with two deuterium atoms, as shown in Tables 14-
16. In addition, according to the 1H NMR and ESI mass spectra, the overall deuterium stage of all
the labelled compounds (detected deuterium amount in the molecule versus expected) was over
97%.
IR was used to study the C–D stretches in deuterated compounds. According to the literature, the
range for C–D stretches is 2200–2080 cm?1, which is beyond ‘normal’ IR vibrations. [Pretsch et.
al. 2000] However, only compound 1l clearly showed bands around this region (~2230 cm?1). In
the other spectra, there were no such clear vibrations in this region, or the bands were so weak or
they may have remained under the highly structured ammonium (NH3+, NH2+) vibrations (3000–
2000 cm?1).
Ta
bl
e 
22
.1
3 C
 N
M
R
 C
he
m
ic
al
 s
hi
fts
 fo
r i
nt
er
m
ed
ia
te
 S
PD
 d
er
iv
at
iv
es
12
a-
g
an
d 
al
ky
la
tin
g 
ag
en
ts
15
a-
d
an
d
10
a-
ba
-c
C
om
pd
R
X
Y
C
-1
C
-2
C
-3
C
-5
C
-6
C
-7
C
-8
12
a
Et
N
s
N
Ph
t
44
.3
27
.5
45
.2
47
.3
25
.4
25
.7
37
.1
12
b
Et
N
s
N
Ph
t
44
.3
27
.3
44
.6
*
(m
)
47
.2
25
.4
25
.7
37
.1
12
c
Et
N
s
N
Ph
t
44
.1
26
.6
*
(m
)
44
.5
*
(m
)
47
.2
25
.4
25
.7
37
.1
12
d
B
n
N
s
N
Ph
t
45
.1
26
.9
44
.9
46
.8
25
.2
25
.6
37
.1
12
e
B
n
N
s
N
Ph
t
45
.1
26
.7
44
.3
*
(m
)
46
.7
25
.2
25
.6
37
.1
12
f
iP
r
N
s
N
Ph
t
40
.5
30
.3
45
.1
46
.8
25
.2
25
.7
37
.2
12
g
cH
ex
N
s
N
Ph
t
41
.4
30
.4
45
.1
46
.8
25
.2
25
.7
37
.2
15
a
Et
N
s
C
l
44
.4
27
.6
45
.1
47
.2
25
.4
29
.3
44
.4
15
b
Et
N
s
C
l
44
.3
26
.7
*
(m
)
44
.4
*
(m
)
47
.1
25
.4
29
.3
44
.4
15
c
Et
N
s
I
44
.4
27
.6
45
.1
46
.7
29
.0
30
.1
5.
9
15
d
Et
N
s
I
44
.3
26
.7
*
(m
)
44
.3
*
(m
)
46
.7
28
.9
30
.1
6.
0
10
a
H
B
oc
C
l
37
.4
28
.6
45
.0
46
.8
25
.4
29
.3
44
.3
10
b
H
B
oc
I
37
.4
28
.6
45
.0
46
.4
28
.9
30
.1
5.
8
a
N
M
R
 so
lv
en
t w
as
 C
D
Cl
3
w
ith
 T
M
S
b 
13
C
 N
M
R
 C
he
m
ic
al
 sh
ift
s f
or
 R
 a
nd
 fo
r p
ro
te
ct
in
g 
gr
ou
ps
 (N
s, 
Ph
t a
nd
 B
oc
) a
re
 p
re
se
nt
ed
 in
 C
ha
pt
er
 6
.3
.2
c
Sh
ift
s m
ar
ke
d 
w
ith
 *
 a
re
 fo
r C
D
2 c
ar
bo
ns
, w
hi
ch
 w
er
e 
ob
se
rv
ed
 a
s m
ul
tip
le
ts
 d
ue
 to
 d
yn
am
ic
 e
ffe
ct
s a
t r
oo
m
 te
m
pe
ra
tu
re
Ta
bl
e 
23
.1
3 C
 N
M
R
 C
he
m
ic
al
 s
hi
fts
 fo
r i
nt
er
m
ed
ia
te
 S
PM
 d
er
iv
at
iv
es
13
a-
fa
nd
14
a-
ga
-c
C
om
p.
R
R
1
X
C
-1
C
-2
C
-3
C
-5
C
-6
C
-7
C
-8
C
-1
0
C
-1
1
C
-1
2
13
a
Et
H
B
oc
 
44
.4
27
.5
44
.9
47
.1
 
25
.0
 
25
.1
 
47
.0
 
45
.2
28
.6
37
.4
13
b
Et
H
B
oc
 
44
.4
27
.3
44
.4
* 
(m
) 
47
.0
 
25
.0
 
25
.1
 
47
.0
 
45
.2
28
.6
37
.4
13
c
B
n
H
B
oc
 
45
.2
26
.9
44
.7
46
.7
 
24
.8
 
25
.0
 
47
.0
 
45
.2
28
.6
37
.4
13
d
B
n
H
B
oc
 
45
.1
26
.0
* 
(m
)
44
.0
* 
(m
) 
46
.6
 
24
.8
 
25
.0
 
47
.0
 
45
.2
28
.6
37
.4
13
e
iP
r
H
B
oc
 
40
.5
30
.2
44
.9
46
.6
 
24
.8
 
25
.1
 
46
.9
 
45
.2
28
.6
37
.4
13
f
cH
ex
H
B
oc
 
41
.4
30
.4
44
.8
46
.6
 
24
.7
 
25
.1
 
46
.9
 
45
.1
28
.6
37
.4
14
a*
*
Et
Et
N
s
44
.4
27
.5
45
.0
47
.2
 
25
.0
 
25
.0
 
47
.2
 
45
.0
27
.5
44
.4
14
b*
*
Et
Et
N
s
44
.4
27
.2
44
.5
* 
(m
) 
47
.0
 
24
.9
 
24
.9
 
47
.0
 
44
.5
* 
(m
) 
27
.2
44
.4
14
c*
*
iP
r
iP
r
N
s
40
.2
29
.8
44
.4
46
.5
 
24
.5
 
24
.5
 
46
.5
 
44
.4
29
.8
40
.2
14
d
cH
ex
cH
ex
N
s
41
.4
30
.3
44
.8
46
.6
 
24
.7
 
24
.7
 
46
.6
 
44
.8
30
.3
41
.4
14
e
B
n
Et
N
s
45
.2
26
.9
44
.8
46
.8
 
24
.8
 
25
.0
 
47
.1
 
45
.0
27
.5
44
.4
14
f
B
n
Et
N
s
45
.1
26
.0
* 
(m
)
44
.1
* 
(m
) 
46
.7
 
24
.8
 
25
.0
 
47
.1
 
45
.0
27
.5
44
.4
14
g
B
n
Et
N
s
45
.1
26
.0
* 
(m
)
44
.3
* 
(m
) 
46
.7
 
24
.8
 
24
.9
 
47
.1
 
44
.3
* 
(m
) 
26
.6
* 
(m
) 
44
.3
a
N
M
R
 so
lv
en
t w
as
 C
D
Cl
3 w
ith
 T
M
S,
 e
xc
ep
t f
or
 *
*,
 w
hi
ch
 w
er
e 
m
ea
su
re
d 
in
 C
D
Cl
3 +
 D
M
SO
-d
6 
w
ith
 T
M
S
b 
13
C
 N
M
R
 C
he
m
ic
al
 sh
ift
s f
or
 R
, R
1  a
nd
 fo
r p
ro
te
ct
in
g 
gr
ou
ps
 (N
s a
nd
 B
oc
) a
re
 p
re
se
nt
ed
 in
 C
ha
pt
er
 6
.3
.2
c
Sh
ift
s m
ar
ke
d 
w
ith
 *
 a
re
 fo
r C
D
2 c
ar
bo
ns
, w
hi
ch
 w
er
e 
ob
se
rv
ed
 a
s m
ul
tip
le
ts
 d
ue
 to
 d
yn
am
ic
 e
ffe
ct
s a
t r
oo
m
 te
m
pe
ra
tu
re
Merja Häkkinen: N-Alkylated Polyamine Analogues – Deuterium Labelling, LC-MS/MS Analysis and Catabolism…
98 Kuopio Univ. Publ. C. Nat. and Environ. Sci. 263: 1-145 (2009)
Figure 20. Deuterium induced changes in 1H and 13C NMR chemical shifts during the deuteration of 6d to
6f. Top: 1H NMR; the exchanged proton signals disappear and the remaining coupling pattern is
simplifying. Bottom: 13C NMR; the carbon signal is splitting into a multiplet due to 13C–2H J coupling (1JCD ?
21 Hz) depending on how many deuteriums are attached to the carbon. Singlet for CH2, 1:1:1 triplet for
CHD and 1:2:3:2:1 quintet for CD2. A: unlabelled (6d), B: labelling in progress, C: labelled (6f)
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Figure 21. Negative deuterium induced isotope shifts, ??, in 13C NMR spectra were observed over one
(0.7 ppm), two (0.17 ppm) and three bonds (0.06 ppm), as demonstrated for compounds 4e, 4f and 4g.
6.2  CONCLUSIONS
A general method was developed to synthesize several deuterium labelled N-alkylated
diaminopropanes containing two or four deuteriums in the non-exchangeable positions. These
key intermediates were used to prepare mono-, di- and unsubstituted, sterically hindered, as well
as symmetrically and non-symmetrically substituted polyamine derivatives, and also their
symmetrically or non-symmetrically deuterium labelled analogues, having two to eight
deuterium atoms in the polyamine backbone. According to the ESI-MS and 1H NMR data, the
isotopic purities were high (87–99%) for all the labelled compounds. Benzyl alkylated
derivatives were found to be convenient precursors in the synthesis of a variety of labelled, non-
N-alkylated diaminopropanes, spermidines and spermines, and they served also as an alternative
route to monosubstituted polyamines.
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6.3  EXPERIMENTAL
6.3.1  Reagents and instrumentation
Dimethylformamide (DMF) was distilled and stored over 4 Å molecular sieves, triethylamine
(TEA) was dried over KOH and distilled, diethylether was dried over sodium-benzophenone
ketyl and distilled, dichloromethane (DCM) and chloroform were dried over P2O5 and distilled.
All other reagents were used without further purification. Reactions were followed with TLC
using analytical pre-coated silica gel 60 F254 plates, while silica gel (63–200 ?m, Merck) was
used for column chromatographic separations. 1H and 13C NMR spectra were measured on a
Bruker Avance (Bruker, Rheinstetter, Germany) 500 DRX spectrometer operating at 500.13 and
125.76 MHz, respectively. TMS was used as an internal standard in organic solvents, and sodium
3-(trimethylsilyl)-1-propionic acid (TSP) in D2O. Relaxation delay (D1) was set to 60 s for 1H
measurements and to 10 s for carbon experiments. 1H and 13C NMR chemical shifts were
assigned based on standard 2D techniques (1H-1H COSY, 1H-13C HSQC and HMBC). Isotope
distribution measurements and high-resolution mass spectra were conducted on a QSTAR XL
hybrid quadrupole TOF instrument (Applied Biosystems, Foster City, CA) using the positive
electrospray ionization mode. Isopropylamine, amino acids and peptides were used as the internal
standards in HRMS measurements. IR spectra as KBr pelleting were recorded on Nexus 470 FT-
IR. Melting points were measured in open capillary tubes and are uncorrected.
6.3.2  Syntheses of polyamines
General protocols to prepare 1a–k
Method A. To a cooled (0 °C) suspension of LiAlH4 or LiAlD4 (20.4 mmol) in dry Et2O (40 mL),
a solution of nitrile 6 (500 mg, 10 mmol) in dry Et2O (10 mL) was added dropwise with stirring
over a period of 45 min. The reaction mixture was allowed to warm to room temperature, heated
at reflux for 3 h and further stirred at room temperature for 20 h. The reaction was quenched at
0–4 °C by dropwise addition of water (1.2 mL) and NaOH (5 M, 7.1 mL) with stirring. The
organic phase was separated and the residue was extracted with hot chloroform (4×20 mL). The
combined organic extracts were dried over MgSO4 and the crude product was precipitated by
treating with dry HCl. The subsequent recrystallization from ethanol–EtOAc yielded 1.
Method B. To a solution of 6 (10.2 mmol) in ethanol (30 mL) was added concd HCl (2 mL) and
the mixture was deoxygenated with argon for 10 min. Adam's catalyst (PtO2, 0.44 mmol) was
added and the mixture was hydrogenated at 3.5 bar pressure for 20 h. The catalyst was filtered
off through Celite, washed with hot ethanol and water, and the combined filtrates were
evaporated to dryness in vacuo. The residue was recrystallized from ethanol–EtOAc to give 1.
Method C. Following the published procedure for N1-benzyl-butane-1,4-diamine, [Martin et. al.
2001] compound 1 was prepared from the corresponding aldehyde (20.5 mmol) and (3-amino-
propyl)carbamic acid tert-butyl  ester  (7, 22.6 mmol) after reduction and amino group
deprotection.
N1-Ethylpropane-1,3-diamine dihydrochloride 1a [as free base: Tarbell et. al. 1946]
Prepared from 6a to give 1a (method A: 43%, method B: 80%) as colourless solid, mp 224–
225 °C. IR (KBr): 3000–2387, 1606, 1459, 1379, 804 cm?1; 1H NMR (D2O): ? 3.17–3.10 (6H, m,
H-?,1,3), 2.12–2.06 (2H, m, H-2), 1.30 (3H, t, J=7.3 Hz, H-?); 13C NMR (D2O): ? 45.9 (C-?),
13.3  (C-?),  rest  in  Table  17;  HRMS  (ESI-MS):  calcd  for  (M+H)  C5H15N2 103.1235, found
103.1229.
N1-Ethyl-3,3-2H2-propane-1,3-diamine dihydrochloride 1b
Prepared from 6a to give 1b (method A, 47%, 99% d) as a colourless solid, mp 219–221 °C. IR
(KBr): 3000–2386, 1604, 1460, 1382, 1144, 855, 804 cm?1; 1H NMR (D2O): ? 3.17–3.10 (4H, m,
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H-?,1), 2.11–2.05 (2H, m, H-2), 1.30 (3H, t, J=7.3 Hz, H-?); 13C NMR (D2O): ? 45.9 (C-?), 13.4
(C-?),  rest  in  Table  17;  HRMS  (ESI-MS):  calcd  for  (M+H)  C5H13N2D2 105.1361, found
105.1354. Isotope distribution: 0% d0, 1% d1, 98% d2.
N1-Ethyl-2,2-2H2-propane-1,3-diamine dihydrochloride 1c
Prepared from 6e to give 1c (method A, 43%, 97% d) as a colourless solid, mp 222–224 °C. IR
(KBr): 3000–2369, 1594, 1462, 1374, 1185, 802 cm?1; 1H NMR (D2O): ? 3.17–3.08 (6H, m, H-
?,1,3), 1.30 (3H, t, J=7.3 Hz, H-?); 13C NMR (D2O): ? 45.9 (C-?), 13.4 (C-?), rest in Table 17;
HRMS (ESI-MS): calcd for (M+H) C5H13N2D2 105.1361, found 105.1356. Isotope distribution:
0% d0, 6% d1, 94% d2.
N1-Ethyl-2,2,3,3-2H4-propane-1,3-diamine dihydrochloride 1d
Prepared from 6e to give 1d (method A, 47%, 98% d) as a colourless solid, mp 218–220 °C. IR
(KBr): 3000–2388, 1603, 1463, 1382, 1171, 837, 806 cm?1; 1H NMR (D2O): ? 3.17–3.10 (4H, m,
H-?,1), 1.30 (3H, t, J=7.3 Hz, H-?); 13C NMR (D2O): ? 46.0 (C-?), 13.4 (C-?), rest in Table 17;
HRMS (ESI-MS): calcd for (M+H) C5H11N2D4 107.1486, found 107.1480. Isotope distribution:
0% d0–d2, 8% d3, 92% d4.
N1-Benzyl-propane-1,3-diamine dihydrochloride 1e [Bolkenius & Seiler 1989, as free base:
Surrey 1949]
Prepared from 6d to give 1e (method A, 74%) as a colourless solid, mp 271–272 °C.
Prepared from benzaldehyde (2.2 g, 20.5 mmol) and (3-amino-propyl)carbamic acid tert-butyl
ester (3.9 g, 22.6 mmol) following method C, which after recrystallization from ethanol–EtOAc
gave 1e in the overall (3 steps) with a 56% yield. IR (KBr): 3050–2410, 1599, 1484, 1174, 744,
697 cm?1; 1H NMR (D2O): ? 7.57–7.48 (5H, m, Ph), 4.29 (2H, s, H-?), 3.24–3.17 (2H, m, H-1),
3.14–3.08 (2H, m, H-3), 2.17–2.07 (2H, m, H-2); 13C NMR (D2O): ? 133.3 (Ph), 132.7 (2C, Ph),
132.6 (Ph), 132.2 (2C, Ph), 54.1 (C-?), rest in Table 17; HRMS (ESI-MS): calcd for (M+H)
C10H17N2 165.1392, found 165.1389.
N1-Benzyl-3,3-2H2-propane-1,3-diamine dihydrochloride 1f
Prepared from 6d to give 1f (method A, 83%, 99% d) as a colourless solid, mp 275 °C. IR (KBr):
3050–2387, 1601, 1478, 854, 744, 697 cm?1; 1H NMR (D2O): ? 7.57–7.48 (5H, m, Ph), 4.29 (2H,
s, H-?), 3.24–3.17 (2H, m, H-1), 2.16–2.07 (2H, m, H-2); 13C NMR (D2O): ? 133.5 (Ph), 132.7
(2C, Ph), 132.6 (Ph), 132.1 (2C, Ph), 54.1 (C-?), rest in Table 17; HRMS (ESI-MS): calcd for
(M+H) C10H15N2D2 167.1517, found 167.1513. Isotope distribution: 0% d0, 2% d1, 98% d2.
N1-Benzyl-2,2,3,3-2H4-propane-1,3-diamine dihydrochloride 1g
Prepared from 6f to give 1g (method A, 88%, 98% d) as a colourless solid, mp 274–275 °C. IR
(KBr): 3050–2429, 1600, 1468, 836, 744, 697 cm?1; 1H NMR (D2O): ? 7.57–7.46 (5H, m, Ph),
4.29 (2H, s, H-?), 3.19 (2H, s, H-1); 13C NMR (D2O): ? 133.3 (Ph), 132.7 (2C, Ph), 132.6 (Ph),
132.2 (2C, Ph), 54.1 (C-?), rest in Table 17; HRMS (ESI-MS): calcd for (M+H) C10H13N2D4
169.1643, found 169.1641. Isotope distribution: 0% d0–d2, 7% d3, 92% d4.
N1-Isopropylpropane-1,3-diamine dihydrochloride 1h [Wysocka-Skrzela et. al. 1981, as free
base: Tarbell et. al. 1946]
Prepared from 6b to give 1h (method A: 58%, method B: 83%) as a colourless solid, mp 184–
186 °C. IR (KBr): 3000–2385, 1597, 1473, 1379, 1136, 766 cm?1; 1H NMR (D2O): ? 3.45 (1H,
sep., J=6.6 Hz, H-?), 3.19–3.09 (4H, m, H-1,3), 2.13–2.03 (2H, m, H-2), 1.33 (6H, d, J=6.6 Hz,
H-?); 13C NMR (D2O): ? 53.9 (C-?), 21.0 (2C-?), rest in Table 17; HRMS (ESI-MS): calcd for
(M+H) C6H17N2 117.1392, found 117.1386.
N1-Isopropyl-3,3-2H2-propane-1,3-diamine dihydrochloride 1i
Prepared from 6b to give 1i (method A, 59%, 99% d) as a colourless solid, mp 182–184 °C. IR
(KBr): 3000–2300, 1594, 1471, 1382, 1161, 845 cm?1; 1H  NMR  (D2O): ? 3.45 (1H, sep.,
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J=6.6 Hz, H-?), 3.18–3.13 (2H, m, H-1), 2.10–2.04 (2H, m, H-2), 1.33 (6H, d, J=6.6 Hz, H-?);
13C NMR (D2O): ? 53.9 (C-?), 21.0 (2C-?), rest in Table 17; HRMS (ESI-MS): calcd for (M+H)
C6H15N2D2 119.1517, found 119.1514. Isotope distribution: 0% d0, 1% d1, 99% d2.
N1-Cyclohexylpropane-1,3-diamine dihydrochloride 1j [Wagner-Jauregg 1961, as free base:
Tarbell et. al. 1946]
Prepared from 6c to give 1j (method A: 65%, method B: 84%) as a colourless solid, mp 200–
202 °C (lit. mp 199–202 °C).[Wagner-Jauregg 1961] IR (KBr): 3000–2368, 1606, 1464, 1164,
783 cm?1; 1H NMR (D2O): ? 3.22–3.08 (5H, m, H-1,3,?), 2.13–2.02 (4H, m, H-2,?eq), 1.90–1.79
(2H, m, H-?eq), 1.72–1.63 (1H, m, H-?eq), 1.41–1.27 (4H, m, H-?ax??ax), 1.25–1.13 (1H, m, H-?ax);
13C  NMR  (D2O): ? 60.3 (C-?), 31.7 (2C-?), 27.3 (C-?), 26.8 (2C-?), rest in Table 17; HRMS
(ESI-MS): calcd for (M+H) C9H21N2 157.1705, found 157.1707.
N1-Cyclohexyl-3,3-2H2-propane-1,3-diamine dihydrochloride 1k
Prepared from 6c to give 1k (method A, 70%, 99% d) as a colourless solid, mp 205–207 °C. IR
(KBr): 3000–2385, 1604, 1467, 855 cm?1; 1H NMR (D2O): ? 3.22–3.08 (3H, m, H-1,?), 2.13–
2.02 (4H, m, H-2,?eq), 1.90–1.79 (2H, m, H-?eq), 1.72–1.63 (1H, m, H-?eq), 1.41–1.27 (4H, m, H-
?ax??ax), 1.25–1.13 (1H, m, H-?ax); 13C NMR (D2O): ? 60.3 (C-?), 31.7 (2C-?), 27.3 (C-?), 26.7
(2C-?),  rest  in  Table  17;  HRMS  (ESI-MS):  calcd  for  (M+H)  C9H19N2D2 159.1830, found
159.1826. Isotope distribution: 0% d0, 2% d1, 98% d2.
1,1-2H2-Propane-1,3-diamine dihydrochloride 1l [Callery et. al. 1992]
To  a  mixture  of 1f (190 mg, 0.79 mmol) in ethanol (30 mL), water was added to dissolve 1f
followed with 10% Pd–C (80 mg) and the reaction mixture was hydrogenated at 3.5 bar pressure
for 20 h. The catalyst was filtered off through Celite, washed with ethanol and water, and the
combined filtrates were evaporated to dryness in vacuo. Recrystallization from ethanol–water–
EtOAc yielded 1l (92 mg, 78%, 99% d) as a colourless solid, mp 249–250 °C (lit. mp 246–
250 °C).[Callery et. al. 1992] IR (KBr): 3000–2300, 2227, 1610, 1463, 1167, 844 cm?1; 1H NMR
(D2O): ? 3.15–3.09 (2H, m, H-1), 2.10–2.04 (2H, m, H-2); 13C  NMR  (D2O): ? in Table 17;
HRMS (ESI-MS): calcd for (M+H) C3H9N2D2 77.1048, found 77.1051. Isotope distribution: 1%
d0, 1% d1, 98% d2.
N1-(3-Ethylaminopropyl)butane-1,4-diamine trihydrochloride 2a [Bergeron et. al. 1997]
A mixture of 12a (1.21 g, 1.79 mmol), PhSH (0.56 mL, 5.40 mmol) and K2CO3 (1.48 g,
10.74 mmol) in DMF (15 mL) was stirred overnight at room temperature. The reaction mixture
was then evaporated to dryness in vacuo. The residue was dissolved in a mixture of DCM and
2 M KOH (2:1, 150 mL), the water layer was extracted with DCM (3×50 mL), and the combined
organic extracts were dried over MgSO4. Solvent was evaporated in vacuo and the residue was
dissolved in ethanol (14 mL) containing N2H4·H2O (135 ?L, 2.78 mmol). After heating for 3 h at
reflux, the solvents were evaporated in vacuo, the residue was suspended in a mixture of dioxane
and concd HCl (3:1, 28 mL) followed by evaporating to dryness in vacuo. After being co-
evaporated once with dioxane, DCM was added to the residue and the product was filtered,
washed with DCM and extracted with water. The filtrate was evaporated in vacuo, dissolved in
water, the insoluble phthalyl hydrazide was filtered off and the solvent was evaporated to dryness
in vacuo. The treatment with water was repeated twice. The product was washed with EtOAc,
DCM and cold ethanol. After recrystallization from ethanol–water–EtOAc, 2a (376 mg, 74%)
was obtained as a colourless solid, mp >298 °C decomp. IR (KBr): 3000–2387, 1611, 1460,
1354, 1147, 805 cm?1; 1H NMR (D2O): ? 3.18–3.08 (8H, m, H-?,1,3,5), 3.06–3.02 (2H, m, H-8),
2.15–2.06 (2H, m, H-2), 1.83–1.71 (4H, m, H-6,7), 1.29 (3H, t, J=7.3 Hz, H-?); 13C NMR (D2O):
? 46.0 (C-?), 13.4 (C-?), rest in Table 18; HRMS (ESI-MS): calcd for (M+H) C9H24N3 174.1970,
found 174.1964.
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N1-(3-Ethylamino-1,1-2H2-propyl)butane-1,4-diamine trihydrochloride 2b
Prepared as 2a from 12b (800 mg, 1.18 mmol) to give 2b (172 mg, 51%, 99% d) as a colourless
solid, mp >308 °C decomp. IR (KBr): 3000–2264, 1612, 1460, 1346, 1144, 844, 803 cm?1; 1H
NMR (D2O): ? 3.17–3.09 (6H, m, H-?,1,5), 3.08–3.02 (2H, m, H-8), 2.13–2.07 (2H, m, H-2),
1.84–1.72 (4H, m, H-6,7), 1.30 (3H, t, J=7.3 Hz, H-?); 13C NMR (D2O): ? 46.0 (C-?), 13.4 (C-?),
rest  in  Table  18;  HRMS  (ESI-MS):  calcd  for  (M+H)  C9H22N3D2 176.2096, found 176.2092.
Isotope distribution: 0% d0, 1% d1, 99% d2.
N1-(3-Ethylamino-1,1,2,2-2H4-propyl)butane-1,4-diamine trihydrochloride 2c
Prepared as 2a from 12c (927 mg, 1.37 mmol) to give 2c (315 mg, 80%, 98% d) as a colourless
solid, mp >285 °C decomp. IR (KBr): 3000–2312, 1611, 1458, 1343, 1123, 823, 806 cm?1; 1H
NMR (D2O): ? 3.18–3.09 (6H, m, H-?,1,5), 3.08–3.02 (2H, m, H-8), 1.85–1.73 (4H, m, H-6,7),
1.30 (3H, t, J=7.3 Hz, H-?); 13C NMR (D2O): ? 45.9 (C-?), 13.4 (C-?), rest in Table 18; HRMS
(ESI-MS): calcd for (M+H) C9H20N3D4 178.2221, found 178.2217. Isotope distribution: 0% d0–
d2, 8% d3, 92% d4.
N1-(3-Benzylamino-propyl)butane-1,4-diamine trihydrochloride 2d [Martin et. al. 2001]
Prepared as 2a from 12d (1.24 g, 1.69 mmol) to give 2d (393 mg, 68%) as a colourless solid, mp
>300 °C decomp. (lit. mp >300 °C).[Martin et. al. 2001] IR (KBr): 3050–2417, 1610, 1448, 744,
698 cm?1; 1H NMR (D2O): ? 7.54–7.47 (5H, m, Ph), 4.28 (2H, s, H-?), 3.22–3.08 (6H, m, H-
1,3,5), 3.07–3.02 (2H, m, H-8), 2.17–2.07 (2H, m, H-2), 1.82–1.71 (4H, m, H-6,7); 13C NMR
(D2O): ? 133.4, 132.8 (2C), 132.7, 132.3 (2C) (totally 6C–Ph), 54.2 (C-?), rest in Table 18;
HRMS (ESI-MS): calcd for (M+H) C14H26N3 236.2127, found 236.2121.
N1-(3-Benzylamino-1,1-2H2-propyl)butane-1,4-diamine trihydrochloride 2e
Prepared as 2a from 12e (1.81 g, 2.45 mmol) to give 2e (542 mg, 64%, 99% d) as a colourless
solid, mp >300 °C decomp. IR (KBr): 3050–2380, 1611, 1447, 843, 744, 698 cm?1; 1H NMR
(D2O): ? 7.55–7.48 (5H, m, Ph), 4.29 (2H, s, H-?), 3.22–3.17 (2H, m, H-1), 3.14–3.09 (2H, m,
H-5), 3.08–3.03 (2H, m, H-8), 2.16–2.10 (2H, m, H-2), 1.84–1.72 (4H, m, H-6,7); 13C NMR
(D2O): ? 133.3, 132.7 (2C), 132.6, 132.2 (2C) (totally 6C–Ph), 54.1 (C-?), rest in Table 18;
HRMS (ESI-MS): calcd for (M+H) C14H24N3D2 238.2252, found 238.2241. Isotope distribution:
0% d0, 3% d1, 97% d2.
N1-(3-Isopropylaminopropyl)butane-1,4-diamine trihydrochloride 2f
Prepared as 2a from 12f (1.26 g, 1.84 mmol), but the stirring was continued at room temperature
for 70 h to give 2f (438 mg, 80%) as a colourless solid, mp 236–239 °C. IR (KBr): 3000–2361,
1606, 1457, 1387, 1099, 964 cm?1; 1H NMR (D2O): ? 3.44 (1H, sep., J=6.5 Hz, H-?), 3.22–3.02
(8H, m, H-1,3,5,8), 2.15–2.05 (2H, m, H-2), 1.84–1.71 (4H, m, H-6,7), 1.33 (6H, d, J=6.5 Hz, H-
?); 13C  NMR  (D2O): ? 54.0 (C-?), 21.1 (2C-?), rest in Table 18; HRMS (ESI-MS): calcd for
(M+H) C10H26N3 188.2127, found 188.2123.
N1-(3-Cyclohexylaminopropyl)butane-1,4-diamine trihydrochloride 2g
Prepared as 2f from 12g (1.33 g, 1.83 mmol) to give 2g (478 mg, 78%) as a colourless solid, mp
277–278 °C. IR (KBr): 3000–2368, 1607, 1456, 1050, 775 cm?1; 1H NMR (D2O): ? 3.22–3.00
(9H, m, H-?,1,3,5,8), 2.15–2.02 (4H, m, H-2,?eq), 1.89–1.71 (6H, m, H-6,7,?eq), 1.70–1.63 (1H,
m, H-?eq), 1.40–1.26 (4H, m, H-?ax??ax), 1.24–1.12 (1H, m, H-?ax); 13C NMR (D2O): ? 60.4 (C-?),
31.8 (2C-?), 27.4 (C-?), 26.8 (2C-?), rest in Table 18; HRMS (ESI-MS): calcd for (M+H)
C13H30N3 228.2440, found 228.2434.
N1-(3-Amino-1,1-2H2-propyl)butane-1,4-diamine trihydrochloride 2h
Prepared as 1l from 2e (300 mg, 0.87 mmol) to give 2h (122 mg, 55%, 99% d) as a colourless
solid, mp 251–252 °C (lit. mp for unlabelled SPD: 250–254 °C).[Carboni et. al. 1993] IR (KBr):
3000–2370, 1596, 1451, 1171, 845 cm?1; 1H NMR (D2O): ? 3.14–3.02 (6H, m, H-1,5,8), 2.11–
2.05 (2H, m, H-2), 1.83–1.72 (4H, m, H-6,7); 13C NMR (D2O): ? in Table 18; HRMS (ESI-MS):
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calcd for (M+H) C7H18N3D2 148.1783, found 148.1787. Isotope distribution: 0% d0, 1% d1, 99%
d2.
N-(3-Aminopropyl)-N?-(3-ethylaminopropyl)butane-1,4-diamine tetrahydrochloride 3a
[Bergeron et. al. 1994]
A mixture of 13a (1.27 g, 1.43 mmol), PhSH (0.67 mL, 6.48 mmol) and K2CO3 (1.78 g,
12.9 mmol) in DMF (13 mL) was stirred for 20 h at room temperature and then evaporated to
dryness in vacuo. The residue was dissolved in a mixture of DCM and 2 M KOH (4:3, 130 mL),
the water layer was extracted with DCM (4×50 mL), and the combined organic extracts were
dried over MgSO4. The solvent was evaporated in vacuo, the residue was dissolved in 1,4-
dioxane (12 mL) followed with concd HCl (3 mL) and the resulting mixture was stirred for 2 h at
room temperature. The reaction mixture was evaporated to dryness in vacuo and co-evaporated
once with dioxane (10 mL). DCM was added to the residue, the product was filtered and washed
with DCM and cold ethanol. Recrystallization from ethanol–water–EtOAc yielded 3a (269 mg,
50%) as a colourless solid, mp >275 °C decomp. IR (KBr): 3000–2388, 1612, 1461, 1355, 1145,
806 cm?1; 1H NMR (D2O): ? 3.21–3.08 (14H, m, H-?,1,3,5,8,10,12), 2.16–2.06 (4H, m, H-2,11),
1.84–1.75 (4H, m, H-6,7), 1.30 (3H, t, J=7.3 Hz, H-?); 13C NMR (D2O): ? 45.9 (C-?), 13.3 (C-?),
rest in Table 19; HRMS (ESI-MS): calcd for (M+H) C12H31N4 231.2549, found 231.2555.
N-(3-Aminopropyl)-N?-(3-ethylamino-1,1-2H2-propyl)butane-1,4-diamine tetrahydrochloride
3b
Prepared as 3a from 13b (1.0 g, 1.13 mmol) to give 3b (199 mg, 47%, 98% d) as a colourless
solid, mp >300 °C decomp. IR (KBr): 3000–2382, 1611, 1460, 1354, 1145, 844 cm?1; 1H NMR
(D2O): ? 3.20–3.08 (12H, m, H-?,1,5,8,10,12), 2.15–2.07 (4H, m, H-2,11), 1.84–1.76 (4H, m, H-
6,7), 1.30 (3H, t, J=7.3 Hz, H-?); 13C NMR (D2O): ? 46.0 (C-?), 13.4 (C-?), rest in Table 19;
HRMS (ESI-MS): calcd for (M+H) C12H29N4D2 233.2674, found 233.2666. Isotope distribution:
0% d0, 3% d1, 97% d2.
N-(3-Aminopropyl)-N?-(3-Benzylamino-propyl)-butane-1,4-diamine tetrahydrochloride 3c
[Tomasi et. al. 1998]
Prepared as 3a from 13c (1.40 g, 1.48 mmol) to give 3c (405 mg, 62%) as a colourless solid, mp
>300 °C decomp. IR (KBr): 3000–2420, 1609, 1460, 874, 744, 698 cm?1; 1H  NMR  (D2O): ?
7.55–7.47 (5H, m, Ph), 4.28 (2H, s, H-?), 3.25–3.05 (12H, m, H-1,3,5,8,10,12), 2.20–2.05 (4H,
m, H-2,11), 1.85–1.73 (4H, m, H-6,7); 13C NMR (D2O): ? 133.3, 132.7 (2C), 132.7, 132.2 (2C)
(totally  6C–Ph),  54.1  (C-?),  rest  in  Table  19;  HRMS  (ESI-MS):  calcd  for  (M+H)  C17H33N4
293.2705, found 293.2698.
N-(3-Aminopropyl)-N?-(3-Benzylamino-1,1,2,2-2H4-propyl)-butane-1,4-diamine
tetrahydrochloride 3d
Prepared as 3a from 13d (2.73 g, 2.86 mmol) to give 3d (904 mg, 71%, 98% d) as a colourless
solid, mp >300 °C decomp. IR (KBr): 3050–2309, 1610, 1450, 825, 744, 698 cm?1; 1H NMR
(D2O): ? 7.55–7.47 (5H, m, Ph), 4.28 (2H, s, H-?), 3.25–3.05 (10H, m, H-1,5,8,10,12), 2.17–2.05
(2H, m, H-11), 1.85–1.73 (4H, m, H-6,7);13C  NMR  (D2O): ? 133.3, 132.7 (2C), 132.7, 132.2
(2C) (totally 6C–Ph), 54.1 (C-?), rest in Table 19; HRMS (ESI-MS): calcd for (M+H)
C17H29N4D4 297.2956, found 297.2947. Isotope distribution: 0% d0–d2, 7% d3, 92% d4.
N-(3-Aminopropyl)-N?-(3-isopropylaminopropyl)butane-1,4-diamine tetrahydrochloride 3e
Prepared as 3a from 13e (1.51 g, 1.68 mmol) to give 3e (452 mg, 69%) as a colourless solid, mp
>269 °C decomp. IR (KBr): 3000–2364, 1625, 1460, 1376, 877 cm?1; 1H  NMR  (D2O): ? 3.44
(1H, sep., J=6.5 Hz, H-?), 3.22–3.00 (12H, m, H-1,3,5,8,10,12), 2.18–2.00 (4H, m, H-2,11),
1.85–1.70 (4H, m, H-6,7), 1.33 (6H, d, J=6.5 Hz, H-?); 13C NMR (D2O): ? 53.9 (C-?), 21.0 (2C-
?), rest in Table 19; HRMS (ESI-MS): calcd for (M+H) C13H33N4 245.2705, found 245.2695.
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N-(3-Aminopropyl)-N?-(3-cyclohexylaminopropyl)butane-1,4-diamine tetrahydrochloride 3f
Prepared as 3a from 13f (1.15 g, 1.22 mmol) to give 3f (380 mg, 72%) as a colourless solid, mp
>285 °C decomp. IR (KBr): 3000–2419, 1610, 1460, 1051, 775 cm?1; 1H NMR (D2O): ? 3.21–
3.07 (13H, m, H-?,1,3,5,8,10,12), 2.15–2.02 (6H, m, H-2,11,?eq), 1.89–1.74 (6H, m, H-6,7,?eq),
1.71–1.64 (1H, m, H-?eq), 1.40–1.26 (4H, m, H-?ax??ax), 1.23–1.13 (1H, m, H-?ax); 13C NMR
(D2O): ? 60.4 (C-?), 31.7 (2C-?), 27.3 (C-?), 26.7 (2C-?), rest in Table 19; HRMS (ESI-MS):
calcd for (M+H) C16H37N4 285.3018, found 285.3009.
N-(3-Amino-1,1,2,2-2H4-propyl)-N?-(3-ethylamino-propyl)butane-1,4-diamine
tetrahydrochloride 3g
Prepared as 1l from 4f (400 mg, 0.85 mmol) to give 3g (259 mg, 80%, 98% d) as a colourless
solid, mp >300 °C decomp. IR (KBr): 3000–2388, 1610, 1459, 1353, 1147, 823 cm?1; 1H NMR
(D2O): ? 3.22–3.07 (12H, m, H-?,1,3,5,8,12), 2.18–2.06 (2H, m, H-2), 1.86–1.75 (4H, m, H-6,7),
1.30 (3H, t, J=7.3 Hz, H-?); 13C NMR (D2O): ? 45.9 (C-?), 13.3 (C-?), rest in Table 19; HRMS
(ESI-MS): calcd for (M+H) C12H27N4D4 235.2800, found 235.2788. Isotope distribution: 0% d0–
d2, 6% d3, 93% d4.
,N?-Bis(3-ethylaminopropyl)butane-1,4-diamine tetrahydrochloride 4a [Bergeron et. al. 2001a]
A mixture of 14a (700 mg, 0.70 mmol), PhSH (0.43 mL, 4.20 mmol) and K2CO3 (1.16 g,
8.41 mmol) in DMF (7 mL) was stirred for 20 h at room temperature and then the reaction
mixture was evaporated to dryness in vacuo. The residue was dissolved in a mixture of DCM and
2 M KOH (4:3, 60 mL), the water layer was extracted with a mixture of ethanol and DCM (1:2,
4×20 mL), and the combined organic extracts were dried over MgSO4. Solvents were evaporated
in vacuo, the residue was dissolved in 1,4-dioxane (6 mL) followed by the addition of concd HCl
(1.5 mL) and the resulting mixture was stirred for 5 min at room temperature. The reaction
mixture was evaporated to dryness in vacuo and co-evaporated once with dioxane (10 mL). DCM
was added to the residue and the product was filtered, washed with DCM and cold ethanol.
Recrystallization from ethanol–water–EtOAc yielded 4a (144 mg, 51%) as a colourless solid, mp
>300 °C decomp. IR (KBr): 3000–2389, 1596, 1460, 1354, 1142, 806 cm?1; 1H  NMR  (D2O)
chemical shifts as reported earlier;[Bergeron et. al. 2001a] 13C NMR (D2O): ? 45.9 (2C-?), 13.3
(2C-?),  rest  in  Table  19;  HRMS  (ESI-MS):  calcd  for  (M+H)  C14H35N4 259.2862, found
259.2854.
N,N?-Bis(3-ethylamino-1,1-2H2-propyl)butane-1,4-diamine tetrahydrochloride 4b
Prepared as 4a from 14b (1.04 g, 1.04 mmol) to give 4b (190 mg, 45%, 99% d) as a colourless
solid, mp >300 °C decomp. IR (KBr): 3000–2265, 1595, 1461, 1348, 1145, 843, 803 cm?1; 1H
NMR (D2O): ? 3.19–3.07 (12H, m, H-?,1,5,8,12), 2.15–2.06 (4H, m, H-2,11), 1.85–1.74 (4H, m,
H-6,7), 1.30 (6H, t, J=7.3 Hz, H-?); 13C NMR (D2O): ? 45.9 (2C-?), 13.3 (2C-?), rest in Table
19;  HRMS  (ESI-MS):  calcd  for  (M+H)  C14H31N4D4 263.3113, found 263.3103. Isotope
distribution: 0% d0–d2, 3% d3, 97% d4.
N,N?-Bis(3-isopropylaminopropyl)butane-1,4-diamine tetrahydrochloride 4c [Bergeron et. al.
2001a]
Prepared as 4a from 14c (1.03 g, 1.0 mmol), PhSH (0.64 mL, 6.2 mmol) and K2CO3 (1.66 g,
12 mmol) in DMF (10 mL), but stirring was continued for 70 h to give 4c (282 mg,  65%) as  a
colourless solid, mp >281 °C decomp. IR (KBr): 3000–2360, 1636, 1478, 1386, 1150, 762 cm?1;
1H NMR (D2O) chemical shifts as reported earlier;[Bergeron et. al. 2001a] 13C NMR (D2O): ?
53.9 (2C-?), 21.0 (4C-?), rest in Table 19; HRMS (ESI-MS): calcd for (M+H) C16H39N4
287.3175, found 287.3165.
N,N?-Bis(3-cyclohexylaminopropyl)butane-1,4-diamine tetrahydrochloride 4d [Weitl &
Raymond 1981]
Prepared as 4c from 14d (968 mg, 0.87 mmol) to give 4d (364 mg, 82%) as colourless solid, mp
>300 °C decomp. IR (KBr): 3000–2420, 1596, 1456, 1052, 775 cm?1; 1H NMR (D2O): ? 3.21–
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3.07 (14H, m, H-?,1,3,5,8,10,12), 2.15–2.02 (8H, m, H-2,11,?eq), 1.89–1.74 (8H, m, H-6,7,?eq),
1.71–1.63 (2H, m, H-?eq), 1.40–1.26 (8H, m, H-?ax??ax), 1.24–1.12 (2H, m, H-?ax); 13C NMR
(D2O): ? 60.4 (2C, C-?), 31.7 (4C, C-?), 27.3 (2C, C-?), 26.7 (4C, C-?), rest in Table 19; HRMS
(ESI-MS): calcd for (M+H) C22H47N4 367.3801, found 367.3785.
N-(3-Benzylaminopropyl)-N?-(3-ethylaminopropyl)butane-1,4-diamine tetrahydrochloride 4e
Prepared as 4a from 14e (927 mg, 0.87 mmol) to give 4e (284 mg, 70%) as a colourless solid, mp
>275 °C decomp. IR (KBr): 3050–2389, 1593, 1460, 873, 743, 698 cm?1; 1H  NMR  (D2O): ?
7.56–7.47 (5H, m, Ph), 4.28 (2H, s, PhCH2–), 3.24–3.05 (14H, m, H-?,1,3,5,8,10,12), 2.19–2.06
(4H, m, H-2,11), 1.85–1.73 (4H, m, H-6,7), 1.30 (3H, t, J=7.3 Hz, H-?); 13C  NMR  (D2O): ?
133.3, 132.7 (2C), 132.7, 132.2 (2C) (totally 6C–Ph), 54.1 (Ph–CH2–), 45.9 (C-?), 13.3 (C-?),
rest in Table 19; HRMS (ESI-MS): calcd for (M+H) C19H37N4 321.3018, found 321.3003.
N-(3-Benzylamino-1,1,2,2-2H4-propyl)-N?-(3-ethylaminopropyl)butane-1,4-diamine
tetrahydrochloride 4f
Prepared as 4a from 14f (2.65 g, 2.48 mmol) to give 4f (790 mg, 68%, 98% d) as a colourless
solid, mp >300 °C decomp. IR (KBr): 3050–2311, 1594, 1455, 825, 743, 698 cm?1; 1H NMR
(D2O): ? 7.56–7.47 (5H, m, Ph), 4.29 (2H, s, PhCH2–), 3.24–3.06 (12H, m, H-?,1,5,8,10,12),
2.18–2.06 (2H, m, H-11), 1.86–1.75 (4H, m, H-6,7), 1.31 (3H, t. J=7.3 Hz, H-?); 13C NMR
(D2O): ? 133.3, 132.7 (2C), 132.6, 132.2 (2C) (totally 6C–Ph), 54.1 (Ph–CH2–), 45.9 (C-?), 13.3
(C-?),  rest  in  Table  19;  HRMS  (ESI-MS):  calcd  for  (M+H)  C19H33N4D4 325.3269, found
325.3260. Isotope distribution: 0% d0–d2, 8% d3, 92% d4.
N-(3-Benzylamino-1,1,2,2-2H4-propyl)-N?-(3-ethylamino-1,1,2,2-2H4-propyl)butane-1,4-
diamine tetrahydrochloride 4g
Prepared as 4a from 14g (1.29 g, 1.21 mmol) to give 4g (381 mg, 66%, 98% d) as a colourless
solid, mp >300 °C decomp. IR (KBr): 3050–2312, 1593, 1452, 822, 744, 698 cm?1; 1H NMR
(D2O): ? 7.56–7.46 (5H, m, Ph), 4.29 (2H, s, PhCH2–), 3.24–3.05 (10H, m, H-?,1,5,8,12), 1.85–
1.74 (4H, m, H-6,7), 1.30 (3H, t, J=7.3 Hz, H-?); 13C  NMR  (D2O): ? 133.3 (Ph), 132.7 (2C),
132.6, 132.2 (2C) (totally 6C–Ph), 54.1 (Ph–CH2–), 45.9 (C-?), 13.3 (C-?), rest in Table 19;
HRMS (ESI-MS): calcd for (M+H) C19H29N4D8 329.3520, found 329.3518. Isotope distribution:
0% d0–d5, 1% d6, 12% d7, 87% d8.
N-(3-Amino-1,1,2,2-2H4-propyl)-N?-(3-aminopropyl)butane-1,4-diamine tetrahydrochloride 4h
Prepared as 1l from 3d (400 mg, 0.90 mmol) to give 4h (262 mg, 82%, 98% d) as a colourless
solid, mp >300 °C decomp. IR (KBr): 3124–2010, 1594, 1479, 1158, 812 cm?1; 1H NMR (D2O):
? 3.22–3.08 (10H, m, H-1,5,8,10,12), 2.16–2.07 (2H, m, H-11), 1.86–1.75 (4H, m, H-6,7); 13C
NMR (D2O): ? in  Table  19;  HRMS  (ESI-MS):  calcd  for  (M+H)  C10H23N4D4 207.2487, found
207.2486. Isotope distribution: 0% d0–d2, 8% d3, 92% d4.
3-Ethylamino-propionitrile 6a [Whitmore et. al. 1944, Rouvier et. al. 1974]
Prepared by the known method [Whitmore et. al. 1944] from 70% ethylamine (20.0 g,
311 mmol) and acrylonitrile (10.6 g, 200 mmol) to give 6a (17.93 g, 91%) as a colourless liquid,
bp 75 °C/10 mbar. IR (neat): 3313 (br), 2969–2834, 2247, 1455, 1375, 1130 cm?1; 1H NMR
(CDCl3): ? 2.94 (2H, t, J=6.6 Hz, H-1), 2.69 (2H, q, J=7.1 Hz, H-?), 2.53 (2H, t, J=6.6 Hz, H-2),
1.68 (1H, br, NH), 1.13 (3H, t, J=7.1 Hz, H-?); 13C NMR (CDCl3): ? 43.5 (C-?), 15.2 (C-?), rest
in Table 20; HRMS (ESI-MS): calcd for (M+H) C5H11N2 99.0922, found 99.0922.
3-Isopropylamino-propionitrile 6b [Zhang et. al. 2005, Pearson et. al. 1946]
Isopropylamine (5.00 g, 85 mmol) was added dropwise with stirring to a solution of acrylonitrile
(6.73 g, 127 mmol) in methanol (10 mL) within 20 min. The stirring was continued for 30 min at
room temperature and for 1 h under reflux. Solvents were evaporated in vacuo and the residue
was distilled (bp 100 °C/35 mbar) to give 6b (7.48 g, 79%) as a colourless liquid. IR (neat): 3313
(br), 2966–2870, 2247, 1472, 1381, 1175 cm?1; 1H NMR (CDCl3): ? 2.92 (2H, t, J=6.7 Hz, H-1),
6. Synthesis of deuterated polyamines
Kuopio Univ. Publ. C. Nat. and Environ. Sci. 263: 1-145 (2009) 107
2.85 (1H, sep., J=6.2 Hz, H-?), 2.51 (2H, t, H-2), 1.09 (1H, br, NH), 1.07 (6H, d, J=6.2 Hz, H-?);
13C NMR (CDCl3): ? 48.1 (C-?), 22.9 (2C-?), rest in Table 20; HRMS (ESI-MS): calcd for
(M+H) C6H13N2 113.1079, found 113.1074.
3-Cyclohexylamino-propionitrile 6c [Rouvier et. al. 1974, Dawber & Massey-Shaw 1989,
Tarbell et. al. 1946]
Prepared as 6b from cyclohexylamine (7.40 g, 75 mmol) and acrylonitrile (5.94 g, 112 mmol) to
give 6c (9.76 g, 86%) as a colourless liquid, bp 140 °C/12 mbar. IR (neat): 3422 (br), 2927, 2853,
2247, 1450, 1130 cm?1; 1H NMR (CDCl3): ? 2.95 (2H, t, J=6.7 Hz, H-1), 2.53–2.43 (3H, m, H-
2,?), 1.90–1.83 (2H, m, H-?eq), 1.77–1.70 (2H, m, H-?eq), 1.65–1.58 (1H, m, H-?eq), 1.31–1.01
(6H, m, H-?ax, ?ax, ?ax, NH); 13C NMR (CDCl3): ? 56.0 (C-?), 33.6 (2C-?), 26.0 (C-?), 24.9 (2C-
?), rest in Table 20; HRMS (ESI-MS): calcd for (M+H) C9H17N2 153.1392, found 153.1391.
3-Benzylamino-propionitrile 6d [Zhang et. al. 2005, King & McMillan 1946]
Prepared as 6b from benzylamine (8.57 g, 80 mmol) and acrylonitrile (6.37 g, 120 mmol) to give
6d (10.75 g, 84%) as a colourless liquid, bp 125 °C/2 mbar. IR (neat): cm?1 as reported
earlier;[Zhang et. al. 2005] 1H NMR (CDCl3): ? 7.36–7.22 (5H, m, Ph), 3.81 (2H, s, H-?), 2.90
(2H, t, J=6.6 Hz, H-1), 2.48 (2H, t, J=6.6 Hz, H-2), 1.54 (1H, br, NH); 13C NMR (CDCl3): ?
139.5 (Ph), 128.6 (2C, Ph), 128.1 (2C, Ph), 127.3 (Ph), 53.2 (C-?), rest in Table 20; HRMS (ESI-
MS): calcd for (M+H) C10H13N2 161.1079, found 161.1082.
3-Ethylamino-2,2-2H2-propionitrile 6e
Nitrile 6a (4.0 g, 40.75 mmol) in the mixture of 0.1 M NaOD in D2O (26 mL) and EtOD (26 mL)
was stirred at room temperature for 24 h. The reaction mixture was saturated with NaCl and
extracted with dry Et2O. Combined organic extracts were dried over K2CO3, solvents were
removed by distillation, after the product was distilled under reduced pressure (2.65 g, 65%,
92%d, bp 72 °C/10 mbar). The reaction cycle was repeated once to give 6e (1.91 g, 47%, 98% d)
as a colourless liquid. IR (neat): 3312 (br), 2969–2340, 2248, 1453, 1384, 1126 cm?1; 1H NMR
(CDCl3): ? 2.92 (2H, s, H-1), 2.69 (2H, q, J=7.1 Hz, H-?), 1.13 (3H, t, J=7.1 Hz, H-?); 13C NMR
(CDCl3): ? 43.4  (C-?),  15.2  (C-?),  rest  in  Table  20;  HRMS  (ESI-MS):  calcd  for  (M+H)
C5H9D2N2 101.1048, found 101.1044.
3-Benzylamino-2,2-2H2-propionitrile 6f
Prepared as 6e from 6d (3.2 g, 20 mmol) to give 6f (2.62 g, 81%, 95% d, bp 120 °C/0.9 mbar)
after the first cycle. The reaction cycle was repeated once to give 6f (2.16 g, 66%, 99% d) as a
colourless liquid. IR (neat): 3336 (br), 3085–2843, 2248, 1454, 743, 700 cm?1; 1H NMR
(CDCl3): ? 7.36–7.22 (5H, m, Ph), 3.82 (2H, s, H-?), 2.91 (2H, s, H-1); 13C NMR (CDCl3): ?
139.5 (Ph), 128.6 (2C, Ph), 128.1 (2C, Ph), 127.3 (Ph), 53.2 (C-?), rest in Table 20; HRMS (ESI-
MS): calcd for (M+H) C10H11D2N2 163.1204, found 163.1209.
[3-(2-Nitro-benzenesulfonylamino)propyl]-carbamic acid tert-butyl ester 9
Prepared from (3-amino-propyl)-carbamic acid tert-butyl ester (3.5 mL, 20 mmol), TEA (3.7 mL,
26.5 mmol) and NsCl (4.7 g, 21 mmol) as described earlier for (R)-N1-(o-nitrophenylsulfonyl)-
N3-(tert-butyloxycarbonyl)-1,3-diaminobutane[Järvinen et. al. 2006b, Grigorenko et. al. 2007] to
give 9 (7.0 g) as yellow solid with 97% yield (lit.[da Silva et. al. 2004] yield 89%). 1H and 13C
NMR chemical shift are in accordance with published data.[Olsen et. al. 2003]
3-[(4-Chlorobutyl)-(2-nitrobenzenesulfonyl)amino]propyl}carbamic acid tert-butyl ester 10a
To a stirred mixture of 9 (7.2 g, 20 mmol) and K2CO3 (8.9 g, 64 mmol) in dry DMF (170 mL), 1-
bromo-4-chlorobutane (14.9 mL, 129 mmol) was added and stirring was continued for 65 h at
room temperature. The precipitates were filtered off, the filtrate was evaporated to dryness in
vacuo, and the residue was suspensed in EtOAc, washed with water (350 mL), brine (350 mL)
and dried over MgSO4. The solvent was evaporated in vacuo to give 10a (8.9 g, 99% yield based
on 9) as a pale yellow oil. IR (neat): 3423 (br), 3095–2850, 1701, 1365, 1163, 746 cm?1; 1H
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NMR (CDCl3): ? 8.03–7.98 (1H, m, Ph), 7.74–7.66 (2H, m, Ph), 7.65–7.61 (1H, m, Ph), 4.78
(1H, br, NH), 3.54–3.49 (2H, m, H-8), 3.38–3.31 (4H, m, H-3,5), 3.18–3.12 (2H, m, H-1), 1.79–
1.66 (6H, m, H-2,6,7), 1.44 (9H, s, Me3C); 13C NMR (CDCl3): ? 156.0 (C=O), 148.1, 133.6,
133.3, 131.7, 130.7, 124.3 (totally 6C–Ph), 79.3 (O–C), 28.4 (3C–Me3), rest in Table 22; HRMS
(ESI-MS): calcd for (M+Na) C18H28ClN3O6SNa 472.1285, found 472.1283.
3-[(4-Iodobutyl)-(2-nitrobenzenesulfonyl)amino]propyl}carbamic acid tert-butyl ester 10b
A mixture of 10a (8.6 g, 19.1 mmol) and NaI (28.7 g, 191 mmol) in acetone (250 mL) was
heated at reflux with stirring for 48 h. The precipitate was filtered off and the filtrate was
evaporated to dryness in vacuo. The residue was dissolved in EtOAc, washed with water
(250 mL) and brine (250 mL), and dried over MgSO4. Solvent was evaporated in vacuo and the
residue was purified on silica gel using EtOAc–hexane 1:1 as an eluent, to give 10b (7.3 g, 70%)
as a yellow oil. Rf 0.54 (EtOAc–hexane 1:1); IR (neat): 3422 (br), 2975, 2935, 1701, 1366, 1162,
748, 584 cm?1; 1H NMR (CDCl3): ? 8.03–7.98 (1H, m, Ph), 7.74–7.67 (2H, m, Ph), 7.66–7.61
(1H, m, Ph), 4.78 (1H, br, NH), 3.40–3.29 (4H, m, H-3,5), 3.19–3.11 (4H, m, H-1,8), 1.81–1.72
(4H, m, H-2,7), 1.69–1.61 (2H, m, H-6), 1.44 (9H, s, Me3C); 13C NMR (CDCl3): ? 156.0 (C=O),
148.1, 133.6, 133.3, 131.7, 130.7, 124.3 (totally 6C–Ph), 79.3 (O–C), 28.4 (3C–Me3), rest in
Table 22; HRMS (ESI-MS): calcd for (M+Na) C18H28IN3O6SNa 564.0641, found 564.0633.
N1-Ethyl-bis-N1,N3-(2-nitrobenzenesulfonyl)propane-1,3-diamine 11a
A suspension of 1a (2.0 g, 11.42 mmol) and TEA (8 mL, 57 mmol) in dry DCM (100 mL) was
cooled to 0 °C. NsCl (5.32 g, 23.99 mmol) in dry DCM (70 mL) was added dropwise with
stirring over a period of 10 min, and stirring was continued for 1 h at 0 °C and then for 3 h at
room temperature. The reaction mixture was washed with water (2×200 mL), 10% citric acid
(1×200 mL), brine (1×200 mL), dried over MgSO4 and evaporated to dryness in vacuo that
resulted in 11a (5.4 g, ~100%) as a pale yellow solid, mp 82–84 °C. IR (KBr): 3321, 3095–2878,
1545, 1380, 1160, 736 cm?1; 1H NMR (CDCl3): ? 8.14–8.09 (1H, m, Ph), 8.03–7.98 (1H, m, Ph),
7.87–7.83 (1H, m, Ph), 7.78–7.67 (4H, m, Ph), 7.64–7.59 (1H, m, Ph), 5.66 (1H, t, J=6.2 Hz,
NH), 3.42–3.31 (4H, m, H-?,1), 3.22–3.16 (2H, m, H-3), 1.89–1.81 (2H, m, H-2), 1.10 (3H, t,
J=7.1 Hz, H-?); 13C NMR (CDCl3): ? 148.1, 148.0, 133.7, 133.6 (2C), 133.3, 132.9, 131.8, 130.9,
130.8, 125.5, 124.2 (totally 12C–Ph), 42.4 (C-?), 13.7 (C-?), rest in Table 21; HRMS (ESI-MS):
calcd for (M+H) C17H21N4O8S2 473.0801, found 473.0793.
N1-Ethyl-bis-N1,N3-(2-nitrobenzenesulfonyl)-3,3-2H2-propane-1,3-diamine 11b
Prepared as 11a from 1b (1.20 g, 6.78 mmol) to give 11b (3.33 g, ~100%) as a pale yellow solid,
mp 79–81 °C. IR (KBr): 3323, 3095–2879, 1545, 1380, 1161, 732 cm?1; 1H NMR (CDCl3): ?
8.14–8.09 (1H, m, Ph), 8.02–7.97 (1H, m, Ph), 7.87–7.84 (1H, m, Ph), 7.78–7.67 (4H, m, Ph),
7.64–7.59 (1H, m, Ph), 5.66 (1H, br, NH), 3.42–3.31 (4H, m, H-?,1), 1.86–1.81 (2H, m, H-2),
1.10 (3H, t, J=7.1 Hz, H-?); 13C NMR (CDCl3): ? 148.1, 148.0, 133.7, 133.6, 133.6, 133.3, 132.9,
131.8, 130.9, 130.8, 125.5, 124.2 (totally 12C–Ph), 42.4 (C-?), 13.7 (C-?), rest in Table 21;
HRMS (ESI-MS): calcd for (M+H) C17H19D2N4O8S2 475.0926, found 475.0925.
N1-Ethyl-bis-N1,N3-(2-nitrobenzenesulfonyl)-2,2,3,3-2H4-propane-1,3-diamine 11c
Prepared as 11a from 1d (700 mg, 3.91 mmol) to give 11c (1.89 g, ~ 100%) as a pale yellow
solid, mp 79–83 °C. IR (KBr): 3323, 3095–2881, 1544, 1380, 1161, 746 cm?1; 1H NMR (CDCl3):
? 8.14–8.10 (1H, m, Ph), 8.04–7.99 (1H, m, Ph), 7.89–7.84 (1H, m, Ph), 7.78–7.67 (4H, m, Ph),
7.64–7.60 (1H, m, Ph), 5.63 (1H, br, NH), 3.38 (2H, s, H-1), 3.35 (2H, q, J=7.2 Hz, H-?), 1.11
(3H, t, J=7.2 Hz, H-?); 13C NMR (CDCl3): ? 148.1, 148.0, 133.7, 133.6, 133.6, 133.2, 132.9
131.8, 130.9, 130.8, 125.5, 124.2 (totally 12C–Ph), 42.4 (C-?), 13.7 (C-?), rest in Table 21;
HRMS (ESI-MS): calcd for (M+H) C17H17D4N4O8S2 477.1052, found 477.1046.
N1-Benzyl-bis-N1,N3-(2-nitrobenzenesulfonyl)propane-1,3-diamine 11d
Prepared as 11a from 1e (600 mg, 2.53 mmol) to give 11d (1.25 g, 92%) as a pale yellow solid,
mp 40–55 °C (amorphous solid). IR (KBr): 3342 (br), 3095–2880, 1541, 1163, 732 cm?1; 1H
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NMR (CDCl3): ? 8.07–8.03 (1H, m, Ph), 8.01–7.98 (1H, m, Ph), 7.86–7.82 (1H, m, Ph), 7.74–
7.64 (5H, m, Ph), 7.31–7.22 (5H, m, Ph), 5.39 (1H, t, J=6.3 Hz, NH), 4.47 (2H, s, H-?), 3.36–
3.32 (2H, m, H-1), 3.02–2.96 (2H, m, H-3), 1.62–1.55 (2H, m, H-2); 13C NMR (CDCl3): ? 148.0,
148.0, 135.5, 133.8, 133.6, 133.6, 133.1, 132.8, 131.9, 131.1, 130.9, 128.9 (2C), 128.3 (2C),
128.3, 125.4, 124.3 (totally 18C–Ph), 52.3 (C-?), rest in Table 21; HRMS (ESI-MS): calcd for
(M+H) C22H23N4O8S2 535.0957, found 535.0984.
N1-Benzyl-bis-N1,N3-(2-nitrobenzenesulfonyl)-3,3-2H2-propane-1,3-diamine 11e
Prepared as 11a from 1f (700 mg, 2.93 mmol) to give 11e (1.43 g, 91%) as a pale yellow solid,
mp 40–48 °C (amorphous solid). IR (KBr): 3341 (br), 3095–2880, 1541, 1163, 740, 699 cm?1; 1H
NMR (CDCl3): ? 8.07–8.03 (1H, m, Ph), 8.01–7.98 (1H, m, Ph), 7.86–7.82 (1H, m, Ph), 7.74–
7.64 (5H, m, Ph), 7.31–7.22 (5H, m, Ph), 5.38 (1H, br, NH), 4.47 (2H, s, H-?), 3.36–3.32 (2H, m,
H-1), 1.59–1.55 (2H, m, H-2); 13C NMR (CDCl3): ? 148.0 (2C), 135.5, 133.8, 133.7 133.6,
133.1, 132.8, 131.9, 131.1, 130.9, 128.9 (2C), 128.3 (2C), 128.2, 125.4, 124.3 (totally 18C–Ph),
52.3  (C-?),  rest  in  Table  21;  HRMS  (ESI-MS):  calcd  for  (M+H)  C22H21D2N4O8S2 537.1083,
found 537.1083.
N1-Benzyl-bis-N1,N3-(2-nitrobenzenesulfonyl)-2,2,3,3-2H4-propane-1,3-diamine 11f
Prepared as 11a from 1g (2.50 g, 10.36 mmol) to give 11f (5.16 g, 93%) as a pale yellow solid,
mp 39–48 °C (amorphous solid). IR (KBr): 3340 (br), 3084–2928, 2225, 1541, 1164, 740 cm?1;
1H NMR (CDCl3): ? 8.06–8.01 (1H, m, Ph), 7.99–7.95 (1H, m, Ph), 7.84–7.80 (1H, m, Ph), 7.75–
7.63 (5H, m, Ph), 7.31–7.21 (5H, m, Ph), 5.41 (1H, br, NH), 4.46 (2H, s, H-?), 3.32 (2H, s, H-1);
13C NMR (CDCl3): ? 148.0 (2C), 135.5, 133.8, 133.7, 133.5, 133.0, 132.9, 132.0, 130.9, 130.8,
128.8 (2C), 128.3 (2C), 128.2, 125.4, 124.3 (totally 18C–Ph), 52.2 (C-?), rest in Table 21;
HRMS (ESI-MS): calcd for (M+H) C22H19D4N4O8S2 539.1208, found 539.1208.
N1-Isopropyl-bis-N1,N3-(2-nitrobenzenesulfonyl)propane-1,3-diamine 11g
Prepared as 11a from 1h (3.00 g, 15.86 mmol) but after 2 h at room temperature, the reaction
mixture was heated at reflux for 20 h to give 11g (3.08  g,  40%)  as  a  pale  yellow  solid  after
column chromatography using EtOAc–hexane 3:2 as an eluent, mp 100–102 °C. Rf 0.52 (EtOAc–
hexane 3:2); IR (KBr): 3332, 3096–2850, 1545, 1380, 1160 cm?1; 1H NMR (CDCl3): ? 8.15–8.12
(1H, m, Ph), 8.05–8.01 (1H, m, Ph), 7.89–7.85 (1H, m, Ph), 7.78–7.66 (4H, m, Ph), 7.62–7.58
(1H, m, Ph), 5.61 (1H, br, NH), 4.10 (1H, sep., J=6.8 Hz, H-?), 3.36–331 (2H, m, H-1), 3.23–
3.19 (2H, m, H-3), 1.94–1.87 (2H, m, H-2), 1.14 (6H, d, J=6.8 Hz, H-?); 13C NMR (CDCl3): ?
148.1 (2C), 133.7, 133.6, 133.6, 133.5, 132.9, 131.7, 131.0, 131.0, 125.5, 124.2 (totally 12C–Ph),
50.1  (C-?),  21.4  (2C-?),  rest  in  Table  21;  HRMS  (ESI-MS):  calcd  for  (M+H)  C18H23N4O8S2
487.0957, found 487.0957.
N1-Cyclohexyl-bis-N1,N3-(2-nitrobenzenesulfonyl)propane-1,3-diamine 11h
Prepared as 11g from 1j (917 mg, 4.0 mmol) to give 11h (1.02 g, 48%) as a pale yellow solid,
mp 134–136 °C. Rf 0.50 (EtOAc–hexane 3:2); IR (KBr): 3311, 3091–2851, 1542, 1164 cm?1; 1H
NMR (CDCl3): ? 8.15–8.11 (1H, m, Ph), 8.04–7.99 (1H, m, Ph), 7.89–7.85 (1H, m, Ph), 7.78–
7.66 (4H, m, Ph), 7.61–7.56 (1H, m, Ph), 5.62 (1H, t, J=6.3 Hz, NH), 3.70–3.62 (1H, m, H-?),
3.37–3.32 (2H, m, H-1), 3.24–3.18 (2H, m, H-3), 1.92–1.85 (2H, m, H-2), 1.78–1.72 (2H, m, H-
?eq), 1.69–1.59 (3H, m, H-?eq??eq), 1.40–1.25 (4H, m, H-?ax??ax), 1.10–0.99 (1H, m, H-?ax); 13C
NMR (CDCl3): ? 148.1 (2C), 133.8, 133.7, 133.6, 133.5, 132.9, 131.7, 130.9, 130.8, 125.5, 124.1
(totally 12C–Ph), 58.3 (C-?), 32.1 (2C-?), 26.0 (2C-?), 25.2 (C-?), rest in Table 21; HRMS (ESI-
MS): calcd for (M+Na) C21H26N4O8S2Na 549.1090, found 549.1098.
2-(4-{[3-(Ethyl-(2-nitrobenzenesulfonyl)amino)propyl]-(2-nitrobenzenesulfonyl)amino}-
butyl)isoindole-1,3-dione 12a
To a mixture of 11a (1.0 g, 2.17 mmol) and K2CO3 (0.88 g, 6.35 mmol) in dry DMF (25 mL), N-
(4-iodobutyl)phthalimide [Järvinen et. al. 2006b] (0.77 g, 2.33 mmol) was added with stirring
and the mixture was allowed to react at room temperature for 17 h. After filtration, the solvents
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were evaporated in vacuo and the residue was purified on silica gel using first EtOAc–hexane 1:1
and then 5:2 as an eluent to give 12a (1.24 g, 85%) as a colourless solid, mp 44–46 °C
(amorphous solid). Rf 0.53 (EtOAc–hexane 5:2); IR (KBr): 3095, 2940 (br), 1709, 1543, 1373,
1158, 720 cm?1; 1H NMR (CDCl3): ? 8.02–7.98 (2H, m, Ph), 7.86–7.81 (2H, m, Ph), 7.74–7.55
(8H, m, Ph), 3.68–3.64 (2H, m, H-8), 3.39–3.26 (8H, m, H-?,1,3,5), 1.91–1.83 (2H, m, H-2),
1.69–1.62 (2H, m, H-7) 1.60–1.52 (2H, m, H-6), 1.12 (3H, t, J=7.1 Hz, H-?); 13C NMR (CDCl3):
? 168.4 (2C, C=O), 148.0 (2C), 134.0 (2C), 133.5, 133.5, 133.4, 133.2, 132.1 (2C), 131.8, 131.8,
130.8 (2C), 124.2 (2C), 123.3 (2C) (totally 18C–Ph), 42.3 (C-?), 13.6 (C-?), rest in Table 22;
HRMS (ESI-MS): calcd for (M+H) C29H32N5O10S2 674.1591, found 674.1584.
2-(4-{[3-(Ethyl-(2-nitrobenzenesulfonyl)amino)-1,1-2H2-propyl]-(2-nitrobenzenesulfonyl)-
amino}butyl) isoindole-1,3-dione 12b
Prepared as 12a from 11b (600 mg, 1.26 mmol) to give 12b (803 mg, 94%) as a colourless solid,
mp 38–44 °C (amorphous solid). Rf 0.53 (EtOAc–hexane 5:2); IR (KBr): 3095, 2940 (br), 1710,
1544, 1373, 1160, 721 cm?1; 1H NMR (CDCl3): ? 8.02–7.97 (2H, m, Ph), 7.86–7.81 (2H, m, Ph),
7.75–7.55 (8H, m, Ph), 3.68–3.63 (2H, m, H-8), 3.39–3.27 (6H, m, H-?,1,5), 1.88–1.83 (2H, m,
H-2), 1.69–1.62 (2H, m, H-7), 1.60–1.52 (2H, m, H-6), 1.11 (3H, t, J=7.1 Hz, H-?); 13C NMR
(CDCl3): ? 168.4 (2C, C=O), 148.0 (2C), 134.0 (2C), 133.6, 133.5, 133.3, 133.1, 132.0 (2C),
131.8, 131.8, 130.7 (2C), 124.2 (2C), 123.3 (2C) (totally 18C–Ph), 42.3 (C-?), 13.6 (C-?), rest in
Table 22; HRMS (ESI-MS): calcd for (M+H) C29H30D2N5O10S2 676.1716, found 676.1721.
2-(4-{[3-(Ethyl-(2-nitrobenzenesulfonyl)amino)-1,1,2,2-2H4-propyl]-(2-nitrobenzenesulfonyl)-
amino}butyl)isoindole-1,3-dione 12c
Prepared as 12a from 11c (715 mg, 1.50 mmol) to give 12c (948 mg, 93%) as a colourless solid,
mp 41–45 °C (amorphous solid). Rf 0.57 (EtOAc–hexane 5:2); IR (KBr): 3095, 2937 (br), 1710,
1544, 1372, 1161, 721 cm?1; 1H NMR (CDCl3): ? 8.04–7.96 (2H, m, Ph), 7.86–7.81 (2H, m, Ph),
7.75–7.54 (8H, m, Ph), 3.68–3.63 (2H, m, H-8), 3.39–3.27 (6H, m, H-?,1,5), 1.69–1.61 (2H, m,
H-7), 1.60–1.52 (2H, m, H-6), 1.12 (3H, t, J=7.1 Hz, H-?); 13C NMR (CDCl3): ? 168.4 (2C,
C=O), 148.0 (2C), 134.0 (2C), 133.6, 133.5, 133.3, 133.1, 132.0 (2C), 131.8, 131.8, 130.7 (2C),
124.2 (2C), 123.3 (2C) (totally 18C–Ph), 42.3 (C-?), 13.6 (C-?), rest in Table 22; HRMS (ESI-
MS): calcd for (M+H) C29H28D4N5O10S2 678.1842, found 678.1848.
2-(4-{[3-(Benzyl-(2-nitrobenzenesulfonyl)amino)propyl]-(2-nitrobenzenesulfonyl)-
amino}butyl)isoindole-1,3-dione 12d
Prepared as 12a from 11d (1.19 g, 2.23 mmol) to give 12d (1.32 g, 81%) as a colourless solid,
mp 47–50 °C (amorphous solid). Rf 0.57 (EtOAc–hexane 5:2); IR (KBr): 3093, 2940, 1710,
1543, 1160, 721 cm?1; 1H NMR (CDCl3): ? 8.01–7.98 (1H, m, Ph), 7.95–7.91 (1H, m, Ph), 7.85–
7.81 (2H, m, Ph), 7.74–7.60 (7H, m, Ph), 7.56–7.52 (1H, m, Ph), 7.34–7.25 (5H, m, Ph), 4.48
(2H, s, H-?), 3.63–3.58 (2H, m, H-8), 3.23–3.18 (2H, m, H-1), 3.16–3.08 (4H, m, H-3,5), 1.68–
1.61 (2H, m, H-2), 1.60–1.52 (2H, m, H-7), 1.45–1.36 (2H, m, H-6); 13C NMR (CDCl3): ? 168.3
(2C, C=O), 148.0, 147.9, 135.6, 134.0 (2C), 133.7, 133.5, 133.2 (2C), 132.1 (2C), 131.9, 131.7,
131.0, 130.7, 128.8 (2C), 128.4 (2C), 128.2, 124.3, 124.1, 123.3 (2C) (totally 24C–Ph), 51.9 (C-
?),  rest  in  Table  22;  HRMS  (ESI-MS):  calcd  for  (M+H)  C34H34N5O10S2 736.1747, found
736.1746.
2-(4-{[3-(Benzyl-(2-nitrobenzenesulfonyl)amino)-1,1-2H2-propyl]-(2-nitrobenzenesulfonyl)-
amino}butyl)isoindole-1,3-dione 12e
Prepared as 12a from 11e (1.42 g, 2.61 mmol) to give 12e (1.83 g, 95%) as colourless solid, mp
50–52 °C (amorphous solid). Rf 0.47 (EtOAc–hexane 3:2); IR (KBr): 3093–2980, 1709, 1541,
1161, 721 cm?1; 1H NMR (CDCl3): ? 8.01–7.98 (1H, m, Ph), 7.95–7.91 (1H, m, Ph), 7.85–7.81
(2H, m, Ph), 7.74–7.60 (7H, m, Ph), 7.56–7.52 (1H, m, Ph), 7.33–7.25 (5H, m, Ph), 4.48 (2H, s,
H-?), 3.63–3.58 (2H, m, H-8), 3.23–3.18 (2H, m, H-1), 3.16–3.11 (2H, m, H-5), 1.66–1.61 (2H,
m, H-2), 1.59–1.52 (2H, m, H-7), 1.44–1.36 (2H, m, H-6); 13C NMR (CDCl3): ? 168.3 (2C,
C=O), 148.0, 147.9, 135.6, 134.0 (2C), 133.7, 133.5, 133.2, 133.2, 132.0 (2C), 131.9, 131.7,
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131.0, 130.7, 128.8 (2C), 128.4 (2C), 128.2, 124.3, 124.1, 123.3 (2C) (totally 24C–Ph), 51.9 (C-
?),  rest  in  Table  22;  HRMS  (ESI-MS):  calcd  for  (M+H)  C34H32D2N5O10S2 738.1873, found
738.1840.
2-(4-{[3-(Isopropyl-(2-nitrobenzenesulfonyl)amino)propyl]-(2-nitrobenzenesulfonyl)-
amino}butyl)isoindole-1,3-dione 12f
Prepared as 12a from 11g (973 mg, 2.0 mmol) to give 12f (1.28 g, 93%) as a colourless solid, mp
46–54 °C (amorphous solid). Rf 0.30 (EtOAc–hexane 2:1); IR (KBr): 3096, 2940 (br), 1710,
1543, 1373, 1159, 721 cm?1; 1H NMR (CDCl3): ? 8.04–7.99 (2H, m, Ph), 7.85–7.80 (2H, m, Ph),
7.74–7.62 (6H, m, Ph), 7.60–7.54 (2H, m, Ph), 4.12 (1H, sep., J=6.7 Hz, H-?), 3.69–3.63 (2H, m,
H-8), 3.39–3.32 (4H, m, H-3,5), 3.23–3.17 (2H, m, H-1), 1.96–1.88 (2H, m, H-2), 1.69–1.54 (4H,
m, H-6,7), 1.12 (6H, d, J=6.7 Hz, H-?); 13C NMR (CDCl3): ? 168.3 (2C, C=O), 148.1, 148.0,
134.0 (2C), 133.6, 133.5, 133.4, 133.4, 132.1 (2C), 131.8, 131.7, 130.9, 130.8, 124.1, 124.0,
123.3 (2C) (totally 18C–Ph), 50.1 (C-?), 21.3 (2 C-?), rest in Table 22; HRMS (ESI-MS): calcd
for (M+H) C30H34N5O10S2 688.1747, found 688.1751.
2-(4-{[3-(Cyclohexyl-(2-nitrobenzenesulfonyl)amino)propyl]-(2-nitrobenzenesulfonyl)-
amino}butyl)isoindole-1,3-dione 12g
Prepared as 12a from 11h (1.05 g, 2.0 mmol) to give 12g (1.35 g, 93%) as a colourless solid, mp
53–63 °C (amorphous solid). Rf 0.56 (EtOAc–hexane 3:2); IR (KBr): 3095, 2935, 2858, 1711,
1544, 1157, 721 cm?1; 1H NMR (CDCl3): ? 8.04–7.98 (2H, m, Ph), 7.85–7.80 (2H, m, Ph), 7.74–
7.62 (6H, m, Ph), 7.59–7.54 (2H, m, Ph), 3.73–3.63 (3H, m, H-7,?), 3.39–3.31 (4H, m, H-3,5),
3.25–3.18 (2H, m, H-1), 1.95–1.86 (2H, m, H-2), 1.79–1.71 (2H, m, H-?eq), 1.69–1.54 (7H, m, H-
6,7,?eq??eq), 1.39–1.25 (4H, m, H-?ax??ax), 1.10–0.99 (1H, m, H-?ax); 13C NMR (CDCl3): ? 168.3
(2C, C=O), 148.0, 148.0, 134.0 (2C), 133.9, 133.5, 133.4, 133.4, 132.1 (2C), 131.8, 131.6, 130.8,
130.7, 124.1, 124.0, 123.3 (2C) (totally 18C–Ph), 58.3 (C-?), 31.9 (2C-?), 26.0 (2C-?), 25.2 (C-
?),  rest  in  Table  22;  HRMS  (ESI-MS):  calcd  for  (M+Na)  C33H37N5O10S2Na 750.1880, found
750.1867.
{3-[{4-[{3-[Ethyl-(2-nitrobenzenesulfonyl)amino]propyl}-(2-nitrobenzenesulfonyl)-
amino]butyl}-(2-nitrobenzenesulfonyl)amino]propyl}carbamic acid tert-butyl ester 13a
To  a  stirred  mixture  of 11a (1.0 g, 2.12 mmol) and K2CO3 (0.88 g, 6.35 mmol) in dry DMF
(21 mL) was added 10b (1.26 g, 2.33 mmol) and the reaction mixture was stirred for 17 h at
room temperature. The solids were filtered off, the filtrate was evaporated to dryness in vacuo
and the residue was purified on silica gel using first EtOAc–hexane 2:1 and then 5:2 as an eluent,
to give 13a (1.3 g, 69%) as a colourless solid, mp 45–54 °C (amorphous solid). Rf 0.35 (EtOAc–
hexane 2:1); IR (KBr): 3422 (br), 3096, 2940 (br), 1707, 1544, 1374, 1160, 744 cm?1; 1H NMR
(CDCl3): ? 8.02–7.97 (3H, m, Ph), 7.73–7.68 (6H, m, Ph), 7.64–7.59 (3H, m, Ph), 4.81 (1H, br,
NH), 3.38–3.23 (12H, m, H-?,1,3,5,8,10), 3.16–3.09 (2H, m, H-12), 1.89–1.81 (2H, m, H-2),
1.76–1.69 (2H, m, H-11), 1.54–1.47 (4H, m, H-6,7), 1.43 (9H, s, Me3C-), 1.11 (3H, t, J=7.1 Hz,
H-?); 13C NMR (CDCl3): ? 156.1 (C=O), 148.0 (2C), 148.0, 133.7, 133.7, 133.6, 133.3, 133.2,
133.0, 131.9, 131.9, 131.8, 130.8, 130.7, 130.6, 124.3, 124.2, 124.2 (totally 18C–Ph), 79.3 (O–
C), 42.4 (C-?), 28.4 (3C–Me3), 13.6 (C-?), rest in Table 23; HRMS (ESI-MS): calcd for (M+Na)
C35H47N7O14S3Na 908.2241, found 908.2234.
{3-[{4-[{3-[Ethyl-(2-nitrobenzenesulfonyl)amino]-1,1-2H2-propyl}-(2-nitrobenzenesulfonyl)-
amino]butyl}-(2-nitrobenzenesulfonyl)amino]propyl}carbamic acid tert-butyl ester 13b
Prepared as 13a from 11b (1.0 g, 2.11 mmol) to give 13b (1.40 g, 75%) as a colourless solid, mp
40–48 °C (amorphous solid). Rf 0.35 (EtOAc–hexane 2:1); IR (KBr): 3424 (br), 3096–2880,
1708, 1544, 1372, 1160, 748 cm?1; 1H NMR (CDCl3): ? 8.02–7.96 (3H, m, Ph), 7.73–7.67 (6H,
m, Ph), 7.64–7.59 (3H, m, Ph), 4.83 (1H, br, NH), 3.38–3.23 (10H, m, H-?,1,5,8,10), 3.16–3.09
(2H, m, H-12), 1.86–1.81 (2H, m, H-2), 1.75–1.68 (2H, m, H-11), 1.54–1.47 (4H, m, H-6,7),
1.43 (9H, s, Me3C–), 1.11 (3H, t, J=7.1 Hz, H-?); 13C NMR (CDCl3): ? 156.1 (C=O), 148.0 (2C),
148.0, 133.7 (2C), 133.6, 133.3 133.2, 133.0, 131.9, 131.9, 131.8, 130.8, 130.7, 130.6, 124.3,
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124.2, 124.2 (totally 18C–Ph), 79.2 (O–C), 42.4 (C-?), 28.4 (3C–Me3), 13.6 (C-?), rest in Table
23; HRMS (ESI-MS): calcd for (M+Na) C35H45D2N7O14S3Na 910.2366, found 910.2392.
{3-[{4-[{3-[Benzyl-(2-nitrobenzenesulfonyl)amino]propyl}-(2-
nitrobenzenesulfonyl)amino]butyl}-(2-nitrobenzenesulfonyl)amino]propyl}carbamic acid tert-
butyl ester 13c
Prepared as 13a from 11d (992 mg, 1.86 mmol) to give 13c (1.42 g, 80%) as a colourless solid,
mp 52–58 °C (amorphous solid). Rf 0.58 (EtOAc–hexane 3:1); IR (KBr): 3422 (br), 3096–2880,
1707, 1543, 1161, 742 cm?1; 1H NMR (CDCl3): ? 8.00–7.90 (3H, m, Ph), 7.74–7.56 (9H, m, Ph),
7.33–7.22 (5H, m, Ph), 4.81 (1H, br, NH), 4.47 (2H, s, H-?), 3.32–3.03 (12H, m, H-
1,3,5,8,10,12), 1.74–1.67 (2H, m, H-11), 1.66–1.57 (2H, m, H-2), 1.48–1.30 (4H, m, H-6,7), 1.43
(9H,  s,  Me3C–); 13C NMR (CDCl3): ? 156.0 (C=O), 148.0, 148.0, 147.9, 135.5, 133.7, 133.7,
133.6, 133.2, 133.1, 133.0, 131.9, 131.9 (2C), 130.9, 130.7, 130.6, 128.8 (2C), 128.4 (2C), 128.2,
124.3, 124.2, 124.2 (totally 24C–Ph), 79.3 (O–C), 52.0 (C-?), 28.4 (3C–Me3), rest in Table 23;
HRMS (ESI-MS): calcd for (M+Na) C40H49N7O14S3Na 970.2397, found 970.2354.
{3-[{4-[{3-[Benzyl-(2-nitrobenzenesulfonyl)-amino]-1,1,2,2-2H4-propyl}-(2-
nitrobenzenesulfonyl)-amino]butyl}-(2-nitrobenzenesulfonyl)amino]propyl}carbamic acid tert-
butyl ester 13d
Prepared as 13a from 11f (1.83 g, 3.39 mmol) to give 13d (2.75 g, 85%) as a colourless solid, mp
44–54 °C (amorphous solid). Rf 0.58 (EtOAc–hexane 3:1); IR (KBr): 3423 (br), 3095–2880,
1707, 1544, 1162, 743 cm?1; 1H NMR (CDCl3): ? 8.00–7.90 (3H, m, Ph), 7.74–7.56 (9H, m, Ph),
7.33–7.23 (5H, m, Ph), 4.82 (1H, br, NH), 4.47 (2H, s, H-?), 3.32–3.05 (10H, m, H-1,5,8,10,12),
1.74–1.66 (2H, m, H-11), 1.48–1.30 (4H, m, H-6,7) 1.43 (9H, s, Me3C–); 13C NMR (CDCl3): ?
156.0 (C=O), 148.0, 148.0, 147.9, 135.5, 133.8, 133.7, 133.6, 133.2, 133.1, 133.0, 132.0, 131.9
(2C), 130.9, 130.7, 130.6, 128.8 (2C), 128.4 (2C), 128.2, 124.3, 124.2, 124.2 (totally 24C–Ph),
79.2 (O–C), 52.0 (C-?), 28.4 (3C–Me3), rest in Table 23; HRMS (ESI-MS): calcd for (M+Na)
C40H45D4N7O14S3Na 974.2648, found 974.2607.
{3-[{4-[{3-[Isopropyl-(2-nitrobenzenesulfonyl)amino]propyl}-(2-nitrobenzenesulfonyl)-
amino]butyl}-(2-nitrobenzenesulfonyl)amino]propyl}carbamic acid tert-butyl ester 13e
Prepared as 13a from 11g (973 mg, 2.0 mmol) to give 13e (1.53 g, 85%) as a colourless solid, mp
50–55 °C (amorphous solid). Rf 0.44 (EtOAc–hexane 2:1); IR (KBr): 3421 (br), 3097–2880,
1707, 1544, 1161, 744 cm?1; 1H NMR (CDCl3): ? 8.04–7.96 (3H, m, Ph), 7.74–7.66 (6H, m, Ph),
7.64–7.57 (3H, m, Ph), 4.84 (1H, br, NH), 4.10 (1H, sep., J=6.7 Hz, H-?), 3.35–3.26 (8H, m, H-
3,5,8,10), 3.22–3.09 (4H, m, H-1,12), 1.93–1.85 (2H, m, H-2), 1.76–1.68 (2H, m, H-11), 1.55–
1.46 (4H, m, H-6,7), 1.43 (9H, s, Me3C-), 1.11 (6H, d, J=6.7 Hz, H-?); 13C NMR (CDCl3): ?
156.1 (C=O), 148.1, 148.0, 148.0, 133.7 (2C), 133.5, 133.5, 133.2, 133.2, 131.9, 131.9, 131.7,
130.8 (2C), 130.6, 124.3, 124.2, 124.1 (totally 18C–Ph), 79.2 (O–C), 50.1 (C-?), 28.4 (3C–Me3),
21.3 (2C-?), rest in Table 23; HRMS (ESI-MS): calcd for (M+Na) C36H49N7O14S3Na 922.2397,
found 922.2361.
{3-[{4-[{3-[Cyclohexyl-(2-nitrobenzenesulfonyl)amino]propyl}-(2-nitrobenzenesulfonyl)-
amino]butyl}-(2-nitrobenzenesulfonyl)amino]propyl}carbamic acid tert-butyl ester 13f
Prepared as 13a from 11h (1.05 g, 2.0 mmol) to give 13f (1.19 g, 63%) as a colourless solid, mp
54–63 °C (amorphous solid). Rf 0.44 (EtOAc–hexane 2:1); IR (KBr): 3442 (br), 3096, 2936,
2861, 1707, 1544, 1159, 742 cm?1; 1H NMR (CDCl3): ? 8.04–7.95 (3H, m, Ph), 7.74–7.66 (6H,
m, Ph), 7.64–7.56 (3H, m, Ph), 4.84 (1H, br, NH), 3.70–3.62 (1H, m, H-?), 3.37–3.25 (8H, m, H-
3,5,8,10), 3.23–3.17 (2H, m, H-1), 3.16–3.09 (2H, m, H-12), 1.91–1.84 (2H, m, H-2), 1.78–1.68
(4H, m, H-11, ?eq), 1.66–1.57 (3H, m, H-?eq??eq), 1.54–1.44 (4H, m, H-6,7), 1.43 (9H, s, Me3C–),
1.38–1.24 (4H, m, H-?ax??ax), 1.10–0.99 (1H, m, H-?ax); 13C NMR (CDCl3): ? 156.0 (C=O),
148.1, 148.0, 148.0, 133.8, 133.7 (2C), 133.5, 133.2, 133.2, 131.9, 131.9, 131.7, 130.9, 130.6,
130.6, 124.3, 124.2, 124.0 (totally 18C–Ph), 79.2 (O–C), 58.4 (C-?), 31.9 (2C-?), 28.4 (3C–Me3),
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26.0 (2C-?), 25.2 (C-?), rest in Table 23; HRMS (ESI-MS): calcd for (M+Na) C39H53N7O14S3Na
962.2710, found 962.2683.
N,N?-Bis[3-(ethyl{2-nitrobenzenesulfonyl}amino)propyl]-N,N?-bis(2-nitrobenzene-
sulfonyl)butane-1,4-diamine 14a
To  a  stirred  mixture  of 11a (894 mg, 1.89 mmol) and K2CO3 (0.75 g, 5.4 mmol) in dry DMF
(10 mL), 1,4-diiodobutane (279 g, 0.90 mmol) was added and stirring was continued for 24 h at
room temperature. The solids were filtered off and the filtrate was evaporated to dryness in
vacuo. The residue was treated with EtOAc (20 mL) and water (20 mL) and this resulted in
precipitation of the product, which was filtered off and dried in vacuo yielding 14a (718 mg,
80%) as a sparingly soluble colourless solid, mp 151–156 °C. IR (KBr): 3102–2850, 1542, 1376,
1161, 744 cm?1; 1H NMR (CDCl3+DMSO-d6): ? 8.01–7.94 (4H, m, Ph), 7.79–7.71 (8H, m, Ph),
7.70–7.64 (4H, m, Ph), 3.39–3.23 (16H, m, H-?,1,3,5,8,10,12), 1.88–1.79 (4H, m, H-2,11), 1.55–
1.48 (4H, m, H-6,7), 1.11 (6H, t, J=7.1 Hz, H-?); 13C NMR (CDCl3+DMSO-d6): ? 148.0 (2C),
148.0 (2C), 133.7 (2C), 133.6 (2C), 133.3 (2C), 132.9 (2C), 132.0 (2C), 131.9 (2C), 130.8 (2C),
130.6 (2C), 124.2 (2C), 124.2 (2C) (totally 24C–Ph), 42.4 (2C-?), 13.6 (2C-?), rest in Table 23;
HRMS (ESI-MS): calcd for (M+K) C38H46N8O16S4K 1037.1552, found 1037.1588.
N,N?-Bis[3-(ethyl-{2-nitrobenzenesulfonyl}amino)-1,1-2H2-propyl]-N,N?-bis(2-nitrobenzene-
sulfonyl)butane-1,4-diamine 14b
Prepared as 14a from 11b (1.50 g, 3.16 mmol) and 1,4-diiodobutane (467 mg, 1.51 mmol) to
give 14b (1.07 g, 71%) as a colourless solid, mp 155–158 °C. IR (KBr): 3102, 2941, 1541, 1374,
1160 cm?1; 1H NMR (CDCl3+DMSO-d6): ? 8.01–7.94 (4H, m, Ph), 7.78–7.70 (8H, m, Ph), 7.69–
7.62 (4H, m, Ph), 3.39–3.23 (12H, m, H-?,1,5,8,12), 1.87–1.78 (4H, m, H-2,11), 1.56–1.46 (4H,
m, H-6,7), 1.11 (6H, t, J=7.1 Hz, H-?); 13C NMR (CDCl3+DMSO-d6): ? 147.9 (2C), 147.9 (2C),
133.8 (2C), 133.7 (2C), 133.0 (2C), 132.7 (2C), 132.0 (2C), 131.9 (2C), 130.5 (2C), 130.4 (2C),
124.2 (2C), 124.1 (2C) (totally 24C–Ph), 42.4 (2C-?), 13.6 (2C-?), rest in Table 23; HRMS (ESI-
MS): calcd for (M+K) C38H42D4N8O16S4K 1041.1803, found 1041.1773.
N,N?-Bis[3-(isopropyl-{2-nitrobenzenesulfonyl}amino)propyl]-N,N?-bis(2-nitrobenzene-
sulfonyl)butane-1,4-diamine 14c
Prepared as 14a from 11g (3.08 g, 6.33 mmol) and 1,4-diiodobutane (934 mg, 3.02 mmol) to give
14c (2.68 g, 87%) as a colourless solid, mp 202–204 °C. IR (KBr): 3090–2850, 1544, 1362,
1157 cm?1; 1H NMR (CDCl3+DMSO-d6): ? 8.03–7.91 (8H, m, Ph), 7.90–7.79 (8H, m, Ph), 3.97
(2H, sep., J=6.7 Hz, H-?), 3.31–3.22 (8H, m, H-3,5,8,10), 3.15–3.09 (4H, m, H-1–12), 1.79–1.71
(4H, m, H-2,11), 1.47–1.40 (4H, m, H-6,7), 1.02 (12H, d, J=6.7 Hz, H-?); 13C NMR
(CDCl3+DMSO-d6): ? 147.4 (2C), 147.4 (2C), 134.4 (4C), 132.3 (2C), 132.2 (2C), 132.0 (2C),
131.7 (2C), 129.8 (4C), 124.2 (2C), 124.1 (2C) (totally 24C–Ph), 49.6 (2C-?), 20.6 (4C-?), rest in
Table 23; HRMS (ESI-MS): calcd for (M+K) C40H50N8O16S4K 1065.1865, found 1065.1844.
N,N?-Bis[3-(cyclohexyl-{2-nitrobenzenesulfonyl}amino)propyl]-N,N?-bis(2-nitrobenzene-
sulfonyl)butane-1,4-diamine 14d
To  a  stirred  mixture  of 11h (1.18 g, 2.24 mmol) and K2CO3 (0.88 g, 6.39 mmol) in dry DMF
(12 mL), 1,4-diiodobutane (330 mg, 1.06 mmol) was added and stirring was continued for 24 h at
room temperature. Solids were filtered off and the filtrate was evaporated to dryness in vacuo.
The residue was treated with EtOAc (25 mL) and water (25 mL), the water layer was extracted
with EtOAc (2×25 mL), and the combined organic phases were washed with brine (25 mL) and
dried over MgSO4. Solvent was evaporated in vacuo and the residue was purified on silica gel
using first EtOAc–hexane 3:2 and then 3:1 as an eluent, affording 14d (993 mg, 84% yield based
on 1,4-diiodobutane) as a colourless solid, mp 62–72 °C (amorphous solid). Rf 0.31 (EtOAc–
hexane 3:2); IR (KBr): 3096, 2935, 2858, 1543, 1158, 741 cm?1; 1H NMR (CDCl3): ? 8.04–7.97
(4H, m, Ph), 7.74–7.66 (8H, m, Ph), 7.63–7.55 (4H, m, Ph), 3.72–3.63 (2H, m, H-?), 3.35–3.26
(8H, m, H-3,5,8,10), 3.24–3.18 (4H, m, H-1,12), 1.92–1.83 (4H, m, H-2,11), 1.78–1.71 (4H, m,
H-?eq), 1.67–1.57 (6H, m, H-?eq??eq), 1.52–1.45 (4H, m, H-6,7), 1.39–1.25 (8H, m, H-?ax??ax),
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1.09–0.98 (2H, m, H-?ax); 13C NMR (CDCl3): ? 148.1 (2C), 147.9 (2C), 133.8 (2C), 133.7 (2C),
133.4 (2C), 133.2 (2C), 132.0 (2C), 131.7 (2C), 130.8 (2C), 130.6 (2C), 124.2 (2C), 124.0 (2C)
(totally 24C–Ph), 58.4 (2C-?), 31.9 (4C-?), 26.0 (4C-?), 25.2 (2C-?), rest in Table 23; HRMS
(ESI-MS): calcd for (M+Na) C46H58N8O16S4Na 1129.2751, found 1129.2792.
N-[3-(Benzyl-{2-nitrobenzenesulfonyl}amino)propyl]-N?-[3-(ethyl-{2-nitrobenzene-
sulfonyl}amino)propyl]-N,N?-bis{2-nitrobenzenesulfonyl}butane-1,4-diamine 14e
To  a  stirred  mixture  of 11d (535 mg, 1.0 mmol) and K2CO3 (414 mg, 3.0 mmol) in dry DMF
(10 mL), 15c (720 mg, 1.1 mmol) was added and stirring was continued for 24 h at room
temperature. Solids were filtered off, the filtrate was evaporated to dryness in vacuo, and the
precipitate was dissolved in EtOAc (20 mL) and water (20 mL). The water layer was extracted
with EtOAc (20 mL) and the combined organic extracts were washed with brine (20 mL) and
dried over MgSO4. After evaporation of the solvent in vacuo, the residue was purified on silica
gel using first EtOAc–hexane 3:2 and then 3:1 as the eluent, to give 14e (939 mg, 88%) as a
colourless solid, mp 45–56 °C (amorphous solid). Rf 0.44 (EtOAc–hexane 3:1); IR (KBr): 3096,
2940 (br), 1543, 1374, 1160, 744 cm?1; 1H NMR (CDCl3): ? 8.02–7.90 (4H, m, Ph), 7.74–7.57
(12H, m, Ph), 7.33–7.23 (5H, m, Ph), 4.47 (2H, s, Ph–CH2–), 3.35 (2H, q, J=7.1 Hz, H-?), 3.30–
3.04 (12H, m, H-1,3,5,8,10,12), 1.88–1.80 (2H, m, H-11), 1.67–1.59 (2H, m, H-2), 1.47–1.31
(4H, m, H-6,7), 1.10 (3H, t, J=7.1 Hz, H-?); 13C NMR (CDCl3): ? 148.0, 148.0, 148.0, 147.9,
135.5, 133.7, 133.7, 133.7, 133.6, 133.3, 133.1, 133.0 (2C), 132.0, 132.0, 131.9, 131.8, 130.8,
130.8, 130.7, 130.6, 128.8 (2C), 128.4 (2C), 128.2, 124.3, 124.2 (2C), 124.2 (totally 30C–Ph),
52.0 (Ph–CH2–), 42.4 (C-?), 13.6 (C-?), rest in Table 23; HRMS (ESI-MS): calcd for (M+Na)
C43H48N8O16S4Na 1083.1969, found 1083.2011.
N-[3-(Benzyl-{2-nitrobenzenesulfonyl}amino)-1,1,2,2-2H4-propyl]-N?-[3-(ethyl-{2-nitro-
benzenesulfonyl}amino)propyl]-N,N?-bis{2-nitrobenzenesulfonyl}butane-1,4-diamine 14f
Prepared as 14e from 11f (1.62 g, 3.0 mmol) and 15c (2.16 g, 3.3 mmol) to give 14f (2.67 g,
83%) as a colourless solid, mp 44–56 °C (amorphous solid). Rf 0.39 (EtOAc–hexane 2:1); IR
(KBr): 3096, 2938 (br), 1544, 1373, 1160, 743 cm?1; 1H NMR (CDCl3): ? 8.02–7.89 (4H, m, Ph),
7.75–7.57 (12H, m, Ph), 7.33–7.23 (5H, m, Ph), 4.47 (2H, s, Ph–CH2–), 3.35 (2H, q, J=7.1 Hz,
H-?), 3.31–3.21 (6H, m, H-8,10,12), 3.19 (2H, s, H-1), 3.14–3.07 (2H, m, H-5), 1.88–1.79 (2H,
m, H-11), 1.46–1.30 (4H, m, H-6,7), 1.10 (3H, t, J=7.1 Hz, H-?); 13C NMR (CDCl3): ? 148.0,
148.0, 148.0, 147.9, 135.5, 133.8, 133.7, 133.7, 133.6, 133.3, 133.1, 133.0, 133.0, 132.0, 132.0,
132.0, 131.9, 130.8, 130.8, 130.6, 130.6, 128.8 (2C), 128.4 (2C), 128.2, 124.3, 124.2 (2C), 124.2
(totally 30C–Ph), 52.0 (Ph–CH2–),  42.4  (C-?),  13.6  (C-?),  rest  in  Table  23;  HRMS (ESI-MS):
calcd for (M+K) C43H44D4N8O16S4K 1103.1959, found 1103.1908.
N-[3-(Benzyl-{2-nitro-benzenesulfonyl}amino)-1,1,2,2-2H4-propyl]-N?-[3-(ethyl-{2-
nitrobenzene-sulfonyl}amino)-1,1,2,2-2H4-propyl]-N,N?-bis{2-nitrobenzenesulfonyl}butane-
1,4-diamine 14g
Prepared as 14e from 11f (792 mg, 1.47 mmol) and 15d (1.07 g, 1.62 mmol) to give 14g (1.32 g,
84%) as a colourless solid, mp 43–54 °C (amorphous solid). Rf 0.39 (EtOAc–hexane 2:1); IR
(KBr): 3096, 2937 (br), 1541, 1373, 1161, 743 cm?1; 1H NMR (CDCl3): ? 8.01–7.89 (4H, m, Ph),
7.74–7.56 (12H, m, Ph), 7.32–7.23 (5H, m, Ph), 4.47 (2H, s, Ph–CH2–), 3.34 (2H, q, J=7.1 Hz,
H-?), 3.27 (2H, s, H-12), 3.25–3.21 (2H, m, H-8), 3.19 (2H, s, H-1), 3.13–3.07 (2H, m, H-5)
1.46–1.31 (4H, m, H-6,7), 1.10 (3H, t, J=7.1 Hz, H-?); 13C NMR (CDCl3): ? 148.0, 148.0, 148.0,
147.9, 135.5, 133.8, 133.7, 133.7, 133.6, 133.3, 133.1, 133.0 (2C), 132.0, 132.0, 132.0, 131.9,
130.8, 130.8, 130.6, 130.6, 128.8 (2C), 128.4 (2C), 128.2, 124.3, 124.2 (2C), 124.2 (totally 30C–
Ph), 52.0 (Ph–CH2–),  42.5  (C-?),  13.6  (C-?),  rest  in  Table  23;  HRMS  (ESI-MS):  calcd  for
(M+Na) C43H40D8N8O16S4Na 1091.2471, found 1091.2467.
N1-(4-Chlorobutyl)-N3-ethyl-N,N3-bis(2-nitrobenzenesulfonyl)propane-1,3-diamine 15a
To a  stirred  mixture  of 11a (2.02 g, 4.26 mmol) and K2CO3 (1.76 g, 12.77 mmol) in dry DMF
(34 mL) was added 1-bromo-4-chlorobutane (2.94 mL, 25.55 mmol) and stirring was continued
6. Synthesis of deuterated polyamines
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for 65 h at room temperature. Solids were filtered off and the filtrate was evaporated to dryness
in vacuo. The residue was treated with EtOAc, washed with water (35 mL), brine (35 mL) and
dried over MgSO4. Solvent was evaporated in vacuo affording 15a (2.45 g, ~100%) as a yellow
oil. IR (neat): 3096, 2940 (br), 1544, 1159, 745 cm?1; 1H NMR (CDCl3): ? 8.04–7.98 (2H, m,
Ph), 7.73–7.66 (4H, m, Ph), 7.64–7.59 (2H, m, Ph), 3.55–3.51 (2H, m, H-8), 3.41–3.27 (8H, m,
H-?,1,3,5), 1.94–1.86 (2H, m, H-2), 1.80–1.66 (4H, m, H-6,7), 1.12 (3H, t, J=7.1 Hz, H-?); 13C
NMR (CDCl3): ? 148.0 (2C), 133.7, 133.5, 133.3, 133.0, 131.9, 131.8, 130.9, 130.8, 124.2, 124.2
(totally 12C–Ph), 42.3 (C-?), 13.6 (C-?), rest in Table 22; HRMS (ESI-MS): calcd for (M+H)
C21H28ClN4O8S2 563.1037, found 563.1038.
N1-(4-Chlorobutyl)-N3-ethyl-1,1,2,2-2H4-N1,N3-bis(2-nitrobenzenesulfonyl)propane-1,3-
diamine 15b
Prepared as 15a from 11c (953 mg, 2.0 mmol) with subsequent purification on silica gel using
EtOAc–hexane 3:2 as an eluent to give 15b (1.07 g, 95%) as a pale yellow oil. IR (neat): 3096,
2939 (br), 2226, 1544, 1161, 745 cm?1; 1H NMR (CDCl3): ? 8.05–7.96 (2H, m, Ph), 7.74–7.65
(4H, m, Ph), 7.65–7.57 (2H, m, Ph), 3.55–3.51 (2H, m, H-8), 3.42–3.25 (6H, m, H-?,1,5), 1.80–
1.65 (4H, m, H-6,7), 1.12 (3H, t, J=7.1 Hz, H-?); 13C NMR (CDCl3): ? 148.0 (2C), 133.7, 133.6,
133.3, 133.1, 131.9, 131.8, 130.8, 130.7, 124.2, 124.2 (totally 12C–Ph), 42.4 (C-?), 13.6 (C-?),
rest  in  Table  22;  HRMS  (ESI-MS):  calcd  for  (M+H)  C21H24D4ClN4O8S2 567.1288, found
567.1302.
N1-(4-Iodobutyl)-N3-ethyl-N1,N3-bis(2-nitrobenzenesulfonyl)propane-1,3-diamine 15c
Prepared as 10b from 15a (2.4 g, 4.26 mmol) to give 15c (2.49 g, 89%) as a slightly yellowish
oil. Rf 0.44 (EtOAc–hexane 3:2); IR (neat): 3096, 2939 (br), 1542, 1159, 744 cm?1; 1H NMR
(CDCl3): ? 8.04–7.98 (2H, m, Ph), 7.74–7.66 (4H, m, Ph), 7.65–7.58 (2H, m, Ph), 3.40–3.26 (8H,
m, H-?,1,3,5), 3.17 (2H, t, J=6.6 Hz, H-8), 1.95–1.86 (2H, m, H-2), 1.83–1.75 (2H, m, H-7),
1.70–1.62 (2H, m, H-6), 1.12 (3H, t, J=7.1 Hz, H-?); 13C NMR (CDCl3): ? 148.0 (2C), 133.7,
133.6, 133.4, 133.0, 131.9, 131.8, 130.9, 130.8, 124.2, 124.2 (totally 12C–Ph), 42.4 (C-?), 13.6
(C-?),  rest  in  Table  22;  HRMS  (ESI-MS):  calcd  for  (M+H)  C21H28IN4O8S2 655.0393, found
655.0393.
N1-(4-Iodobutyl)-N3-ethyl-1,1,2,2-2H4-N1,N3-bis(2-nitrobenzenesulfonyl)propane-1,3-diamine
15d
Prepared as 10b from 15b (1.04 g, 1.84 mmol) to give 15d (1.15 g, 95%) as a yellowish oil. Rf
0.44 (EtOAc–hexane 3:2); IR (neat): 3096, 2937 (br), 2224, 1541, 1772, 1160, 744 cm?1; 1H
NMR (CDCl3): ? 8.04–7.97 (2H, m, Ph), 7.74–7.66 (4H, m, Ph), 7.65–7.58 (2H, m, Ph), 3.40–
3.26 (6H, m, H-?,1,5), 3.17 (2H, t, J=6.6 Hz, H-8), 1.83–1.74 (2H, m, H-7), 1.70–1.61 (2H, m,
H-6), 1.12 (3H, t, J=7.1 Hz, H-?); 13C NMR (CDCl3): ? 148.0 (2C), 133.7, 133.6, 133.3, 133.0,
131.9, 131.8, 130.8, 130.7, 124.2, 124.2 (totally 12C–Ph), 42.4 (C-?), 13.6 (C-?), rest in Table
22; HRMS (ESI-MS): calcd for (M+H) C21H24D4IN4O8S2 659.0644, found 659.0656.
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7. METABOLISM OF N-ALKYLATED SPERMINE ANALOGUES BY
POLYAMINE AND SPERMINE OXIDASES
Accepted to Amino Acids, Häkkinen M. R., Hyvönen M. T., Auriola S., Casero R. A. Jr., Vepsäläinen J., Khomutov A. R.,
Alhonen L. I., Keinänen T. A. Metabolism of N-alkylated spermine analogues by polyamine and spermine oxidases. The
original publication is available at www.springerlink.com after publication.
In this study we have thoroughly investigated the substrate properties of DESPM, BnEtSPM and
DBSPM and their predicted secondary metabolites with PAO and SMO. In addition, experiments
were performed to evaluate the cellular accumulation, catabolism, and excretion of the
metabolites of N,N’-bis-alkylated spermine analogues in DU145 prostate cancer cells.
7.1 RESULTS
7.1.1  LC-MS/MS method used for polyamine and polyamine analogue quantification
Polyamine quantification was based on the previously described LC-MS/MS method. (Chapters
4. and 5.) Structures and abbreviations for the studied polyamines are shown in Table 24 together
with their deuterium-labelled derivatives used in the LC-MS/MS measurements as the internal
standards. All of the 14 amines tested were quantifiable in a single run (Fig. 22). The dynamic
range for each analyte was 0.03-60 µM, except for DAP which was 0.03-10 µM. The correlation
coefficients (R2) were always > 0.995 for all analytes. Inter-day accuracy of the assay for all
analytes ranged between 88.8 and 109.8 % and the inter-day precision of the method was always
< 13.4 %.
Figure 22. Overlaid RP-LC-MS/MS SRM chromatograms of all the tested 14 amines, which were able to
quantify in a single run. Interday accuracy for all was between 88.8-109.8 % and precision < 13.4 %.
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Table 24. Structures of the amine compounds in the study and their deuterated analogues as internal
standards in LC-MS/MS quantification.
Structure and abbreviation Internal standard (IS)
DAP DAP-2D
PUT PUT-8D H2N
NH2
D
DD
D
DD
D D
SPD SPD-2D
SPM SPM-4D
EtDAP EtDAP-2D
EtSPD EtSPD-2D
EtSPM EtSPM-2D
DESPM DESPM-4D
BnNH2 BnNH2-2D
BnDAP BnDAP-4D
BnSPD BnSPD-4D
BnSPM BnSPM-4D
BnEtSPM BnEtSPM-8D
DBSPM DBSPM-8D
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7.1.2  SMO activity at various pH
SMO activity was the highest between pH 8.5 and 9.5 (Fig. 23) Therefore, all the kinetic
determinations were carried out at pH 9.5 being near optimal for both PAO and SMO [Hölttä
1977, Royo & Fitzpatrick 2005].
Figure 23. Reaction velocities (µmol/min) for SMO were determined by using 500 µM SPM as a substrate
at different pH in 170 mM Bis-Tris propane buffer
7.1.3  Terminally N,N’-bis-alkylated polyamine analogues as substrates for recombinant
human PAO and SMO
As  shown  in  Table  25,  DESPM was  catabolized  to  EtSPD by  SMO and  PAO.  Minor N4-endo
cleavage pathways resulting in formation of EtDAP was detected with both oxidases. Moreover,
very minor de-ethylation takes place with PAO. BnEtSPM was likewise catabolized to EtSPD.
However, in the case of SMO some competing debenzylation occurred and evolved EtSPM was
readily being cleaved to SPD. Moreover, some other cleavage site products were detected that
were formed from secondary metabolites by both the oxidases. DBSPM was mainly metabolized
to BnSPD by PAO. However, DBSPM was metabolized to BnSPM and BnSPD by SMO (Table
25).
7.1.4  Metabolism of predicted secondary metabolites by PAO and SMO
As shown in Table 25, EtSPM was readily degraded to SPD by both oxidases. PAO metabolized
EtSPM variably, other competing pathways being less efficient. BnSPM was readily metabolized
to SPD by PAO and SMO. PAO showed again more versatile substrate usage in comparison with
SMO. Benzylamine is formed either from direct N1-endo or N4-exo cleavage and subsequent
chemical decomposition of benzylaminopropanal under alkaline conditions (Fig. 24). BnSPD
was debenzylated to yield SPD by both oxidases. EtSPD was catabolized to SPD inefficiently by
both the oxidases. Interestingly, EtDAP was not metabolized by either of the oxidases, but PAO
was able to debenzylate BnDAP to DAP with reasonable catalytic efficiency (Table 25).
Figure 24. Endo- and exo-cleavage sites of N-alkylated polyamine analogue are shown with arrows. R1,
R2 = Et and/or Bn.
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Table 25. Kinetic values of N-alkylated polyamine analogues and their predicted secondary metabolites for
recombinant polyamine and spermine oxidases
Kinetic data was obtained as described in Chapter 7.3 by using human recombinant PAO or SMO. The abbreviations
and structures are shown in Table 24. Apparent Km(µM), Vmax (µmol/min/µmol protein), kcat (1/s).  NA  =  not
applicable. Reference activity for SMO by using 250 µM SPM as a substrate was 460 ± 62 µmol/min and for PAO
270 ± 15 µmol/min by using 250 µM N1-AcSPD as a substrate.
7.1.5  Metabolism of N,N’-bis-alkylated polyamine analogues in DU145 cells
The effects of 50 µM analogues on intracellular polyamine levels in DU145 cells are shown in
Table 26. DESPM accumulated readily inside the cells and most efficiently depleted the natural
polyamine pools. EtSPD was detected as the major metabolite in conjunction with trace of
EtSPM. BnEtSPM accumulated as efficiently as DESPM inside the cells, but did not deplete
Substrate Metabolites PAO SMO
Vmax Km kcat Vmax Km kcat
DAP 36.9 84 0.62 NA NA NA
PUT 18.5 0.4 0.31 0.33 54 0.01
SPD 209 2.5 3.49 32.2 60 0.54
BnDAP NA NA NA 0.30 75 0.01
N
H
N
H
H
N NH2
BnNH2 26.1 5.0 0.44 13.2 9.8 0.22
SPD 166 6.0 2.77 44.9 19 0.75
SPM 3.79 12 0.06 NA NA NA
BnSPD 7.51 20 0.12 NA NA NA
BnNH2 5.59 1.4 0.09 9.79 8.3 0.16
BnDAP 3.17 6.3 0.05 4.53 34 0.08
BnSPD 121 5.4 2.02 17.8 33 0.30
BnSPM 5.45 17 0.09 16.7 117 0.28
PUT 0.38 36 0.01 0.28 47 0.00
SPD 5.90 37 0.01 2.83 48 0.05
EtDAP 0.23 48 0.00 0.09 79 0.00
SPD 87.6 16 1.46 490 25 8.17
SPM 1.73 11 0.03 NA NA NA
EtSPD 2.51 25 0.04 NA NA NA
EtDAP 1.48 4.7 0.02 NA NA NA
EtSPD 64.2 10 1.07 45.6 28 0.76
EtDAP 4.05 6.6 0.07 1.56 33 0.03
EtSPM 4.66 17 0.08 NA NA NA
EtSPM 4.17 1.9 0.07 8.28 651 0.14
EtSPD 63.5 0.9 1.06 21.1 51 0.35
EtDAP 5.00 0.2 0.08 1.73 27 0.03
BnNH2 5.96 1.0 0.09 8.89 49 0.15
SPD NA NA NA 8.44 5.7 0.14
BnSPD NA NA NA 4.95 34 0.08
BnDAP NA NA NA 1.51 28 0.02
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polyamine  pools  as  efficiently  as  the  treatment  with  DESPM  did.  EtSPD  and  EtSPM  were
detected as the major metabolites and some BnSPD accumulated during 48 hours in the
BnEtSPM-treated cells. DBSPM was taken up least efficiently among the studied analogues.
Moreover, it distorted intracellular polyamine pools less efficiently in comparison with DESPM
and BnEtSPM. BnSPM and BnSPD were detected as the major metabolites from DBSPM. In
culture medium from cell samples treated with DESPM or BnEtSPM, only EtSPD was detected
together with intact drugs (data not shown). BnSPD and a trace amount of BnDAP (48 hour time
point) were detected as the metabolites of DBSPM treatment. Total excretion of each metabolite
from the cells was less than 0.2 µM (equals to 400 pmol/metabolite in two ml of medium) in
culture medium within 48 hours with all the drugs studied.  Some PUT and SPD, at less than 0.8
µM concentrations, were detected in control and drug supplemented culture media in 24 hour and
48 hour samples (2 ml medium/well, data not shown). Interestingly, no SPM was detected in any
of the culture media samples (data not shown). Moreover, SPD was present at 2.5-5 times higher
concentrations in drug-treated medium samples in comparison with control medium samples
(data not shown). This could imply that SPM is metabolized to SPD prior to being excreted from
the cells.
7.2 DISCUSSION
N-Alkylated polyamine analogues have been shown to be metabolized by cellular oxidase(s)
which are sensitive to MDL 72527. [Bergeron et. al. 1995 and 1997, Bolkenius & Seiler 1989,
Bitonti et. al. 1990] The oxidase responsible was thought to be PAO but recent cloning and
characterization of SMO has complicated the picture of how these drugs are being metabolized in
vivo and in vitro. It has been clearly shown that human and murine recombinant PAO is capable
of metabolizing DENSPM. [Wu et. al. 2003, Vujcic et. al. 2003] Some unsymmetrically N-
substituted norspermine analogues are substrates of PAO. [Wang et. al. 2005a] In the case of
SMO, studies have shown the affinity of many of the studied analogues to the enzyme and many
of them have been thought to be inhibitors, not substrates. [Wang et. al. 2003, Vujcic et. al. 2002]
The assay method used has been based on fluorometric detection of hydrogen peroxide in a dual
enzyme assay system. [Wang et. al. 2003] The fluorometric detection method is sensitive, but
lacks the ability to distinguish which drug in a combination of analogues/polyamine is used as a
substrate and how it is being metabolized in the reaction mixtures. However, other methods are
valid for testing substrate properties of tested compounds and can be used in inhibition studies. A
recent application of using 13C NMR for the detection of oxidase-mediated catabolism of labelled
tracer drug in vitro offers means to characterize different reaction products. [Bacchi et. al. 2009]
NMR is a feasible method but lacks sensitivity, and mixtures of polyamine analogues and
reaction products are sometimes hard to interpret accordingly. We have recently developed a
novel LC-MS/MS method that was exploited to reveal versatile cleavage of DESPM by PAO and
shed some light on earlier controversy related to degradation pathways of diethylated SPM
analogues. (Chapters 4. and 5.) Now, we have further extended these studies to analyze the
metabolism of three different SPM analogues in vitro and in situ.
The LC-MS/MS method proved to be functional for analyzes of N-alkylated polyamine
analogues and their metabolites in in vitro enzyme assay mixtures. Moreover, the method was
sufficiently sensitive for quantifying polyamines and their N-alkylated analogues in cell and
medium  samples  i.e.  different  sample  matrix.  The  validity  of  the  assay  is  based  on  the  use  of
deuterated reference compounds with LC-MS/MS analysis of each compound. Advantages over
existing HPLC methods are the increased sensitivity, and exact quantification and identification
of each analyte.
PAO- and SMO-mediated catabolism of N-alkylated polyamine analogues was mediated through
the same major catabolic pathways. Both enzymes showed ability for versatile cleavages of the
studied substrates in the pilot studies with DESPM, BnEtSPM or DBSPM. Thus, a systemic
study with all predicted metabolites of DESPM, BnEtSPM or DBSPM was required to dissociate
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direct metabolism from the metabolism of secondary metabolites. SMO and PAO metabolized
DESPM to EtSPD, thus mimicking the degradation of N1,N12-DiAcSPM by PAO. The aromatic
benzyl end of BnEtSPM was strongly preferred by SMO and PAO, resulting in formation of
EtSPD. However, with SMO there was an active debenzylation pathway present, and evolved
EtSPM was effectively further metabolized to SPD. In the case of SMO, N1-exo and N4-exo
cleavage were equally active when DBSPM was used as a substrate. Furthermore, some BnDAP
was detected indicating the presence of N4-endo cleavage. PAO strongly preferred N4-exo
cleavage yielding BnSPD with DBSPM as substrate and other competing pathways were less
than 5 % active when compared to the turnover number of the major pathway.
EtSPM was metabolized very efficiently to SPD by SMO. It has been shown that SMO is able to
degrade N1-AcSPM and it seems that an ethyl substituent that retains the amine as positively
charged strongly accelerates reaction velocity. [Wang et. al. 2003] Similarly, SPD was a major
metabolite with PAO, but some other competing pathways were also detected. Interestingly, with
charge retaining EtSPM and DESPM the reaction velocity is slower when compared with N1-
AcSPM and N1,N12-DiAcSPM, respectively. [Järvinen et. al. 2006a] BnSPM was metabolized to
SPD by both oxidases, PAO being more efficient than SMO. Some other competing pathways
were also present. EtSPD was a very weak substrate for both oxidases and was de-ethylated to
SPD. However, BnSPD was very efficiently debenzylated by PAO to yield SPD, and with a 15 %
reaction velocity by SMO in comparison to PAO. Moreover, PAO was capable in debenzylating
BnDAP to DAP with a reasonable catalytic efficiency. SPD has been shown to be an inhibitor for
SMO, but it seems that the aromatic N-terminal substituent evokes catalytic activity with SMO.
The metabolite formation was linear with all tested metabolites except for BnNH2, which may
also be formed via further chemical degradation of produced benzylaminopropanal liberating
acrolein in the incubation solutions of high pH. This was noted as an increased reaction velocity
of the formation of BnNH2 after a longer (2x) incubation time in comparison to velocities
obtained with T1/2 reference samples. Thus, rapid acidification of reaction mixture stabilizes
benzylaminopropanal and prevents its chemical decomposition to BnNH2 and acrolein. The
previous data rules out N1-endo cleavage as a source of BnNH2.
PAO is constitutively expressed in various tissues but SMO activity has been shown to be
inducible by some of the N-alkylated polyamine analogues in certain cell lines. [Wang et. al.
2001 and 2005b Devereux et. al. 2003] Significant PAO activity has been determined from post
mortem human specimens [Suzuki et. al. 1984] and furthermore SMO and PAO expression could
be estimated by using virtual Northern analysis of EST databases as described in [Vujcic et. al.
2003]. Evaluation of the previous data strongly supports our view that the role of N-alkylated
analogue degradation in determining the drug effect should be systematically studied. The basal
activity of 431 ± 92 pmol/mg/h for SMO in DU145 cell has been determined earlier. [Hyvönen
et.  al.  2007]  We  did  not  determine  the  induction  of  SMO  or  PAO  activity  by N-alkylated
analogues in our current study. Cell culture study was included to test the applicability of LC-
MS/MS method for quantification of polyamines, N-alkylated polyamine analogues and their
metabolites from different sample matrix than in vitro enzyme assay mixture.
Recently, SMO was shown to be responsible for drug-induced apoptosis acting as the primary
source of hydrogen peroxide, and thus, playing an important role in polyamine catabolism-
mediated cytotoxic response. [Pledgie et. al. 2005] Our present data clearly shows that inducible
SMO is capable of metabolizing N-alkylated polyamine analogues. This is not in agreement with
earlier publications showing that none of the studied N,N’-bis-alkylated polyamine analogues
were metabolized by SMO. [Wang et. al. 2003, Vujcic et. al. 2002] This discrepancy could be
explained by structural difference (3-3-3) or (4-4-4), instead of (3-4-3) carbon backbone in
conjunction with different conditions in in vitro assay  system.  We  did  use  the  same  cDNA
described in [Vujcic et. al. 2002] for production of recombinant SMO. However, Vucjic et al. did
not use purified enzyme instead they used cell lysates that could have caused DESPM to behave
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like an inhibitor of SMO, not a substrate like EtSPM. Thus, some apparent toxicity or low
efficacies of the polyamine-based drugs in some cell lines may be explained by the ability of
these two enzymes to metabolize these drugs and their metabolites. It should be noted that some
of the metabolites generated from N-alkylated polyamine analogues by SMO or PAO could be
substrates for other cellular oxidases e.g. mono- or diamine oxidase. Although cellular PAO and
SMO activities might have a significant impact on drug efficacy, kinetic studies of DESPM,
BnEtSPM or DBSPM and their predicted secondary metabolites using purified polyamine
oxidases  have  not  been  done  until  now.  It  is  clear  that  the  present  data  should  be  taken  into  a
consideration when novel N-alkylated polyamine analogues are being developed and used for the
treatment of proliferative disorders or parasitic diseases. Further studies are clearly needed in
order  to  assess  the role  of  PAO and SMO in polyamine analogue-mediated drug response.  The
large versatility in their substrate properties and flexible cleavage of their substrates could
indicate that SMO and PAO may have other natural substrates in addition to natural polyamines.
[Bacchi et. al. 2009, Lentini et. al. 2007] It should be noted that the studied analogues resembled
the SPM (3-4-3) carbon backbone. Many analogues based on norspermine (3-3-3) or
homospermine (4-4-4) carbon backbone and several analogues having a variable length carbon
chain between charged amines have been synthesized. [Casero & Marton 2007, Bergeron et. al.
1997] Alterations in carbon backbone could have a profound effect on their substrate properties
with PAO and SMO and should be systematically studied in future. This work may require
synthesis of appropriate reference compounds for exact quantification of reaction products by
using LC-MS/MS. However, screening of reaction mixtures simply to detect some of the
metabolites derived from the tested drugs could be carried out without internal reference
compounds.
In summary, here we show for the first time that both PAO and SMO are capable of metabolizing
several N-alkylated polyamine derivatives. This suggests that they might have a role in drug-
mediated cytotoxic response, especially after the natural polyamines have been depleted.
Although, the exact mechanism of drug action of N-alkylated polyamine analogues remains
obscure, polyamine metabolism is still an attractive target for drug design. It is evident that
further studies including clarification of the substrate properties of analogues with PAO and
SMO are required.
7.3  EXPERIMENTAL
7.3.1 Reagents
Ultra-gradient HPLC-grade acetonitrile (ACN) was from J.T. Baker, heptafluorobutyric acid
(HFBA, >99%) from Fluka, benzonitrile from Lancaster, and succinonitrile-d4 and benzylamine
from Aldrich. Formic acid, glycine and NaOH were from Sigma. Ultrapure water was prepared
using a Milli-Q Gradient system (Millipore, Milford, MA, USA). Human recombinant PAO and
SMO were produced as described earlier. [Järvinen et. al. 2005] PAO and SMO were stored
frozen in 20% glycerol at -80ºC, until use. Some loss of activity was detected during storage, thus
250  µM  SPM  or N1-AcSPD activity controls in triplicates were always included for all the
analyses. Propane-1,3-diamine dihydrochloride (DAP, 98%) was from Aldrich. Butane-1,4-
diamine dihydrochloride (PUT, 98%), N1-(3-aminopropyl)butane-1,4-diamine trihydrochloride
(SPD, 98%), N,N’-bis(3-aminopropyl)butane-1,4-diamine tetrahydro-chloride (SPM, >95%)
were from Sigma. All the deuterated reference compounds except those described below were
prepared as previously described. [Chapter 6.] Benzylamine hydrochloride (BnNH2) was
prepared from benzylamine and recrystallized from ethanol-ethyl acetate.
???-2H2-Benzylamine hydrochloride (BnNH2-2D) was prepared from benzonitrile (1 g, 9.7
mmol) and LiAlD4 (815 mg, 19.4 mmol) using the previously described methods (Chapter 6.) to
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give BnNH2-2D as colourless crystals. (974 mg, 69 %). 1H NMR (D2O): ? 7.57-7.43 (5H, m); 13C
NMR (D2O): ? 135.3, 132.1 (4C), 131.7, 45.4 (quintet, J = 22 Hz).
1,1,2,2,3,3,4,4-2H8-Butane-1,4-diamine dihydrochloride (PUT-8D) was prepared from
succinonitrile-d4 (200 mg, 2.38 mmol) by catalytic deuteration essentially as described in [Smith
& Daves 1978] to give PUT-8D as colourless crystals. (158 mg, 39 %). 13C NMR (D2O): ? 41.0
(2C, quintet, J = 22 Hz), 25.6 (2C, quintet, J = 19 Hz)
N1-(3-Benzylamino-1,1,2,2-2H4-propyl)butane-1,4-diamine trihydrochloride (BnSPD-4D)
was prepared from N1-benzyl-bis-N1,N3-(2-nitrobenzenesulfonyl)-2,2,3,3-2H4-propane-1,3-
diamine as described in Chapter 6. (808 mg, 1.5 mmol) and N-(4-iodobutyl)phthalimide
[Järvinen et. al. 2006b] (545 mg, 1.65 mmol) using method described in Chapter 6. to give
BnSPD-4D (193 mg,  37 %) as a colourless solid. 1H NMR (D2O): ? 7.55-7.48 (5H, m), 4.29
(2H, s), 3.20 (2H, s), 3.16-3.10 (2H, m), 3.10-3.03 (2H, m), 1.85-1.73 (4H, m); 13C NMR (D2O):
? 133.3, 132.7 (2C), 132.6, 132.2 (2C), 54.1, 49.8, 46.6 (2C, s + m), 41.7, 26.7, 25.6, 24.7
(quintet, J = 20 Hz).
N,N´-bis(3-Benzylaminopropyl)butane-1,4-diamine tetrahydrochloride (DBSPM) was
prepared from N1-benzyl-bis-N1,N3-(2-nitro-benzenesulfonyl)propane-1,3-diamine (Chapter 6.)
(1 g, 1.87 mmol) and 1,4-diiodobutane (276 mg, 0.89 mmol) using methods described in Chapter
6. to give DBSPM (211 mg, 45 %) as a colourless solid. 1H NMR chemical shifts as described
earlier [Bergeron et. al. 2001a]; 13C NMR (D2O): ? 133.4 (2C), 132.8 (4C), 132.7 (2C), 132.2
(4C), 54.1 (2C), 49.9 (2C), 47.4 (2C), 46.8 (2C), 25.6 (2C), 25.5 (2C).
N,N´-bis(3-Benzylamino-1,1,2,2-2H4-propyl)butane-1,4-diamine tetrahydrochloride
(DBSPM-8D) was prepared from N1-benzyl-bis-N1,N3-(2-nitrobenzenesulfonyl)-2,2,3,3-2H4-
propane-1,3-diamine (Chapter 6.) (1.13 g, 2.1 mmol) and 1,4-diiodobutane (310 mg, 1 mmol)
using the methods described in Chapter 6 to give DBSPD-8D (318 mg, 59 %) as a colourless
solid. 1H NMR (D2O): ? 7.56-7.47 (10H, m), 4.29 (4H, s), 3.20 (4H, s), 3.17-3.08 (4H, m), 1.85-
1.73 (4H, m); 13C NMR (D2O): ? 133.3 (2C), 132.7 (4C), 132.6 (2C), 132.2 (4C), 54.1 (2C), 49.8
(2C), 46.6 (4C, s + m), 25.6 (2C), 24.7 (2C, quintet J = 19 Hz).
7.3.2 Instrumentation
LC separations, MS/MS detection and analysis of the compounds were achieved with Agilent
6410 Triple Quad LC/MS equipped with Agilent 1200 Series Binary Pump SL pumping system
and Agilent 1200 Autosampler. Data acquisition and analysis were performed using an Agilent
MassHunter Workstation software (Agilent Corporation, MA, USA). 1H and 13C NMR spectra
were measured on a Bruker Avance (Bruker, Rheinstetter, Germany) 500 DRX spectrometer as
described earlier (Chapter 6.).
7.3.3 Analytical conditions
LC-MS/MS experiments were based on selected reaction monitoring (SRM) analysis and were
performed essentially as described earlier (Chapter 5). The chromatographic separations were
carried out using a Phenomenex Gemini reversed phase C18 column (3 µm, 50 mm × 2 mm, 110
Å) protected with a Phenomenex C18 guard column (4 mm × 2 mm). A gradient solvent system
consisting of 0.1% (v/v) HFBA in water (solvent A) and 0.1 % (v/v) HFBA in ACN (solvent B)
was used as before (Chapter 5.), but the gradient was increased from 2-50 % B over 12 min at a
flow rate of 0.2 mL/min. Two time segments were used, turning point being 7.5 min. In the first
time segment (0-7.5 min) dwell times were set to 100 (10 ion transitions), and after 7.5 min dwell
time were 20 (30 ion transitions). The precursor and the product spectra of each polyamine were
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recorded similarly as described earlier in Chapter 4. Fragmentor voltage value was set to 60 V for
DAP, DAP-2D, PUT, PUT-8D, BnNH2 and BnNH2-2D,  and  to  90  V  for  rest  of  the  analytes.
Precursor ions, selected product ions for quantification and qualification, and collision energy
values for all analytes used in the quantitative SRM analysis are given in Table 27. DAP and
PUT have only one product ion.
Table 27. LC-MS/MS properties of polyamines used in this study
Amine
standard
Precursor
[M+H]+ QT
CID
(eV) QL
CID
(eV)
Deuterated
internal standard
Precursor
[M+H]+ QT
CID
(eV)
Retention
time
DAP 75 58 5 - - DAP-2D 77 60 5 4.4
PUT 89 72 5 - - PUT-8D 97 80 5 4.6
EtDAP 103 86 5 58 15 EtDAP-2D 105 88 5 5.7
BnNH2 108 91 10 65 20 BnNH2-2D 110 93 10 6.7
SPD 146 72 15 112 10 SPD-2D 148 114 10 7.8
EtSPD 174 72 15 86 15 EtSPD-2D 176 88 15 8.2
BnDAP 165 148 5 91 20 BnDAP-4D 169 152 5 8.3
SPM 203 129 5 112 15 SPM-4D 207 133 5 8.9
EtSPM 231 157 10 129 10 EtSPM-2D 233 159 10 9.1
DESPM 259 157 10 112 20 DESPM-4D 263 159 10 9.3
BnSPD 236 148 15 112 15 BnSPD-4D 240 152 15 9.4
BnSPM 293 219 10 112 20 BnSPM-4D 297 223 10 9.9
BnEtSPM 321 219 10 112 20 BnEtSPM-8D 329 223 10 10.1
DBSPM 383 219 15 112 20 DBSPM-8D 391 223 15 10.8
Chemical structures with abbreviated names are shown in Table 24, and the chemical names are given in
“Abbreviations”. QT, quantifier ion; QL, qualifier ion; CID, collision energy
7.3.4  Preparation of standards and quality controls
Standard working solutions (concentrations of 0.03, 0.1, 0.3, 1, 3, 10, 30 and 60 µM) and
working solutions for quality control (QC) samples (concentrations of 0.05, 0.2, 2 and 20 µM) in
90 mM glycine-NaOH-formic acid buffer, and internal standard (IS) working solution containing
1 µM of each 14 deuterated amine in water, were prepared essentially as described earlier in
Chapter 5.
Two types of calibration standards and QC samples were prepared using these working solutions
by adding 50 µl of each STD working solution or QC working solution, 50 µl of 1 µM IS
working solution and 25 µl 0.5 % HFBA (calibration curve 1 for enzyme kinetic analyses) or 10
% HFBA (calibration curve 2 for cell culture experiments). Additional HFBA was used to
maintain the chromatographic performance of samples containing sulphosalisylic acid. Samples
were transferred into Agilent polypropylene vial inserts for the LC-MS/MS analysis. The
calibration curves included also a blank sample and a “zero” sample as described earlier in
Chapter 5.
7.3.5  Calibration curves and assay validation
Calibration curves were constructed from accurate concentrations of working solutions of each
analyte in x-axis, and peak-area ratio sample vs. internal standard in y-axis using 1/x weighted
linear or quadratic (for SPD and EtSPM) least-squares regression model. The assay validation
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was performed according to the FDA guideline for bioanalytical method validation [FDA 2001]
essentially as described earlier in Chapter 5.
7.3.6  Enzyme Kinetic Analyses with Human Recombinant PAO and SMO
The kinetic studies were carried out twice in triplicates at 4 to 7 different (SMO 25-250 µM and
100-1000 µM; PAO 10-1000 µM) substrate concentrations. The enzyme stock solution was
diluted with 50 mM sodium phosphate buffer (pH 8.0) (containing 0.1% Triton X-100) before
kinetic studies to yield 0.1–2.0 µg/10 µl of PAO or SMO for each reaction mixture. Reactions
were carried out in a total volume of 180 µl in the 100 mM glycine-NaOH at pH 9.5 buffer and
were allowed to proceed for 2 to 60 min at 37 °C before addition of 20 µl of 50 % (v/v) formic
acid. All kinetic determinations included a T1/2 reference (incubated half of the reaction time of
actual samples to monitor linearity of reaction) and the reaction mixture without enzyme
supplements both with the highest studied drug concentration treated identically as the analysed
sample to exclude non-enzymatic degradation of the studied compounds. Moreover, with some
selected reaction mixtures, preincubation with 100 µM MDL 72527 was used to inactivate SMO
in order to rule out any nonenzymatic degradation of the tested drug. LC-MS/MS was used to
determine the concentrations of the polyamines and their analogues as described above. Prior to
LC-MS/MS analysis, concentrated samples ( > 50 µM) were diluted with 90 mM glycine-NaOH-
formic acid buffer and all samples were passed through a 0.22 µm filter. LC-MS/MS samples
were prepared similarly to calibration standards and QC samples (Chapter 5.).
7.3.7  SMO activity at different pH in Bis-Tris propane buffer
Fixed 500 µM SPM in 170 mM Bis-Tris propane at pH 7.5, 8.0, 8.5, 9.0, 9.5 or 10.0 was used
with 0.2 µg of SMO in total volume of 180 µl, incubated for 5 or 2.5 minutes at 37 ºC water bath.
Reactions carried out twice in triplicates were stopped by adding 20 µl of 50% sulphosalicylic
acid containing 100 µM 1,7-diaminoheptane and the SPD content was determined by using
HPLC method described earlier. [Hyvönen et. al. 1992]
7.3.8  Cell culture
The prostate carcinoma cell line DU145 was obtained from American Type Culture Collection,
USA. The cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented
with 10% fetal bovine serum and 50 µg/ml gentamycin under conditions of +37 ºC and 10%
CO2. The cells were harvested by trypsinization, counted electronically (Coulter Counter model
Z1) and divided to six well plates. Cells were allowed to attach and after 24h, medium
supplemented with or without 50 µM DESPM, BnEtSPM or BnSPM was added. Samples were
collected at 24 and 48 hours post-treatment and analyzed for polyamines and N-alkylated
analogues or their metabolites. LC-MS/MS samples were prepared similarly as calibration
standards for calibration curve 2, and QC samples. Assays were carried out twice in triplicates.
7.3.9  Statistical Analyses
The data are expressed as the mean ± S.D. A software package, GraphPad Prism 4.03 (GraphPad
Software, Inc., San Diego, CA) was used for the analyses of enzyme kinetic data using
Michaelis-Menten equation with nonlinear fitting (Mw of 55,382 for PAO and Mw of 68,000 for
SMO were used in calculations).
127 Kuopio Univ. Publ. C. Nat. and Environ. Sci. 263: 1-145(2009)
8. SUMMARY AND FUTURE REMARKS
The reversed-phase LC approach with the addition of a volatile ion-pairing reagent (HFBA) to
the mobile phase was developed to enhance the interaction between C18 load stationary phase
and polyamines, which could not be retained under traditional mobile phase conditions. The
column effluent was directly connected to the ESI source as part of the MS/MS system.
Simultaneous selective reaction monitoring of all analytes and the stable isotope labelled internal
standards in the positive mode were used for the quantitative assay. The impact of mobile phase
composition containing different ion-pairing agents on the ionisation efficiencies and
chromatographic performance of the test compounds was investigated. The presence of HFBA as
an additive in the LC separations proved to have two important functions in the analysis of
polyamines. It enabled the chromatographic separation of the highly polar analytes, giving them
good symmetrical peak shapes and prevented the unwanted interaction of these basic analytes to
free silanol groups in the column and to capillaries in the instrument. Moreover, two different
methods utilizing propionic acid were evaluated as ways to reduce the ion suppression caused by
the ionpairing reagent used. Finally, the method was validated for polyamine analysis. Compared
with conventional methods for polyamine analysis, the developed LC–MS/MS method is easier
to use and is substantially faster due to minimal sample pre-treatment and rapid chromatographic
separation. Moreover, the method allows clear identification of the products by highly sensitive
MS and the possibility to eliminate interfering peaks arising from the matrix by selective
MS/MS. The developed method was used in metabolic studies with purified enzymes as well as
in cell culture and medium samples, without any polyamine derivatization. This new method
might also help to solve other problems encountered in polyamine analysis, and thus shed light
on those numerous physiological and pathophysiological functions of polyamines and their
analogues which still await clarification.
To enhance the reliablility of the developed LC-MS/MS method, stable deuterium labelled
analogues of the studied analytes were used as internal standards in the quantification. Various
protocols had already been developed for polyamine synthesis and labelling, but there was no
general method to prepare N-alkylated polyamine derivatives with deuterium. The selective
derivatization of polyamines is not straightforward, even in the simplest cases for the synthesis of
N-monosubstituted alkane-diamines, and is especially complicated with non-symmetrical
diamines. However, a simple and straightforward general method was developed to synthesise
several mono- and dialkylated polyamines, in which backbone carbons were either symmetrically
or unsymmetrically labelled with several deuterium atoms. In addition to their benefits as internal
standards in quantitative LC-MS/MS measurements, these deuterium labelled compounds were
also applicable in structural determinations in NMR analyses and MS fragmentation. In the
future, due to the possible isotope effects of deuterated molecules, it would be interesting to test
also these deuterated analogues as well as the other synthesised polyamine analogues (e.g. iPr, c-
hex substituted) as substrates for polyamine metabolising enzymes and in cell culture. Questions
to be answered include, are they transported or do they penetrate into cell similarly, do they have
similar physiological effects on drug metabolism and are deuterium labelled analogues more
resistant to metabolic changes compared to their non-labelled counterparts. In addition, it would
be important to study the metabolism of the molecules as well as the developed LC-MS/MS
method for example in liver homogenate, since the liver is the main tissue for metabolic
reactions.
Using the quantitative LC-MS/MS method, the involvement of PAO in the enzymatic
degradation of DESPM was verified. Next the substrate properties of several N-alkylated
polyamine analogues were thoroughly investigated with purified human PAO and SMO. Even
though SMO has very different substrate specificities for the natural polyamines as compared
with PAO, unexpectedly both of the oxidases metabolized symmetrically or unsymmetrically bis-
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alkylated spermine derivatives (DESPM, BnEtSPM, DBSPM) through the same major catabolic
pathways. However, some small differences between SMO and PAO were observed, with PAO
showing more versatile substrate usage in comparison with SMO. The aromatic benzyl end of
BnEtSPM was strongly preferred by SMO and PAO, thus it is possible to alter the cleavage site,
at least partly, with different N-alkyl substituents. In addition, as expected, also mono-alkylated
spermine  analogues  (EtSPM and  BnSPM)  were  substrates  for  PAO and  SMO,  but  also  mono-
alkylated spermidine analogues (EtSPD and BnSPD) were metabolized by both oxidases. In
addition, experiments were performed to evaluate the cellular accumulation, catabolism, and
excretion of the metabolites of N,N’-bis-alkylated spermine analogues in DU145 prostate cancer
cells. BnEtSPM accumulated as efficiently as DESPM inside the cells, but did not deplete
polyamine pools as efficiently. DBSPM was taken up, but disturbed the intracellular polyamine
pools least efficiently of all the studied analogues. The same major metabolites as with purified
enzyme studies (EtSPD and/or BnSPD) were detected both in the culture medium and
intracellularly. Moreover, also spermine derivatives (EtSPM and BnSPM) were detected from
cell samples.
The clear demonstration, that these analogues as well as their metabolites are substrates for the
human  PAO  as  well  as  for  SMO,  may  account  for  some  of  the  apparent  toxicity  or  the  low
efficacy of polyamine-based drugs in certain cell lines. This suggests that these oxidases could
have a significant impact on the efficiency of these drugs and it is one possibility to explain why
the  results  of  clinical  trials  with  the  polyamine  analogues  have  not  been  as  successful  as
predicted. In addition, also N-alkylated polyamine analogue catabolism might have an important
role in the drug-mediated cytotoxic response, especially after the natural polyamines have been
depleted. Most importantly, the results of these studies provide important information of the
substrate properties of these two catabolic enzymes that will facilitate future drug design. Further
studies are clearly needed in order to reveal the role of N-alkylated analogue degradation by PAO
and SMO in the polyamine analogue-mediated drug response. Alterations in the carbon backbone
as well as other N-alkyl substituents could have a profound effect on substrate properties of
polyamine based drugs with PAO and SMO and should be systematically studied in the future.
Moreover, if the metabolic behaviour of polyamines could be regulated, either with N-alkylation,
backbone deuteration or in some other way, this might be of benefit in the design of more stable
polyamine analogues and inhibitors as well as providing new therapeutic possibilities for novel
prodrugs.
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